,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,41,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
21,43,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
22,45,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
23,47,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
24,49,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
25,51,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
26,53,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
27,55,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
28,57,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
29,59,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
30,61,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
31,63,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
32,65,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
33,67,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
34,69,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
35,71,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
36,73,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
37,75,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
38,77,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
39,79,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
40,81,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
41,83,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
42,85,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
43,87,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
44,89,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
45,91,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
46,93,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
47,95,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
48,97,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
49,99,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
50,101,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
51,103,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
52,105,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
53,107,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
54,109,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
55,111,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line,Confirmatory,,
56,113,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
57,115,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
58,117,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line,Confirmatory,,
59,119,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
60,121,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
61,123,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
62,125,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
63,127,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line,Confirmatory,,
64,129,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
65,131,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
66,133,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
67,135,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
68,137,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
69,139,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
70,141,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
71,143,1,1,,87663,5746,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
72,145,1,1,,87663,5746,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
73,147,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad52 strain,Other,,
74,149,1,1,,87663,5746,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt1 strain,Other,,
75,151,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50EPP+ strain,Other,,
76,153,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain,Other,,
77,155,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
78,157,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
79,159,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad14 strain,Other,,
80,161,1,1,,87663,5746,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
81,163,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain,Other,,
82,165,1,1,,87663,5746,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
83,167,1,1,,87663,5746,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
84,169,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt2 strain,Other,,
85,171,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain,Other,,
86,173,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain,Other,,
87,175,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
88,177,1,1,,87663,5746,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,Other,,
89,179,1,1,,87663,5746,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
90,180,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
91,182,1,1,,87663,5746,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 06 and 41 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
92,184,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,Other,,
93,186,1,1,,87663,5746,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
94,188,1,1,,87663,5746,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
95,192,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
96,194,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
97,200,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
98,206,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
99,208,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
100,210,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
101,212,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
102,214,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6C3F1 mice,Other,,
103,220,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
104,228,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
105,248,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
106,250,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
107,256,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
108,258,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,Other,,
109,262,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
110,264,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
111,268,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice,Other,,
112,270,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
113,272,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intramuscular) in B6D2F1 (BDF1) mice,Other,,
114,274,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
115,276,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
116,278,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  A549 Human Adenocarcinoma of Lung with characteristics of Type II Alveolar Epithelial cells (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
117,280,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
118,288,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
119,292,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
120,296,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
121,298,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
122,300,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in unknown mice,Other,,
123,314,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in DBA/2 mice,Other,,
124,316,1,1,,87663,5746,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
125,322,1,1,,87663,5746,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 08 (intraperitoneal) in CD2F1 (CDF1) mice",Other,,
126,324,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
127,326,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Dihydroxy Anthracenedione; NSC 299195 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
128,328,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
129,330,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
130,336,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
131,342,1,1,,87663,5746,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
132,344,1,1,,87663,5746,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lieberman Plasma Cell No. 1 (LPC-1) (intraperitoneal) in unknown mice,Other,,
133,1189,1,5,,48414068,5746,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
134,1194,1,3,,48414068,5746,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
135,1195,1,2,,48416286,5746,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
136,1205,1,4,,48414068,5746,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
137,1208,1,3,,48414068,5746,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
138,1850,2,1,,57260126,5746,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
139,1863,2,1,,57260126,5746,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
140,1899,1,3,,57260126,5746,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
141,1903,2,3,,57260126,5746,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
142,1906,1,3,,57260126,5746,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
143,1947,1,2,,57260126,5746,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
144,1950,1,3,,57260126,5746,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
145,1962,1,2,,57260126,5746,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
146,1974,1,2,,57260126,5746,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
147,1987,1,2,,57260126,5746,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
148,2016,1,3,,57260126,5746,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
149,2023,1,3,,57260126,5746,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
150,2025,1,3,,57260126,5746,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
151,2029,1,3,,57260126,5746,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
152,2052,2,1,,57260126,5746,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
153,2057,1,2,,57260126,5746,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
154,2066,1,4,,57260126,5746,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
155,2101,1,1,,57260126,5746,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
156,2129,1,2,,57260126,5746,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
157,2130,1,3,,57260126,5746,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
158,2174,1,3,,57260126,5746,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
159,2177,1,3,,57260126,5746,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
160,2234,1,2,,57260126,5746,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
161,2235,1,2,,57260126,5746,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
162,2240,1,1,,85787782,5746,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
163,2241,1,1,,85787782,5746,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
164,2275,1,1,,85787782,5746,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
165,2280,2,3,,57260126,5746,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
166,2300,1,3,,57260126,5746,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
167,2313,1,1,,85787782,5746,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
168,2316,1,1,,85787782,5746,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
169,2322,1,1,,85787782,5746,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
170,2330,1,1,,85787782,5746,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
171,2380,1,2,,57260126,5746,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
172,2391,1,1,,57260126,5746,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
173,2435,1,2,,57260126,5746,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
174,2445,1,2,,57260126,5746,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
175,2462,1,1,,57260126,5746,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
176,2462,1,1,,57260126,5746,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
177,2517,2,1,,57260126,5746,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
178,2517,2,1,,144205046,5746,Inconclusive,6980812.0,,35.4813,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
179,2520,1,4,,57260126,5746,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
180,2521,1,3,,57260126,5746,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
181,2524,1,2,,57260126,5746,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
182,2540,1,2,,57260126,5746,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
183,2544,1,2,,57260126,5746,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
184,2557,1,3,,57260126,5746,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
185,2599,1,2,,57260126,5746,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
186,2606,1,2,,57260126,5746,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
187,2629,1,1,,57260126,5746,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
188,2650,2,1,,57260126,5746,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
189,2661,1,1,,57260126,5746,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
190,2676,1,2,,57260126,5746,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
191,2685,1,1,,57260126,5746,Inconclusive,,,1.2995,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
192,2690,1,2,,57260126,5746,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
193,2716,1,1,,57260126,5746,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
194,2717,1,2,,57260126,5746,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
195,2718,1,1,,57260126,5746,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
196,2751,2,2,,57260126,5746,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
197,2796,1,4,,57260126,5746,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
198,2797,1,2,,57260126,5746,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
199,2805,2,2,,57260126,5746,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
200,2806,2,2,,57260126,5746,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
201,2825,1,2,,57260126,5746,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
202,3024,8,2,,103176321,5746,Inactive,,,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Other,1920349.0,
203,3026,8,2,,103176321,5746,Inactive,,,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Other,1920349.0,
204,3214,4,4,,103176321,5746,Active,,,0.2,IC50,In vitro inhibition of 2780/DOX ovarian cancer cell line,Confirmatory,1920349.0,
205,3215,4,4,,103176321,5746,Active,,,0.1,IC50,In vitro inhibition of 2780/S ovarian cancer cell line,Confirmatory,1920349.0,
206,7026,4,4,,103176321,5746,Active,,,0.2,IC50,In vitro inhibition of 7226/S myeloma cancer cell line,Confirmatory,1920349.0,
207,8282,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against A549 human lung carcinoma cell line,Other,2754710.0,
208,8283,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Other,2754710.0,
209,8284,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Other,2754710.0,
210,8298,6,2,,103176321,5746,Unspecified,,,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Other,11585450.0,
211,8429,6,2,,103176321,5746,Active,,,0.32799999999999996,IC50,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Confirmatory,8709111.0,
212,9807,4,1,,103176321,5746,Unspecified,,,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Other,2500528.0,
213,23271,4,4,,103176321,5746,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
214,23684,3,3,,103176321,5746,Unspecified,,,,,Tumor cell uptake,Other,1906109.0,
215,23702,3,3,,103176321,5746,Unspecified,,,,,Partition coefficient (logP),Other,6699880.0,
216,26788,3,5,,103176321,5746,Unspecified,,,,,Distribution between 1-octanol and water containing phosphate buffer at pH 7.4,Other,6425501.0,
217,37914,4,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration in B-16 melanoma in mice (dose mg/kg/day),Other,6827524.0,
218,37916,3,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration inB-16 melanoma in mice (dose mg/kg/day),Other,6827524.0,
219,37917,4,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration of in B-16 melanoma in mice (dose mg/kg/day),Other,6827524.0,
220,38002,3,5,,103176321,5746,Unspecified,,,,,Average change in weight between treated and control groups at 12 mg/kg in mice infected with L1210 leukemia cells,Other,7328580.0,
221,38046,4,3,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration in B-16 melanoma in mice (dose mg/kg/day); 0,Other,6827524.0,
222,38049,4,3,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration in B-16 melanoma in mice (dose mg/kg/day); 6/10,Other,6827524.0,
223,38058,3,4,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration of in B-16 melanoma in mice (dose mg/kg/day); 0,Other,6827524.0,
224,38185,3,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration of of a dose of 1 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
225,38186,3,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration of of a dose of 2 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
226,38188,3,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration of of a dose of 4 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
227,38190,3,5,,103176321,5746,Unspecified,,,,,Average weight change after ip administration of of a dose of 3 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
228,38191,3,4,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration of a dose of 1 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
229,38192,3,4,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration of a dose of 2 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
230,38194,3,4,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration of a dose of 3 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
231,38195,3,4,,103176321,5746,Unspecified,,,,,Tumor free survivors on 62nd day after ip administration of a dose of 4 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
232,38196,3,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration of a dose of 1 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
233,38197,3,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration of a dose of 2 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
234,38198,3,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration of a dose of 3 mg/kg/day in B-16 melanoma in mice,Other,6620304.0,
235,38199,3,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration of a dose of 4 mg/kg/day inB-16 melanoma in mice,Other,6620304.0,
236,40604,4,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration in B-16 melanoma in mice (dose mg/kg/day),Other,6827524.0,
237,40605,3,4,,103176321,5746,Unspecified,,,,,Median survival time (% T/C) after ip administration in B-16 melanoma in mice (dose mg/kg/day),Other,6827524.0,
238,40892,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against B16-BN murine melanoma cell line,Other,2754710.0,
239,40895,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against B16-F10 murine melanoma cell line,Other,2754710.0,
240,42897,6,3,,103176321,5746,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells,Other,,
241,43723,5,3,,103176321,5746,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells,Other,,
242,44716,6,2,,103176321,5746,Unspecified,,,,,"In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay",Other,12620075.0,
243,45745,4,4,,103176321,5746,Active,,,0.00108,IC50,Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours),Confirmatory,2909741.0,
244,50723,6,2,,103176321,5746,Active,,,1.5,IC50,"Inhibitory activity against clone62, a mouse melanoma cell line in absence of Enterobacter cloacae bL",Confirmatory,9276025.0,
245,51924,3,3,,103176321,5746,Unspecified,,,,,Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.,Other,2362268.0,
246,53601,6,2,,103176321,5746,Active,,,0.08199999999999999,IC50,Inhibition of cell growth was studied in chinese hamster lung cells (DC-3F),Confirmatory,8709111.0,
247,53619,6,2,,103176321,5746,Active,,,0.11,IC50,Inhibition of cell growth was studied in chinese hamster lung cells resistant to actinomycin D (DC-3F/AD-II).,Confirmatory,8709111.0,
248,54621,3,3,,103176321,5746,Unspecified,,,,,Apparent binding constant against calf thymus DNA was determined,Other,15163210.0,
249,57470,4,6,,103176321,5746,Unspecified,,,,,Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate,Other,6699880.0,
250,67455,6,2,,103176321,5746,Unspecified,,,,,"In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay",Other,12620075.0,
251,67634,8,1,,103176321,5746,Active,,,0.7,ED50,Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.,Confirmatory,7452674.0,
252,67635,8,1,,103176321,5746,Active,,,0.001,ED50,Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.,Confirmatory,7452674.0,
253,78806,6,2,,103176321,5746,Unspecified,,,,,in vitro inhibition of tumor cell growth in cultured HCT-8 human tumor cell line,Other,11585450.0,
254,79010,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against HCT116 human colon carcinoma cell line experiment 1,Other,2754710.0,
255,79011,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against HCT116 human colon carcinoma cell line experiment 2,Other,2754710.0,
256,80386,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against HCT116 human colon carcinoma cell line,Other,2754710.0,
257,80662,6,2,,103176321,5746,Active,,,1.6,IC50,"Inhibitory activity against H2987, human lung adenocarcinoma cell line in absence of Enterobacter cloacae bL",Confirmatory,9276025.0,
258,81859,6,2,,103176321,5746,Active,,,0.07,IC50,In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
259,82843,6,2,,103176321,5746,Active,,,0.05,IC50,Inhibition of cell growth was studied in human promyelocytic leukemic (HL-60) cells.,Confirmatory,8709111.0,
260,85760,6,2,,103176321,5746,Unspecified,,,,,"In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay",Other,12620075.0,
261,86391,6,3,,103176321,5746,Active,,,0.27,IC50,"Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).",Confirmatory,,
262,86403,7,1,,103176321,5746,Active,,,,,"Compound was evaluated for the cytotoxicity against human hepatocellular carcinoma, HepG2 (ATCC HB8065)",Other,,
263,86522,7,1,,103176321,5746,Active,,,,,"Compound was evaluated for the cytotoxicity against human cervix epithelioid carcinoma, HeLa (ATCC CCL2).",Other,,
264,87473,6,2,,103176321,5746,Active,,,0.81,IC50,In vitro anticellular activity against HeLa cells.,Confirmatory,1495011.0,
265,87724,6,2,,103176321,5746,Active,,,0.59,IC50,In vitro anticellular activity against HeLa S3 cells,Confirmatory,8021919.0,
266,87729,6,2,,103176321,5746,Active,,,1.1,IC50,In vitro anticellular activity against HeLa S3 cells; 0.59-1.1,Confirmatory,8021918.0,
267,87730,6,2,,103176321,5746,Active,,,1.4,IC50,In vitro anticellular activity against HeLa S3 cells; 0.82-1.4,Confirmatory,8021918.0,
268,88791,6,2,,103176321,5746,Active,,,0.04,IC50,The compound was evaluated for the cytotoxicity against human CH1 (ovarian) tumor cell lines.,Confirmatory,10698444.0,
269,88850,4,3,,103176321,5746,Active,,,0.0148,IC50,Antitumor potency on human ovarian 2780 cell lines.,Confirmatory,1906109.0,
270,88954,6,2,,103176321,5746,Active,,,0.04,IC50,The compound was evaluated for the cytotoxicity against human HT-29 (colon) tumor cell lines.,Confirmatory,10698444.0,
271,89626,6,2,,103176321,5746,Active,,,0.2,IC50,The compound was evaluated for the cytotoxicity against human SKOV-3 (ovarian) tumor cell lines.,Confirmatory,10698444.0,
272,90128,4,4,,103176321,5746,Active,,,0.0322,IC50,Antitumor potency on human breast MCF-7 cell lines.,Confirmatory,1906109.0,
273,90437,4,3,,103176321,5746,Active,,,0.013000000000000001,IC50,Antitumor potency on human colon WIDR cell lines.,Confirmatory,1906109.0,
274,91259,6,2,,103176321,5746,Active,,,0.05,IC50,The compound was evaluated for the cytotoxicity against human A2780 (ovarian) tumor cell lines.,Confirmatory,10698444.0,
275,91260,6,2,,103176321,5746,Active,,,0.06,IC50,The compound was evaluated for the cytotoxicity against human A2780cisR (ovarian) tumor cell lines.,Confirmatory,10698444.0,
276,91966,5,2,,103176321,5746,Active,,,0.83176,GI50,In vitro anticancer activity against cultured 60 human tumor cell lines,Confirmatory,15163210.0,
277,94811,4,4,,103176321,5746,Active,,,0.001,IC50,In vitro inhibitory activity against K562 leukemia cells,Confirmatory,12699386.0,
278,94812,4,4,,103176321,5746,Active,,,0.0158,IC50,In vitro inhibitory activity against K562 leukemia cells in the presence of pd2,Confirmatory,12699386.0,
279,95051,6,1,,103176321,5746,Unspecified,,,,,Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 12 mg/kg per injection,Other,3761307.0,
280,95054,6,1,,103176321,5746,Unspecified,,,,,Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 6 mg/kg per injection,Other,3761307.0,
281,95061,3,4,,103176321,5746,Unspecified,,,,,Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 1.5 mg/kg per injection,Other,3761307.0,
282,95063,3,4,,103176321,5746,Unspecified,,,,,Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 3 mg/kg per injection,Other,3761307.0,
283,95330,6,2,,103176321,5746,Unspecified,,,,,in vitro anticancer activity against cultured KB(epidermoid) human tumor cell line,Other,11585450.0,
284,95332,4,3,,103176321,5746,Active,,,0.5,IC50,In vitro cytotoxicity expressed as conc. that inhibits 50% of KB (human) cell proliferation,Confirmatory,11606141.0,
285,95842,6,3,,103176321,5746,Active,,,0.4,IC50,In vitro antitumor activity against human epidermoid carcinoma KB cells by MTT assay.,Confirmatory,,
286,95851,6,3,,103176321,5746,Active,,,0.4,IC50,In vitro cytotoxicity determined against human epidermoid carcinoma KB cells by MTT assay,Confirmatory,,
287,96793,4,1,,103176321,5746,Unspecified,,,,,In vitro antitumor activity against L1210 lymphocytic leukemia tumor cell line was determined,Other,2500528.0,
288,97544,3,5,,103176321,5746,Unspecified,,,,,Average change in weight between treated and control groups at 1.5 mg/kg in mice infected with L1210 leukemia cells,Other,7328580.0,
289,97547,3,5,,103176321,5746,Unspecified,,,,,Average change in weight between treated and control groups at 3 mg/kg in mice infected with L1210 leukemia cells,Other,7328580.0,
290,97549,3,5,,103176321,5746,Unspecified,,,,,Average change in weight between treated and control groups at 6 mg/kg in mice infected with L1210 leukemia cells,Other,7328580.0,
291,98094,3,5,,103176321,5746,Unspecified,,,,,Maximum % T/C against L-1210 leukemia cells in mice.,Other,6827524.0,
292,98095,3,4,,103176321,5746,Unspecified,,,,,Median survival time against L1210 murine leukemia at 1.5 mg/kg in mice when compared with control,Other,7328580.0,
293,98096,3,4,,103176321,5746,Unspecified,,,,,Median survival time against L1210 murine leukemia at 12 mg/kg in mice when compared with control,Other,7328580.0,
294,98099,3,4,,103176321,5746,Unspecified,,,,,Median survival time against L1210 murine leukemia at 3 mg/kg in mice when compared with control,Other,7328580.0,
295,98100,3,4,,103176321,5746,Unspecified,,,,,Median survival time against L1210 murine leukemia at 6 mg/kg in mice when compared with control,Other,7328580.0,
296,98416,3,5,,103176321,5746,Unspecified,,,,,Minimum effective dose required for antitumor activity against L-1210 leukemia cells in mice.,Other,6827524.0,
297,98653,3,5,,103176321,5746,Unspecified,,,,,Optimal dose required for antitumor activity L-1210 leukemia cells in mice.,Other,6827524.0,
298,98721,6,3,,103176321,5746,Active,,,0.6,IC50,In vitro antitumor activity against murine lymphoma L1210 cells by MTT assay.,Confirmatory,,
299,98742,6,3,,103176321,5746,Active,,,0.6,IC50,In vitro cytotoxicity determined against murine leukemia L1210 cells by MTT assay,Confirmatory,,
300,99173,3,4,,103176321,5746,Unspecified,,,,,Cross resistance profile versus L1210/R71 cells.,Other,2362268.0,
301,101082,6,2,,103176321,5746,Active,,,1.5,IC50,Inhibitory concentration on multidrug-resistant L1210 leukemia cells.,Confirmatory,1906107.0,
302,101083,6,2,,103176321,5746,Active,,,0.09,IC50,Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.,Confirmatory,1906107.0,
303,101097,8,1,,103176321,5746,Active,,,3.1,ID50,"Inhibition of L1210 leukemia cells, after exposure to compound for period of 1 hr",Confirmatory,3397995.0,
304,101212,8,1,,103176321,5746,Active,,,0.18,ID50,"Inhibition of L1210 leukemia cells, after exposure to compound for period of 8-9 hr",Confirmatory,3397995.0,
305,101236,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -5)M conc",Other,3397995.0,
306,101237,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -6)M conc",Other,3397995.0,
307,101238,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -7)Mconc",Other,3397995.0,
308,101239,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 5*(10e -5)M conc",Other,3397995.0,
309,101240,3,6,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -6)M conc",Other,3397995.0,
310,101241,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -7)M conc",Other,3397995.0,
311,101242,3,5,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -8)Mconc",Other,3397995.0,
312,101243,3,6,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -9)M conc",Other,3397995.0,
313,101244,3,6,,103176321,5746,Unspecified,,,,,"The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 5*(10e -8)M conc",Other,3397995.0,
314,102508,6,3,,103176321,5746,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against Lu-99 human pulmonary large cell carcinoma,Other,,
315,103358,6,2,,103176321,5746,Unspecified,,,,,in vitro inhibition of tumor cell growth in cultured MCF-7 human tumor cell line,Other,11585450.0,
316,103403,6,2,,103176321,5746,Unspecified,,,,,"In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay",Other,12620075.0,
317,103424,8,1,,103176321,5746,Active,,,42.92,ID50,Antiproliferative activity of compound was evaluated on MCF-7 cells from human breast adenocarcinoma,Confirmatory,11012027.0,
318,104106,6,2,,103176321,5746,Active,,,0.27,IC50,In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
319,109892,3,3,,103176321,5746,Unspecified,,,,,Half-wave potential produced by the compound at their optimal dose,Other,7328599.0,
320,109973,6,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.,Other,10509925.0,
321,109974,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 20.9/25.7,Other,10509925.0,
322,109975,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 21.4/23.5,Other,10509925.0,
323,109976,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.; 19.3/17,Other,10509925.0,
324,109988,6,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.,Other,10509925.0,
325,109989,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 21.3/21.4,Other,10509925.0,
326,109990,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 22.2/21.25,Other,10509925.0,
327,109991,5,2,,103176321,5746,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx9) administered i.p.,Other,10509925.0,
328,110913,3,3,,103176321,5746,Unspecified,,,,,Degree of leukopenia produced by compound is assessed form Percent change in white cells on day 3,Other,7328599.0,
329,111110,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 3",Other,7328599.0,
330,111111,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 5",Other,7328599.0,
331,111112,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 7",Other,7328599.0,
332,111250,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 3",Other,7328599.0,
333,111251,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 5",Other,7328599.0,
334,111252,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 7",Other,7328599.0,
335,111268,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 5",Other,7328599.0,
336,111269,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 7",Other,7328599.0,
337,111270,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 3",Other,7328599.0,
338,111420,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 3",Other,7328599.0,
339,111421,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 5",Other,7328599.0,
340,111422,3,3,,103176321,5746,Unspecified,,,,,"Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 7",Other,7328599.0,
341,111747,3,3,,103176321,5746,Unspecified,,,,,Percentage change in WBC at optimum dose on day 3,Other,6425501.0,
342,112163,6,3,,103176321,5746,Unspecified,,,,,Effective dose that gave 50 percent inhibition of sarcoma 180 tumor growth in ddY mice,Other,8021919.0,
343,112165,6,2,,103176321,5746,Unspecified,,,,,Effective dose that gave 50% inhibition of tumor growth was calculated towards sarcoma 180 cells which were inoculated subcutaneously to the axillary region of ddY mice; 1.9-3.7,Other,8021918.0,
344,112764,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 (adriamycin sensitive tumors) in terms of % increase in life span in mice at an optimal dose of 3.0 ug/kg administered ip,Other,2985784.0,
345,112767,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388/ADR (adriamycin resistant tumors) in terms of % increase in life span in mice at an optimal dose of 3.0 ug/kg administered ip,Other,2985784.0,
346,113333,7,2,,103176321,5746,Unspecified,,,,,50% inhibition of solid tumor growth (Sarcoma 180 cells) in mice,Other,7636865.0,
347,114879,4,3,,103176321,5746,Unspecified,,,,,In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 2.0 mg/kg (Q2dx10) administered i.p.,Other,10509925.0,
348,115601,3,5,,103176321,5746,Unspecified,,,,,"Antitumor activity against P-388 leukemia in mice, activity is expressed as Minimum effective dose",Other,3091833.0,
349,115614,3,4,,103176321,5746,Unspecified,,,,,Minimum effective dose against P388 leukemic cells,Other,6425501.0,
350,115629,3,3,,103176321,5746,Unspecified,,,,,"Minimum effective dose that show activity against P-388 murine leukemia cells in CDF1 female mice, after intraperitoneal administration (optimal dose is 3.2 mg/kg)",Other,7328599.0,
351,115705,4,2,,103176321,5746,Unspecified,,,,,Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/10,Other,10509925.0,
352,115706,4,2,,103176321,5746,Unspecified,,,,,Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.; 10/10,Other,10509925.0,
353,115830,5,2,,103176321,5746,Unspecified,,,,,Inhibitory activity against human lung adenocarcinoma xenograft LAX-83 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.,Other,10509925.0,
354,115831,4,2,,103176321,5746,Unspecified,,,,,Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/10,Other,10509925.0,
355,115832,5,2,,103176321,5746,Unspecified,,,,,Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.,Other,10509925.0,
356,115833,4,2,,103176321,5746,Unspecified,,,,,Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 10/10,Other,10509925.0,
357,115834,4,2,,103176321,5746,Unspecified,,,,,Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 22.2/21.25,Other,10509925.0,
358,115835,4,2,,103176321,5746,Unspecified,,,,,Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx9) administered i.p.,Other,10509925.0,
359,117203,2,6,,103176321,5746,Unspecified,,,,,In vivo antineoplastic activity against Ehrlich ascites carcinoma (EAC) cells in mice at 1 mg/kg body weight upon intraperitoneal administration,Other,,
360,117205,2,5,,103176321,5746,Unspecified,,,,,In vivo antineoplastic activity against Ehrlich ascites carcinoma fluid in mice at 1 mg/kg body weight upon intraperitoneal administration,Other,,
361,117388,4,3,,103176321,5746,Unspecified,,,,,In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 2.0 mg/kg (Q2dx10) administered i.p.,Other,10509925.0,
362,117389,3,3,,103176321,5746,Unspecified,,,,,In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 2.0 mg/kg (Q2dx9) administered i.p.,Other,10509925.0,
363,119952,3,4,,103176321,5746,Unspecified,,,,,"Compound was tested for antitumor activity against P-388 leukemia in mice, activity is expressed as Optimal dose; 3.2-4.8",Other,3091833.0,
364,119960,3,6,,103176321,5746,Unspecified,,,,,Optimal dose against sarcoma 180 tumor in ddY mice,Other,8021919.0,
365,119965,3,4,,103176321,5746,Unspecified,,,,,Optimal dose was calculated towards sarcoma 180 cells which were inoculated subcutaneously to the axillary region of ddY mice; 4.0-6.0,Other,8021918.0,
366,119966,4,4,,103176321,5746,Unspecified,,,,,Optimal dose was measured against sarcoma 180 cell in mice,Other,7636865.0,
367,119971,3,5,,103176321,5746,Unspecified,,,,,Optimum dose (mg/kg) against P388 leukemic cells,Other,6425501.0,
368,120317,3,4,,103176321,5746,Unspecified,,,,,"Number of cured survivors, 45 days after administration of compound at a dose of 1 mg/kg/day in mice",Other,7328599.0,
369,120660,3,4,,103176321,5746,Unspecified,,,,,"Number of tumored survivors, 45 days after administration of compound at a dose of 1 mg/kg/day in mice",Other,7328599.0,
370,120665,3,4,,103176321,5746,Unspecified,,,,,"Number of tumored survivors, 45 days after administration of compound at a dose of 8 mg/kg/day in mice",Other,7328599.0,
371,120835,3,3,,103176321,5746,Unspecified,,,,,"Compound was tested for antitumor activity against P-388 leukemia in mice, activity is expressed as maximum effect (% T/C) = MST(median survival time) treated/ MST control in the presence of compound only; 132->344",Other,3091833.0,
372,120904,4,3,,103176321,5746,Unspecified,,,,,T/C value was measured as tumor volume in the treated versus control mice.,Other,7636865.0,
373,121171,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
374,121172,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 1 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
375,121174,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
376,121175,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
377,121386,3,5,,103176321,5746,Unspecified,,,,,Treated versus control value of tumor volume was measured in ddY mice,Other,8021919.0,
378,121516,3,3,,103176321,5746,Unspecified,,,,,Tumor volume was calculated against sarcoma 180 cells which were inoculated intravenously to the axillary region of ddY mice; 0.28-0.46,Other,8021918.0,
379,121603,3,3,,103176321,5746,Unspecified,,,,,Activity of compound dose of 0.5 mg/kg/day against Murine B-16 Melanocarcinoma in mice,Other,7328599.0,
380,121604,3,3,,103176321,5746,Unspecified,,,,,Activity of compound dose of 1 mg/kg/day against Murine B-16 Melanocarcinoma in mice,Other,7328599.0,
381,121615,3,3,,103176321,5746,Unspecified,,,,,Activity of compound dose of 4 mg/kg/day against Murine B-16 Melanocarcinoma in mice,Other,7328599.0,
382,121619,3,3,,103176321,5746,Unspecified,,,,,Activity of compound dose of 8 mg/kg/day against Murine B-16 Melanocarcinoma in mice,Other,7328599.0,
383,121921,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P-388 murine leukemia cells in CDF1 female mice after intraperitoneal administration at the specified optimal dose of 3.2 mg/kg,Other,7328599.0,
384,122182,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 5 mg/kg (on day 7, 11,15) in subcutaneously infected BDF1 mice on day 16",Other,,
385,122183,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 5 mg/kg (on day 7, 11,15) in subcutaneously infected BDF1 mice on day 9",Other,,
386,122184,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 10,Other,,
387,122185,3,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 100 ug/kg(on day 1) in subcutaneously infected BDF1 mice on day 12,Other,,
388,122186,3,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 100 ug/kg(on day 1) in subcutaneously infected BDF1 mice on day 20,Other,,
389,122187,3,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intraperitoneally at dose 100 ug/kg(on day 1) in subcutaneously infected BDF1 mice on day 13,Other,,
390,122306,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 14,Other,,
391,122307,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 18,Other,,
392,122308,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 20,Other,,
393,122309,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 11,Other,,
394,122310,2,4,,103176321,5746,Unspecified,,,,,Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1) in subcutaneously infected BDF1 mice on day 22,Other,,
395,122311,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1,5,9) in subcutaneously infected BDF1 mice on day 8",Other,,
396,122312,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1,5,9) in subcutaneously infected BDF1 mice on day 12",Other,,
397,122313,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 1,5,9) in subcutaneously infected BDF1 mice on day 20",Other,,
398,122314,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 10, 14, 18 ) in subcutaneously infected BDF1 mice on day 12",Other,,
399,122315,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 10, 14, 18 ) in subcutaneously infected BDF1 mice on day 16",Other,,
400,122316,4,3,,103176321,5746,Inconclusive,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day 10, 14, 18 ) in subcutaneously infected BDF1 mice on day 8; Not measured",Other,,
401,122317,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day1,5,9) in subcutaneously infected BDF1 mice on day 16",Other,,
402,122318,2,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 5 mg/kg (on day10, 14, 18 ) in subcutaneously infected BDF1 mice on day 20",Other,,
403,122330,3,4,,103176321,5746,Unspecified,,,,,"Percent of tumor growth inhibition ratio (TGIR)of the compound administered intravenously at dose 100 ug/kg(on day 7, 11,15) in subcutaneously infected BDF1 mice on day 16",Other,,
404,122441,3,4,,103176321,5746,Unspecified,,,,,Maximum percent T/C (antitumor activity) against P388 leukemia cells for the compound; 144-325,Other,6425501.0,
405,122585,3,3,,103176321,5746,Unspecified,,,,,Activity of compound dose of 2 mg/kg/day against Murine B-16 Melanocarcinoma in mice,Other,7328599.0,
406,123448,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
407,123449,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.",Other,8709111.0,
408,123450,4,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.",Other,8709111.0,
409,123451,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 2.0 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.",Other,8709111.0,
410,123452,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.",Other,8709111.0,
411,123453,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.",Other,8709111.0,
412,123455,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
413,123456,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
414,123457,4,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
415,123458,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 2.0 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
416,123573,6,1,,103176321,5746,Unspecified,,,,,"In vivo antitumor activity (reduction of tumor volume) was determined against lewis lung carcinoma, subcutaneously in mice at a dose of 1.65 mg/kg",Other,15109660.0,
417,123575,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
418,123576,3,4,,103176321,5746,Unspecified,,,,,"Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average weight change was reported.",Other,8709111.0,
419,123581,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice aat a dose 1 mg/kg day, ip,on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
420,123585,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
421,123586,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
422,123592,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell",Other,6425501.0,
423,123685,6,1,,103176321,5746,Unspecified,,,,,"In vivo antitumor activity (reduction of tumor volume) was determined against lewis lung carcinoma, subcutaneously in mice at a dose of 3.3 mg/kg",Other,15109660.0,
424,123709,4,3,,103176321,5746,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.,Other,10509925.0,
425,123710,3,3,,103176321,5746,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/10,Other,10509925.0,
426,123711,3,3,,103176321,5746,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.,Other,10509925.0,
427,123717,4,3,,103176321,5746,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.,Other,10509925.0,
428,124395,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 62",Other,6425501.0,
429,124397,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 1 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 62",Other,6425501.0,
430,124399,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 62",Other,6425501.0,
431,124403,3,3,,103176321,5746,Unspecified,,,,,"Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 62",Other,6425501.0,
432,125425,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against moser human colon carcinoma cell line,Other,2754710.0,
433,125493,8,1,,103176321,5746,Active,,,2.66,ID50,Antiproliferative activity of compound was evaluated on Molt3 cells from human lymphoblastic leukemia,Confirmatory,11012027.0,
434,128414,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.2 mg/kg per injection.,Other,3925147.0,
435,128415,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.4 mg/Kg per injection.,Other,3925147.0,
436,128416,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.8 mg/kg per injection.,Other,3925147.0,
437,128417,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 1.6 mg/kg per injection.,Other,3925147.0,
438,128420,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 3.2 mg/kg per injection.,Other,3925147.0,
439,128421,3,4,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 4.8 mg/kg per injection.,Other,3925147.0,
440,128585,3,3,,103176321,5746,Unspecified,,,,,Body wieght treated/body weight untreated controls of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 12,Other,2500528.0,
441,128586,3,3,,103176321,5746,Unspecified,,,,,Body wieght treated/body weight untreated controls of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 4,Other,2500528.0,
442,128587,3,3,,103176321,5746,Unspecified,,,,,Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 14 in nude mice,Other,2500528.0,
443,128588,3,3,,103176321,5746,Unspecified,,,,,Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 28 in nude mice,Other,2500528.0,
444,128727,3,3,,103176321,5746,Unspecified,,,,,Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 21 in nude mice,Other,2500528.0,
445,128732,3,3,,103176321,5746,Unspecified,,,,,Percent change in body weight [(day 6 - day 1)/ day 1] when P388 Leukemic CD2 mice were treated with a compound (6 mg/Kg),Other,2500528.0,
446,128737,3,3,,103176321,5746,Unspecified,,,,,Percentage change in body weight [(day 6 - day 1)/ day 1] for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg,Other,2500528.0,
447,128741,3,3,,103176321,5746,Unspecified,,,,,Percentage change in body weight [(day 6 - day 1)/ day 1] for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg,Other,2500528.0,
448,128822,6,2,,103176321,5746,Unspecified,,,,,Anti cancer activity was determined as effective dose,Other,8496913.0,
449,130503,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity against P388 leukemia cells (ip)in mice and maximal increase in life span calculated as (T/C-1)*100 at the optimal dose of 4.0-6.0 mg/kg,Other,1495011.0,
450,131323,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity against lymphatic leukemia P388 cells resistant to mitomycin C (MMC) was measured as maximal increase in life span of the treated mice at optimal dose of 1.0-4.0 mg/kg,Other,8021918.0,
451,131333,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity against lymphatic leukemia P388 cells sensitive to mitomycin C (MMC) was measured as maximal increase in life span of the treated mice at optimal dose of 1.0-6.0 mg/kg; 38-84,Other,8021918.0,
452,132316,3,3,,103176321,5746,Unspecified,,,,,Percent inhibition of compound (50 mg/Kg) was evaluated in vivo for antitumor activity against MAC 13 in female NMRI mice on day 29,Other,2500528.0,
453,132317,3,3,,103176321,5746,Unspecified,,,,,Percent inhibition of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 13 in female NMRI mice on day 2,Other,2500528.0,
454,133089,3,3,,103176321,5746,Unspecified,,,,,Minimum effective dose (MED) of compound against P388 Leukemia in mice was determined,Other,3397999.0,
455,133590,6,1,,103176321,5746,Unspecified,,,,,Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at a single dose treatment of 6 mg/kg,Other,2500528.0,
456,133594,6,1,,103176321,5746,Unspecified,,,,,Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg,Other,2500528.0,
457,133598,6,1,,103176321,5746,Unspecified,,,,,Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg,Other,2500528.0,
458,134403,6,2,,103176321,5746,Unspecified,,,,,Anti cancer activity was determined as lethal dose,Other,8496913.0,
459,134539,3,3,,103176321,5746,Unspecified,,,,,In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14),Other,11311054.0,
460,136706,3,3,,103176321,5746,Unspecified,,,,,Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 14 in nude mice,Other,2500528.0,
461,136707,3,3,,103176321,5746,Unspecified,,,,,Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 21 in nude mice,Other,2500528.0,
462,136708,3,3,,103176321,5746,Unspecified,,,,,Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 28 in nude mice,Other,2500528.0,
463,136797,3,3,,103176321,5746,Unspecified,,,,,Relative tumor size on day 28 was reported when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 in nude mice,Other,2500528.0,
464,137200,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.2 mg/Kg per injection.,Other,3925147.0,
465,137201,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.4 mg/Kg per injection.,Other,3925147.0,
466,137202,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.8 mg/Kg per injection.,Other,3925147.0,
467,137203,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 1.6 mg/Kg per injection.,Other,3925147.0,
468,137205,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 3.2 mg/Kg per injection.,Other,3925147.0,
469,137206,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 4.8 mg/Kg per injection.,Other,3925147.0,
470,137385,3,3,,103176321,5746,Unspecified,,,,,Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at a single dose treatment of 6 mg/kg,Other,2500528.0,
471,137389,3,3,,103176321,5746,Unspecified,,,,,Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg,Other,2500528.0,
472,137393,3,3,,103176321,5746,Unspecified,,,,,Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg,Other,2500528.0,
473,138038,3,3,,103176321,5746,Unspecified,,,,,Compound (40 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 12 and ratio of tumor weight of treated to that of control was determined,Other,2500528.0,
474,138039,3,3,,103176321,5746,Unspecified,,,,,Compound (40 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 29 and ratio of tumor weight of treated to that of control was determined,Other,2500528.0,
475,138043,3,3,,103176321,5746,Unspecified,,,,,Compound (6 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 2 and ratio of tumor weight of treated to that of control was determined,Other,2500528.0,
476,138044,3,3,,103176321,5746,Unspecified,,,,,Compound (6 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 4 and ratio of tumor weight of treated to that of control was determined,Other,2500528.0,
477,138874,3,4,,103176321,5746,Unspecified,,,,,Average weight change of BDF1 female mice at a dose of 1.5 mg/kg per injection,Other,3761307.0,
478,138876,3,4,,103176321,5746,Unspecified,,,,,Average weight change of BDF1 female mice at a dose of 12 mg/kg per injection,Other,3761307.0,
479,138881,3,4,,103176321,5746,Unspecified,,,,,Average weight change of BDF1 female mice at a dose of 3 mg/kg per injection,Other,3761307.0,
480,138887,3,4,,103176321,5746,Unspecified,,,,,Average weight change of BDF1 female mice at a dose of 6 mg/kg per injection,Other,3761307.0,
481,138973,3,3,,103176321,5746,Unspecified,,,,,In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14),Other,11311054.0,
482,139404,4,2,,103176321,5746,Unspecified,,,,,Compound (0.05 ug/mL) was evaluated in vitro for antitumor activity against human tumor xenografts in nude mice; Value expressed as active /total = 42/104,Other,2500528.0,
483,139765,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14); 8/8,Other,11311054.0,
484,144114,6,2,,103176321,5746,Active,,,1.7,IC50,Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay,Confirmatory,11855992.0,
485,144115,3,4,,103176321,5746,Unspecified,,,,,Maximal percent of fibroblast cell growth inhibition using antiproliferative assay,Other,11855992.0,
486,150189,3,4,,103176321,5746,Unspecified,,,,,Leukopenia % change in WBC at optimal dose on 3rd day.,Other,6620304.0,
487,150218,3,5,,103176321,5746,Unspecified,,,,,Optimal dose required for antitumor activity against P-388 murine leukemia cells in mice.,Other,6620304.0,
488,150952,6,2,,103176321,5746,Unspecified,,,,,"In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay",Other,12620075.0,
489,152272,6,2,,103176321,5746,Unspecified,,,,,In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.,Other,9873721.0,
490,152274,5,3,,103176321,5746,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells,Other,,
491,152723,3,6,,103176321,5746,Unspecified,,,,,"Antitumor activity against P388/ADR (adriamycin resistant), in male BDF1 mice measured as % increase in life span (%ILS) at dose 1.0-5.0 mg/Kg/inj, ip",Other,3351854.0,
492,152724,3,6,,103176321,5746,Unspecified,,,,,"Antitumor activity against P388/S (AMD sensitive) in male BDF1 mice measured as % increase in life span (%ILS) at dose 1.0-5.0 mg/Kg/inj, ip",Other,3351854.0,
493,153213,4,4,,103176321,5746,Active,,,0.0508,IC50,Antitumor potency on P388 leukemia cells in culture,Confirmatory,1906109.0,
494,153389,4,4,,103176321,5746,Active,,,0.535,IC50,Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells,Confirmatory,8544183.0,
495,153525,3,4,,103176321,5746,Unspecified,,,,,"Antitumor activity against P388/ADR cells in ip implanted CDF1 mice, qd 1-9 measured as optimal dose",Other,3397991.0,
496,153531,3,4,,103176321,5746,Unspecified,,,,,"Antitumor activity measured as %ILS against P388/ADR cells in ip implanted CDF1 mice, qd 1-9",Other,3397991.0,
497,153534,6,1,,103176321,5746,Unspecified,,,,,"Antitumor activity measured as Median survival time in days against P388/ADR cells in ip implanted CDF1 mice, qd 1-9",Other,3397991.0,
498,153918,3,5,,103176321,5746,Unspecified,,,,,Maximum % T/C against P-388 murine leukemia cells in mice.,Other,6827524.0,
499,153919,3,5,,103176321,5746,Unspecified,,,,,Maximum % T/C against P-388 murine leukemia cells in mice.,Other,6620304.0,
500,153920,3,5,,103176321,5746,Unspecified,,,,,Maximum % T/C with mitomycin C against P-388 murine leukemia cells in mice.,Other,6827524.0,
501,153986,4,4,,103176321,5746,Active,,,0.048,IC50,Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells,Confirmatory,8544183.0,
502,154360,3,4,,103176321,5746,Unspecified,,,,,Leukopenia % change in WBC at optimal dose on 3rd day.,Other,6827524.0,
503,154375,3,5,,103176321,5746,Unspecified,,,,,Optimal dose required for antitumor activity against P-388 murine leukemia cells in mice.,Other,6827524.0,
504,154486,3,4,,103176321,5746,Unspecified,,,,,Minimum effective dose required for antitumor activity against P-388 murine leukemia cells,Other,6827524.0,
505,154487,3,5,,103176321,5746,Unspecified,,,,,Minimum effective dose required for antitumor activity against P-388 murine leukemia cells in mice.,Other,6620304.0,
506,156010,6,2,,103176321,5746,Unspecified,,,,,in vitro inhibition of tumor cell growth in cultured PC-3 human tumor cell line,Other,11585450.0,
507,200824,6,2,,103176321,5746,Unspecified,,,,,In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.,Other,9873721.0,
508,201876,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against SW1271 human lung carcinoma cell line,Other,2754710.0,
509,202213,4,4,,103176321,5746,Active,,,0.006999999999999999,IC50,In vitro inhibition of SW480 colon cancer cell line,Confirmatory,1920349.0,
510,202378,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against SW900 human lung carcinoma cell line,Other,2754710.0,
511,202508,6,2,,103176321,5746,Active,,,0.18,IC50,In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
512,202676,6,2,,103176321,5746,Active,,,0.993,IC50,Inhibition of cell growth was studied in human mammary adenocarcinoma (SKBR-3).,Confirmatory,8709111.0,
513,209162,8,1,,103176321,5746,Active,,,0.7,ID50,Antiproliferative activity of compound was evaluated on SupT1 cells from human non-Hodgkin lymphoma,Confirmatory,11012027.0,
514,210114,6,2,,103176321,5746,Active,,,0.4,IC50,In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
515,210134,7,1,,103176321,5746,Unspecified,,,,,"Concentration of compound required for cross linking 50% T-7 DNA, Acid",Other,15163210.0,
516,210136,7,1,,103176321,5746,Active,,,,,"Concentration of compound required for cross linking 50% of T-7 DNA, Na2S2O4",Other,15163210.0,
517,212880,3,4,,103176321,5746,Unspecified,,,,,Hypoxic cytotoxic ratios of the concentration required to kill 50% of the aerobic cells and concentration required to kill hypoxic cells,Other,9240349.0,
518,214043,6,2,,103176321,5746,Unspecified,,,,,in vitro anticancer activity against cultured U87MG (glioblastoma) human tumor cell line,Other,11585450.0,
519,216602,4,1,,103176321,5746,Unspecified,,,,,In vitro antitumor activity against WiDr colon carcinoma tumor cell line was determined,Other,2500528.0,
520,216610,4,4,,103176321,5746,Active,,,0.01,IC50,In vitro inhibition of WiDr colon cancer cell line,Confirmatory,1920349.0,
521,216747,6,2,,103176321,5746,Active,,,0.8,IC50,Inhibitory concentration required to kill 50% of the cells was evaluated under aerobic conditions from chinese hamster V79 cells.,Confirmatory,7966141.0,
522,216748,6,2,,103176321,5746,Active,,,0.4,IC50,Inhibitory concentration required to kill 50% of the cells was evaluated under anaerobic (N2) conditions from chinese hamster V79 cells.,Confirmatory,7966141.0,
523,217040,7,1,,103176321,5746,Active,,,,,In vitro concentration required to kill 50% of the aerobic cells,Other,9240349.0,
524,217041,7,1,,103176321,5746,Active,,,,,In vitro concentration required to kill hypoxic cells V79-379A cells,Other,9240349.0,
525,221155,6,2,,103176321,5746,Unspecified,,,,,in vitro inhibition of tumor cell growth in cultured HepG2 human tumor cell line,Other,11585450.0,
526,222136,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against human colon CX-1 tumor Xenografts in Athymic mice at a dose of 9180 micro g/kg,Other,11311062.0,
527,222600,6,4,,103176321,5746,Active,,,0.09,IC50,Compound was evaluated for the inhibition of cell proliferation of human ocular lens epithelium (CECH).,Confirmatory,,
528,227069,4,4,,103176321,5746,Unspecified,,,,,Inhibition of HeLa S3 cell growth relative to mitomycin C action (ratio of IC50 values),Other,7636865.0,
529,228639,7,1,,103176321,5746,Unspecified,,,,,"Concentration of compound required for cross linking 5% of tyrT DNA, Na2S2O4",Other,15163210.0,
530,228640,7,1,,103176321,5746,Unspecified,,,,,"Concentration of compound required for cross linking 50% of tyrT DNA, Na2S2O4",Other,15163210.0,
531,228641,7,1,,103176321,5746,Active,,,,,"Concentration of compound required for cross linking 50% of tyrT DNA, acid; undetectable",Other,15163210.0,
532,228712,3,3,,103176321,5746,Unspecified,,,,,E1/2 value related to the saturated calomal electrode.,Other,6620304.0,
533,228938,3,3,,103176321,5746,Unspecified,,,,,Mean IC50 for all seven tumor cell lines was determined,Other,11585450.0,
534,229265,4,3,,103176321,5746,Unspecified,,,,,Ratio of IC50 for Parental L1210 to that of multidrug resistant L1210.,Other,1906107.0,
535,229557,3,4,,103176321,5746,Unspecified,,,,,Ratio of IC50 against chinese hamster V79 cells in aerobic and anaerobic conditions,Other,7966141.0,
536,229741,3,3,,103176321,5746,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (EM-9) of compound for repair deffective mutants,Other,2909741.0,
537,229742,3,3,,103176321,5746,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-4) of compound for repair deffective mutants,Other,2909741.0,
538,229743,3,3,,103176321,5746,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-5) of compound for repair deffective mutants,Other,2909741.0,
539,231332,3,4,,103176321,5746,Unspecified,,,,,Ratio of toxicity in areobic conditions to hypoxic condition of EMT6 cells,Other,7452674.0,
540,231378,3,3,,103176321,5746,Unspecified,,,,,"Ratio value, Optimal dose / Minimum effective dose",Other,3091833.0,
541,232291,3,5,,103176321,5746,Unspecified,,,,,"Cytotoxicity ratio for Human hepatocellular carcinoma, HepG2 (ATCC HB 8065) cells",Other,,
542,234588,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity (reduction of tumor volume) was determined over treated/control mice at a dose of 1.65 mg/kg,Other,15109660.0,
543,234591,3,4,,103176321,5746,Unspecified,,,,,In vivo antitumor activity (reduction of tumor volume) was determined over treated/control mice at a dose of 3.3 mg/kg,Other,15109660.0,
544,235400,3,3,,103176321,5746,Unspecified,,,,,Therapeutic ratio is expressed as ratio of optimal dose and minimum effective dose,Other,7328599.0,
545,235401,3,4,,103176321,5746,Unspecified,,,,,Therapeutic ratio as optimal dose/minimal effective dose,Other,6827524.0,
546,235769,3,5,,103176321,5746,Unspecified,,,,,Ratio of optimal dose (OD) and minimum effective dose (MED) required for antitumor activity in mice bearing P-388 lymphocytic leukemia,Other,6425501.0,
547,248198,4,4,,103176321,5746,Active,,,0.251,IC50,Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 4th hour; n=1,Confirmatory,15743178.0,
548,248241,4,4,,103176321,5746,Active,,,0.04,IC50,Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 96th hour; n=14,Confirmatory,15743178.0,
549,248288,4,3,,103176321,5746,Active,,,0.525,IC50,Inhibitory concentration againstHuman Karpas 299 Anaplastic Large Cell Lymphoma (CD30+) at 4th hour; n=1,Confirmatory,15743178.0,
550,248344,4,3,,103176321,5746,Active,,,0.133,IC50,Inhibitory concentration againstHuman Karpas 299 Anaplastic Large Cell Lymphoma (CD30+) at 96th hour; n=39,Confirmatory,15743178.0,
551,261768,7,1,,103176321,5746,Active,,,,,Cytotoxicity against HCT15 cell line by SRB assay,Other,16384701.0,
552,263756,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against human Bcap37 cell line by MTT assay,Other,16455245.0,
553,263757,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against human RKO cell line by MTT assay,Other,16455245.0,
554,263758,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against human SMMC7721 cell line by MTT assay,Other,16455245.0,
555,263759,6,2,,103176321,5746,Unspecified,,,,,Antitumor activity against human K562 cell line by MTT assay,Other,16455245.0,
556,288804,3,3,,103176321,5746,Unspecified,,,,,Growth inhibition of Streptomyces 85E at 20 ug/disk by hyphae formation inhibition assay,Other,17506585.0,
557,300327,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against mouse P388 cells by MTT assay,Other,17576066.0,
558,303269,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs,Other,17950603.0,
559,303270,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DU145 cells at 10 uM after 48 hrs,Other,17950603.0,
560,303271,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human SW620 cells at 10 uM after 48 hrs,Other,17950603.0,
561,303272,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human 502713 cells at 10 uM after 48 hrs,Other,17950603.0,
562,303273,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HT29 cells at 10 uM after 48 hrs,Other,17950603.0,
563,303285,6,2,,103176321,5746,Active,,,0.14,EC50,Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
564,303286,6,2,,103176321,5746,Active,,,0.43,EC50,Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
565,303287,6,2,,103176321,5746,Active,,,0.96,EC50,Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
566,303288,6,3,,103176321,5746,Active,,,0.93,EC50,Cytotoxicity against human Fb cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
567,303289,6,3,,103176321,5746,Active,,,1.46,EC50,Cytotoxicity against human Hc cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
568,303290,6,3,,103176321,5746,Active,,,2.1,EC50,Cytotoxicity against human MPC5 cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
569,303291,6,3,,103176321,5746,Active,,,1.46,EC50,Cytotoxicity against human IE cells assessed as cell viability by tryptan blue staining method,Confirmatory,17950604.0,
570,320487,6,2,,103176321,5746,Active,,,0.2,IC50,Cytotoxicity against human MCF7 cells by Alamar blue assay,Confirmatory,18037301.0,
571,320488,6,2,,103176321,5746,Active,,,0.4,IC50,Cytotoxicity against human A549 cells by Alamar blue assay,Confirmatory,18037301.0,
572,320490,6,2,,103176321,5746,Active,,,5.0,IC50,Cytotoxicity against human MCF7 cells after 24 hrs,Confirmatory,18037301.0,
573,320491,6,2,,103176321,5746,Active,,,1.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,18037301.0,
574,320494,6,2,,103176321,5746,Active,,,4.5,IC50,Cytotoxicity against human A549 cells after 24 hrs,Confirmatory,18037301.0,
575,320495,6,2,,103176321,5746,Active,,,0.24,IC50,Cytotoxicity against human A549 cells after 72 hrs,Confirmatory,18037301.0,
576,335109,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay,Other,8254344.0,
577,337075,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against mouse L1210 cells,Other,12662110.0,
578,337076,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,12662110.0,
579,337077,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,12662110.0,
580,337078,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells,Other,12662110.0,
581,338960,8,1,,103176321,5746,Active,,,0.068,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay,Confirmatory,11975488.0,
582,338961,4,4,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against rat XC cells assessed as inhibition of colony formation after 5 to 8 days by colony assay,Confirmatory,11975488.0,
583,338962,4,4,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells assessed as inhibition of colony formation after 5 to 8 days by colony assay,Confirmatory,11975488.0,
584,338963,4,4,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against MDCK cells assessed as inhibition of colony formation after 5 to 8 days by colony assay,Confirmatory,11975488.0,
585,354538,3,4,,103176321,5746,Inactive,,,,,Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Other,8988604.0,
586,354542,3,4,,103176321,5746,Inactive,,,,,Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs,Other,8988604.0,
587,354543,3,4,,103176321,5746,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
588,355578,9,1,,103176321,5746,Active,,,0.099,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
589,355580,3,5,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
590,355581,3,5,,103176321,5746,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
591,355582,3,5,,103176321,5746,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
592,355583,9,1,,103176321,5746,Active,,,3.0,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
593,355584,3,5,,103176321,5746,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
594,355585,3,5,,103176321,5746,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
595,355586,3,5,,103176321,5746,Inactive,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
596,356086,8,1,,103176321,5746,Active,,,20.2,ED50,Cytotoxicity against human SCL cells by MTT assay,Confirmatory,12880314.0,
597,356087,8,1,,103176321,5746,Active,,,20.7,ED50,Cytotoxicity against human SCL6 cells by MTT assay,Confirmatory,12880314.0,
598,356088,8,1,,103176321,5746,Active,,,19.0,ED50,Cytotoxicity against human SCL37'6 cells by MTT assay,Confirmatory,12880314.0,
599,356089,8,1,,103176321,5746,Active,,,17.4,ED50,Cytotoxicity against human SCL9 cells by MTT assay,Confirmatory,12880314.0,
600,356090,8,1,,103176321,5746,Active,,,49.0,ED50,Cytotoxicity against human KATO III cells by MTT assay,Confirmatory,12880314.0,
601,356091,8,1,,103176321,5746,Active,,,19.1,ED50,Cytotoxicity against human NUGC4 cells by MTT assay,Confirmatory,12880314.0,
602,356956,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs by methylene blue assay,Other,12502326.0,
603,356957,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HEPA 59T/VGH cells after 72 hrs by methylene blue assay,Other,12502326.0,
604,357025,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs by methylene blue assay,Other,11473432.0,
605,357026,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HepA cells after 72 hrs by methylene blue assay,Other,11473432.0,
606,359196,6,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay,Other,11277765.0,
607,359197,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against Aedes albopictus C6/36 cells after 24 hrs by MTT assay,Other,11277765.0,
608,363580,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal breaks in bone marrow cells at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
609,363581,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal fragments in bone marrow cells at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
610,363582,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal centromere/centromeric fusion in bone marrow cells at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
611,363583,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as number of metaphase chromosome telomere/telomeric fusion in bone marrow cells at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
612,363584,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as bone marrow cells with abberation at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
613,363585,3,3,,103176321,5746,Unspecified,,,,,"Clastogenic effect on C57BL mouse assessed as mitotic index in bone marrow cells at 3.5 mg/kg, ip after 24 hrs",Other,17950497.0,
614,364282,6,2,,103176321,5746,Active,,,2.1,IC50,Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol,Confirmatory,18222567.0,
615,364285,6,2,,103176321,5746,Active,,,0.9,IC50,Cytotoxicity against human HT29 cells after 72 hrs by MTT assay,Confirmatory,18222567.0,
616,365412,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
617,365436,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
618,373320,6,2,,103176321,5746,Active,,,0.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay,Confirmatory,18752870.0,
619,373321,6,2,,103176321,5746,Active,,,0.4,IC50,Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay,Confirmatory,18752870.0,
620,376599,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs,Other,16643051.0,
621,376600,8,1,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against human WiDr cells after 72 hrs,Confirmatory,16643051.0,
622,376601,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hepa cells after 72 hrs,Other,16643051.0,
623,380008,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against mouse P388 cells at 0.06 ug/mL after 72 hrs by MTT assay,Other,10785435.0,
624,389699,6,2,,103176321,5746,Active,,,0.083,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay,Confirmatory,18845441.0,
625,389700,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
626,389701,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
627,389702,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
628,389703,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
629,389704,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
630,389705,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
631,389706,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
632,389707,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
633,389708,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
634,389709,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
635,389710,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
636,389711,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
637,389712,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
638,389713,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
639,389714,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
640,389715,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
641,389716,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
642,389717,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
643,389718,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
644,389719,3,4,,103176321,5746,Unspecified,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
645,389720,4,4,,103176321,5746,Inconclusive,,,,,Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
646,389721,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs by flow cytometry,Other,18845441.0,
647,389722,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs of drug washout by flow cytometry,Other,18845441.0,
648,389723,3,4,,103176321,5746,Unspecified,,,,,Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 48 hrs of drug washout by flow cytometry,Other,18845441.0,
649,393856,3,4,,103176321,5746,Unspecified,,,,,Anticancer activity against mouse EAC cells xenografted in Swiss albino mouse assessed as inhibition of ascitic fluid weight at 1 mg/kg,Other,18456372.0,
650,393857,3,4,,103176321,5746,Unspecified,,,,,Anticancer activity against mouse EAC cells xenografted in Swiss albino mouse assessed as inhibition of ascitic cell count at 1 mg/kg,Other,18456372.0,
651,397759,6,3,,103176321,5746,Active,,,0.034,GI50,Cytotoxicity against human breast cancer cells,Confirmatory,11473418.0,
652,397760,6,3,,103176321,5746,Active,,,0.064,GI50,Cytotoxicity against human CNS cancer cells,Confirmatory,11473418.0,
653,397761,6,3,,103176321,5746,Active,,,0.18,GI50,Cytotoxicity against human colon cancer cells,Confirmatory,11473418.0,
654,397762,6,3,,103176321,5746,Active,,,0.023,GI50,Cytotoxicity against human lung cancer cells,Confirmatory,11473418.0,
655,397763,6,3,,103176321,5746,Active,,,0.12,GI50,Cytotoxicity against human ovarian cancer cells,Confirmatory,11473418.0,
656,397764,6,3,,103176321,5746,Active,,,0.1,GI50,Cytotoxicity against human stomach cancer cells,Confirmatory,11473418.0,
657,399041,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by methylene blue staining,Other,16309320.0,
658,399042,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining,Other,16309320.0,
659,399043,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human medulloblastoma cells after 3 days by methylene blue staining,Other,16309320.0,
660,401262,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against mouse P388 cells at 0.06 ug/mL,Other,15104507.0,
661,401378,6,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days by methylene blue assay,Other,9644081.0,
662,401379,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay,Other,9644081.0,
663,402670,6,2,,103176321,5746,Active,,,0.3,IC50,Cytotoxicity against human A549 cells after 3 days by SRB assay,Confirmatory,16038545.0,
664,402671,6,2,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human MCF7 cells after 3 days by SRB assay,Confirmatory,16038545.0,
665,402673,6,2,,103176321,5746,Active,,,0.6,IC50,Cytotoxicity against human KB cells after 3 days by SRB assay,Confirmatory,16038545.0,
666,402675,6,2,,103176321,5746,Active,,,0.6,IC50,Cytotoxicity against human HCT8 cells after 3 days by SRB assay,Confirmatory,16038545.0,
667,405950,6,3,,103176321,5746,Active,,,0.005,IC50,Cytotoxicity against BRCA2-deficient Chinese hamster V-C8 mutant cells after 3 days by WST1 cell viability assay,Confirmatory,18505284.0,
668,405951,6,3,,103176321,5746,Active,,,0.4,IC50,Cytotoxicity against BRCA2-proficient Chinese hamster BAC29 mutant cells after 3 days by WST1 cell viability assay,Confirmatory,18505284.0,
669,405952,3,3,,103176321,5746,Unspecified,,,,,Selectivity ratio for IC50 of BRCA2-deficient Chinese hamster V-C8 mutant cells to IC50 of BRCA2-proficient Chinese hamster BAC29 mutant cells,Other,18505284.0,
670,409523,8,1,,103176321,5746,Active,,,0.21,ED50,Cytotoxicity against human Daoy cells by MTT assay,Confirmatory,19061391.0,
671,409524,8,1,,103176321,5746,Active,,,0.18,ED50,Cytotoxicity against human WiDr cells by MTT assay,Confirmatory,19061391.0,
672,418210,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay,Other,19201604.0,
673,418211,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay,Other,19201604.0,
674,418212,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human SW620 cells after 48 hrs by SRB assay,Other,19201604.0,
675,418216,3,4,,103176321,5746,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay,Other,19201604.0,
676,426845,3,3,,103176321,5746,Unspecified,,,,,Induction of DNA interstrand cross-linking in human H1299 cells at 100 uM under aerobic condition for 1 hr followed by irradiated with 20 Gy of X-ray by modified comet assay relative to irradiated untreated control,Other,19576785.0,
677,426952,7,2,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human HL60 cells after 48 hrs by SRB assay,Confirmatory,19432411.0,
678,426953,7,3,,103176321,5746,Active,,,5.4,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay,Confirmatory,19432411.0,
679,426954,7,2,,103176321,5746,Active,,,3.3,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,19432411.0,
680,432750,5,1,,103176321,5746,Unspecified,,,,,Toxicity in ip dosed ddY mouse bearing mouse S180 cells,Other,19540628.0,
681,432751,6,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days,Other,19540628.0,
682,434955,1,2,,57260126,5746,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
683,434959,1,1,,85787782,5746,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
684,434962,1,2,,57260126,5746,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
685,434973,1,3,,57260126,5746,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
686,434989,1,1,,57260126,5746,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
687,435003,1,3,,57260126,5746,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
688,435019,1,1,,57260126,5746,Active,,,40.0,CC50,A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Mycobacterium Tuberculosis,Confirmatory,,
689,435022,2,2,,57260126,5746,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
690,435030,1,2,,57260126,5746,Active,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
691,435030,1,2,,57260126,5746,Active,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
692,442341,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human Hep2 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
693,442342,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
694,442343,3,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human 502713 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
695,442344,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
696,442346,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human A549 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
697,442348,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human IMR32 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
698,442550,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
699,442553,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
700,442556,3,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human OVCAR-3 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
701,442567,8,2,,103176321,5746,Active,,,1.5,IC50,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19939522.0,
702,442570,8,3,,103176321,5746,Active,,,1.5,IC50,Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19939522.0,
703,449728,1,2,,57260126,5746,Active,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
704,449762,1,2,,57260126,5746,Active,,,39.58,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
705,449763,1,3,,57260126,5746,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
706,449764,1,1,,57260126,5746,Active,,,74.89,IC50,A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol,Confirmatory,,
707,451329,5,2,,103176321,5746,Active,,,0.14,EC50,Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
708,451330,5,2,,103176321,5746,Active,,,0.43,EC50,Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
709,451331,5,2,,103176321,5746,Active,,,0.96,EC50,Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
710,451332,5,2,,103176321,5746,Active,,,0.93,EC50,Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
711,451333,5,2,,103176321,5746,Active,,,1.46,EC50,Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
712,451334,5,3,,103176321,5746,Active,,,2.1,EC50,Antiproliferative activity against human MPC5 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
713,451335,5,3,,103176321,5746,Active,,,1.46,EC50,Antiproliferative activity against human IE cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
714,451336,5,3,,103176321,5746,Active,,,0.56,EC50,Antiproliferative activity against human Hs888Lu cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
715,451337,5,3,,103176321,5746,Active,,,0.96,EC50,Antiproliferative activity against human SVCT-M12 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,19674905.0,
716,459267,5,2,,103176321,5746,Active,,,0.47,IC50,Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
717,459268,5,2,,103176321,5746,Inconclusive,,,,IC50,Growth inhibition of human HL60 cells after 72 hrs by MTT assay,Confirmatory,20117936.0,
718,459269,5,2,,103176321,5746,Active,,,2.75,IC50,Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
719,459270,5,2,,103176321,5746,Inconclusive,,,,IC50,Growth inhibition of human Raji cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
720,459271,5,2,,103176321,5746,Inconclusive,,,,IC50,Growth inhibition of human Jurkat cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
721,459272,5,2,,103176321,5746,Active,,,0.45,IC50,Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
722,459273,5,2,,103176321,5746,Active,,,4.03,IC50,Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay,Confirmatory,20117936.0,
723,461532,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,20144547.0,
724,461533,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human WiDr cells by MTT assay,Other,20144547.0,
725,461534,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep2 cells by MTT assay,Other,20144547.0,
726,461535,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DaOY cells by MTT assay,Other,20144547.0,
727,463079,1,2,,57260126,5746,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
728,463082,1,1,,57260126,5746,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
729,463104,1,2,,57260126,5746,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
730,463141,1,2,,57260126,5746,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
731,463190,1,2,,57260126,5746,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
732,463195,1,2,,57260126,5746,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
733,463210,1,2,,57260126,5746,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
734,463212,1,1,,57260126,5746,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
735,463254,1,1,,57260126,5746,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
736,465496,3,4,,103176321,5746,Unspecified,,,,,Mutagenic activity in Salmonella Typhimurium TA102 assessed as increase in number of revertants at 0.002 ug/plate by Ames test absence of S9 fraction (Rvb=290+/-10),Other,20055434.0,
737,466462,6,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay,Other,20149652.0,
738,473259,3,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human PC3 cells assessed as cell growth inhibition at 10 uM after 48 hrs by SRB assay,Other,20188544.0,
739,473422,3,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human SF295 cells assessed as cell growth inhibition at 10 uM after 48 hrs by SRB assay,Other,20188544.0,
740,477295,3,3,,103176321,5746,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
741,478238,5,3,,103176321,5746,Active,,,0.9,IC50,Cytotoxicity against human GM00637 cells after 24 hrs by MTT assay,Confirmatory,20122765.0,
742,478476,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against ip dosed mouse EAC implanted in Swiss albino mouse assessed as inhibition of ascitic fluid administered daily for 7 days measured on 9th day relative to control,Other,20133022.0,
743,478477,3,3,,103176321,5746,Unspecified,,,,,Antitumor activity against ip dosed mouse EAC implanted in Swiss albino mouse assessed as inhibition of ascitic cell administered daily for 7 days measured on 9th day relative to control,Other,20133022.0,
744,485270,1,1,,57260126,5746,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
745,485272,1,1,,57260126,5746,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
746,485273,2,1,,57260126,5746,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
747,485275,1,3,,57260126,5746,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
748,485294,1,1,,57260126,5746,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
749,485297,1,1,,57260126,5746,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
750,485298,1,1,,57260126,5746,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
751,485313,1,2,,57260126,5746,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
752,485317,1,2,,57260126,5746,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
753,485341,1,1,,57260126,5746,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
754,485344,1,1,,57260126,5746,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
755,485346,1,1,,57260126,5746,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
756,485346,1,1,,57260126,5746,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
757,485347,1,2,,57260126,5746,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
758,485349,1,1,,57260126,5746,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
759,485350,1,2,,99301072,5746,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
760,485358,1,1,,57260126,5746,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
761,485360,1,1,,57260126,5746,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
762,485364,1,1,,57260126,5746,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
763,485367,1,2,,57260126,5746,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
764,488837,1,1,,57260126,5746,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
765,488839,1,1,,57260126,5746,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
766,488839,1,1,,57260126,5746,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
767,488847,1,3,,57260126,5746,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
768,488862,1,1,,57260126,5746,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
769,488890,1,2,,57260126,5746,Inconclusive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
770,488895,1,2,,57260126,5746,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
771,488896,1,1,,57260126,5746,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
772,488899,1,1,,57260126,5746,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
773,488942,1,1,,57260126,5746,Active,15645703.0,899625.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
774,488942,1,1,,57260126,5746,Active,15646160.0,899738.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
775,488955,1,1,,57260126,5746,Active,16130723.0,947287.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
776,488955,1,1,,57260126,5746,Active,16130724.0,947286.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
777,488955,1,1,,57260126,5746,Active,16130726.0,947294.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
778,488956,1,1,,57260126,5746,Active,,,,,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Screening,,
779,488965,1,2,,57260126,5746,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
780,488966,1,1,,57260126,5746,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
781,488975,1,2,,57260126,5746,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
782,488977,1,2,,57260126,5746,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
783,489030,2,1,,57260126,5746,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
784,489031,2,1,,57260126,5746,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
785,492947,1,1,,57260126,5746,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
786,492953,1,1,,57260126,5746,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
787,492956,1,1,,57260126,5746,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
788,492972,1,1,,57260126,5746,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
789,493005,1,1,,57260126,5746,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
790,493008,1,1,,57260126,5746,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
791,493008,1,1,,57260126,5746,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
792,493008,1,1,,57260126,5746,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
793,493008,1,1,,57260126,5746,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
794,493011,1,1,,57260126,5746,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
795,493012,1,1,,57260126,5746,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
796,493014,1,1,,57260126,5746,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
797,493033,1,2,,99301072,5746,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
798,493036,1,2,,57260126,5746,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
799,493056,1,1,,57260126,5746,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
800,493084,1,1,,57260126,5746,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
801,493087,1,1,,57260126,5746,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
802,493091,1,1,,57260126,5746,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
803,493098,1,1,,57260126,5746,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
804,493131,1,1,,57260126,5746,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
805,493160,1,1,,57260126,5746,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
806,493162,1,2,,99302592,5746,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
807,493187,1,2,,57260126,5746,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
808,493244,1,1,,57260126,5746,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
809,493244,1,1,,57260126,5746,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
810,493244,1,1,,57260126,5746,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
811,493244,1,1,,57260126,5746,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
812,504326,1,2,,57260126,5746,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
813,504326,1,2,,57260126,5746,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
814,504327,1,1,,57260126,5746,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
815,504329,1,1,,57260126,5746,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
816,504332,1,1,,57260126,5746,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
817,504333,1,1,,57260126,5746,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
818,504339,1,1,,57260126,5746,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
819,504357,1,1,,57260126,5746,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
820,504357,1,1,,57260126,5746,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
821,504406,1,1,,57260126,5746,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
822,504411,1,1,,57260126,5746,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
823,504414,1,1,,57260126,5746,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
824,504414,1,1,,57260126,5746,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
825,504423,1,1,,57260126,5746,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
826,504441,1,1,,57260126,5746,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
827,504444,1,1,,57260126,5746,Inconclusive,224028257.0,4780.0,3.6626,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
828,504454,1,3,,57260126,5746,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
829,504462,1,1,,57260126,5746,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
830,504466,1,1,,57260126,5746,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
831,504467,1,1,,57260126,5746,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
832,504490,1,2,,57260126,5746,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
833,504523,1,1,,57260126,5746,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
834,504523,1,1,,57260126,5746,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
835,504558,1,1,,57260126,5746,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
836,504577,2,2,,57260126,5746,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
837,504582,2,1,,57260126,5746,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
838,504621,1,1,,57260126,5746,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
839,504634,1,1,,57260126,5746,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
840,504648,1,1,,57260126,5746,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
841,504651,1,1,,57260126,5746,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
842,504652,1,1,,57260126,5746,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
843,504660,1,1,,57260126,5746,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
844,504690,1,3,,57260126,5746,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
845,504692,2,2,,57260126,5746,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
846,504700,1,1,,57260126,5746,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
847,504700,1,1,,57260126,5746,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
848,504706,1,1,,57260126,5746,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
849,504707,1,1,,57260126,5746,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
850,504707,1,1,,57260126,5746,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
851,504720,1,1,,57260126,5746,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
852,504734,1,1,,57260126,5746,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
853,504766,2,1,,57260126,5746,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
854,504775,1,1,,57260126,5746,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
855,504803,1,1,,57260126,5746,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
856,504810,1,2,,57260126,5746,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
857,504812,1,2,,57260126,5746,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
858,504832,1,1,,57260126,5746,Active,,,13.1154,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
859,504834,1,1,,57260126,5746,Active,,,5.2213,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
860,504842,1,1,,57260126,5746,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
861,504845,1,1,,57260126,5746,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
862,504847,1,1,,57260126,5746,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
863,504884,1,2,,57260126,5746,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
864,504891,1,1,,57260126,5746,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
865,504894,1,1,,57260126,5746,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
866,504937,1,2,,57260126,5746,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
867,510379,4,3,,103176321,5746,Active,,,0.46,IC50,Cytotoxicity against human GM00637 cells after 72 hrs by MTT assay,Confirmatory,20605274.0,
868,510380,4,2,,103176321,5746,Active,,,0.27,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,20605274.0,
869,510381,4,2,,103176321,5746,Active,,,0.17,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,20605274.0,
870,537865,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human HeLa cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay,Other,21074431.0,
871,537866,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human HL60 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay,Other,21074431.0,
872,537867,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human ZR-75-1 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay,Other,21074431.0,
873,537868,2,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human COLO205 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay,Other,21074431.0,
874,537869,2,4,,103176321,5746,Unspecified,,,,,Anticancer activity against mouse P388D1 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay,Other,21074431.0,
875,540253,1,1,,57260126,5746,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
876,540253,1,1,,57260126,5746,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
877,540253,1,1,,57260126,5746,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
878,540263,1,1,,57260126,5746,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
879,540263,1,1,,57260126,5746,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
880,540267,1,1,,57260126,5746,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
881,540275,1,1,,57260126,5746,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
882,540277,1,1,,57260126,5746,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
883,540295,1,1,,57260126,5746,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
884,540299,1,2,,99302592,5746,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
885,540303,1,1,,57260126,5746,Inconclusive,6679377.0,18792.0,3.9811,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
886,540303,1,1,,57260126,5746,Inconclusive,7242179.0,18793.0,3.9811,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
887,540303,1,1,,57260126,5746,Inconclusive,257471003.0,18815.0,3.9811,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
888,540308,1,1,,57260126,5746,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
889,540317,1,1,,57260126,5746,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
890,540336,1,1,,57260126,5746,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
891,540336,1,1,,57260126,5746,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
892,540364,1,2,,57260126,5746,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
893,542121,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 15 mins by quantitative PCR method relative to control,Other,19029320.0,
894,542122,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
895,542127,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 15 mins by quantitative PCR method relative to control,Other,19029320.0,
896,542128,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
897,542130,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrA1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
898,542132,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli AB1157 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
899,542134,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB4 gene expression in recA-positive lexA deficient Escherichia coli AB1157 expressing deffective lexA gene at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
900,542136,2,4,,103176321,5746,Unspecified,,,,,Induction of qnrB4 gene expression in recA-positive Escherichia coli DM49 expressing protease-resistant lexA at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control,Other,19029320.0,
901,550001,4,2,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human HL60 by MTT assay,Confirmatory,20968296.0,
902,550002,4,2,,103176321,5746,Active,,,5.4,IC50,Cytotoxicity against human HepG2 by MTT assay,Confirmatory,20968296.0,
903,552864,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DaOY cells after 3 days by MTT assay,Other,21115251.0,
904,552865,6,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 3 days by MTT assay,Other,21115251.0,
905,552866,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Other,21115251.0,
906,552867,5,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days by MTT assay,Other,21115251.0,
907,588211,2,3,,103176321,5746,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
908,588212,2,3,,103176321,5746,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
909,588213,2,3,,103176321,5746,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
910,588334,1,1,,57260126,5746,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
911,588335,1,1,,57260126,5746,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
912,588342,1,1,,57260126,5746,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
913,588352,1,2,,57260126,5746,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
914,588354,1,1,,57260126,5746,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
915,588358,1,2,,57260126,5746,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
916,588391,1,1,,57260126,5746,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
917,588405,1,1,,57260126,5746,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
918,588413,1,2,,57260126,5746,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
919,588436,1,1,,57260126,5746,Active,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
920,588453,1,1,,57260126,5746,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
921,588456,1,1,,57260126,5746,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
922,588458,1,1,,57260126,5746,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
923,588473,1,1,,57260126,5746,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
924,588473,1,1,,57260126,5746,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
925,588475,1,2,,57260126,5746,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
926,588475,1,2,,57260126,5746,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
927,588489,1,1,,57260126,5746,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
928,588492,1,1,,57260126,5746,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
929,588493,1,2,,57260126,5746,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
930,588497,1,2,,57260126,5746,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
931,588497,1,2,,57260126,5746,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
932,588497,1,2,,57260126,5746,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
933,588499,1,3,,57260126,5746,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
934,588499,1,3,,57260126,5746,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
935,588499,1,3,,57260126,5746,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
936,588501,1,2,,57260126,5746,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
937,588501,1,2,,57260126,5746,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
938,588501,1,2,,57260126,5746,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
939,588511,1,2,,57260126,5746,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
940,588519,1,2,,99301072,5746,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
941,588519,1,2,,99302592,5746,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
942,588549,1,1,,57260126,5746,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
943,588579,1,1,,57260126,5746,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
944,588590,1,1,,57260126,5746,Inconclusive,154350220.0,11201.0,89.1251,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
945,588591,1,1,,57260126,5746,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
946,588621,1,1,,57260126,5746,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
947,588627,1,1,,57260126,5746,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
948,588664,1,2,,57260126,5746,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
949,588664,1,2,,57260126,5746,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
950,588674,1,2,,57260126,5746,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
951,588675,1,1,,57260126,5746,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
952,588676,1,1,,57260126,5746,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
953,588689,1,1,,57260126,5746,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
954,588692,2,1,,57260126,5746,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
955,588726,1,2,,57260126,5746,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
956,588727,1,1,,57260126,5746,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
957,588795,1,1,,57260126,5746,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
958,588814,1,3,,57260126,5746,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
959,588819,1,4,,57260126,5746,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
960,588834,2,1,,144205046,5746,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
961,588850,1,1,,57260126,5746,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
962,588852,1,3,,57260126,5746,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
963,588855,1,1,,57260126,5746,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
964,588856,1,1,,57260126,5746,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
965,596548,1,5,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep2 cells assessed as cell growth inhibition at 1 uM after 48 hrs by sulforhodamine B assay,Other,21482109.0,
966,602123,1,1,,57260126,5746,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
967,602141,1,1,,57260126,5746,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
968,602162,1,1,,57260126,5746,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
969,602163,1,1,,57260126,5746,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
970,602179,1,2,,57260126,5746,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
971,602229,1,1,,57260126,5746,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
972,602233,1,1,,57260126,5746,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
973,602244,1,2,,57260126,5746,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
974,602247,1,2,,57260126,5746,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
975,602248,1,2,,57260126,5746,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
976,602250,1,2,,57260126,5746,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
977,602252,1,1,,57260126,5746,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
978,602252,1,1,,57260126,5746,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
979,602261,1,1,,57260126,5746,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
980,602274,1,2,,57260126,5746,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
981,602281,1,1,,57260126,5746,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
982,602281,1,1,,57260126,5746,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
983,602310,1,2,,57260126,5746,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
984,602313,1,1,,57260126,5746,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
985,602314,1,2,,99301072,5746,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
986,602329,1,1,,57260126,5746,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
987,602332,1,1,,57260126,5746,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
988,602340,1,2,,57260126,5746,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
989,602342,2,1,,57260126,5746,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
990,602346,1,1,,57260126,5746,Inconclusive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
991,602363,1,1,,57260126,5746,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
992,602393,1,1,,57260126,5746,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
993,602396,1,2,,57260126,5746,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
994,602399,1,2,,57260126,5746,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
995,602405,1,1,,57260126,5746,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
996,602410,1,1,,57260126,5746,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
997,602429,1,1,,57260126,5746,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
998,602438,1,1,,57260126,5746,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
999,602440,1,1,,57260126,5746,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1000,602449,1,2,,57260126,5746,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1001,602481,1,1,,57260126,5746,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1002,613374,1,5,,103176321,5746,Unspecified,,,,,Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv of Et3P,Other,21658959.0,
1003,613377,1,5,,103176321,5746,Unspecified,,,,,Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv of L-ditiothreitol,Other,21658959.0,
1004,613379,1,5,,103176321,5746,Unspecified,,,,,Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv glutathione,Other,21658959.0,
1005,621741,1,4,,103176321,5746,Unspecified,,,,,"Antitumor activity against mouse EAC cells transplanted in Swiss albino mouse assessed as tumor weight inhibition in ascetic fluid at 1 mg/kg, ip administered qd for 7 days measured on 8th day",Other,21875796.0,
1006,621742,1,4,,103176321,5746,Unspecified,,,,,"Antitumor activity against mouse EAC cells transplanted in Swiss albino mouse assessed as tumor cell inhibition in ascetic fluid at 1 mg/kg, ip administered qd for 7 days measured on 8th day",Other,21875796.0,
1007,623870,1,1,,57260126,5746,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1008,623870,1,1,,57260126,5746,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1009,623877,1,1,,57260126,5746,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1010,623901,1,1,,57260126,5746,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1011,624037,1,3,,57260126,5746,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1012,624038,1,3,,57260126,5746,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1013,624040,1,3,,57260126,5746,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1014,624101,1,2,,85787782,5746,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1015,624125,1,4,,57260126,5746,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1016,624126,1,3,,57260126,5746,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1017,624127,1,2,,57260126,5746,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1018,624136,1,1,,85787782,5746,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
1019,624138,1,1,,85787782,5746,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
1020,624139,1,1,,85787782,5746,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
1021,624141,1,1,,85787782,5746,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
1022,624151,1,1,,85787782,5746,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1023,624156,1,1,,85787782,5746,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1024,624168,1,1,,57260126,5746,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1025,624169,1,1,,57260126,5746,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1026,624170,1,1,,57260126,5746,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1027,624171,1,1,,57260126,5746,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1028,624172,1,1,,57260126,5746,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1029,624173,1,3,,57260126,5746,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1030,624178,1,1,,57260126,5746,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1031,624202,1,1,,57260126,5746,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1032,624204,1,2,,57260126,5746,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1033,624246,1,1,,57260126,5746,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1034,624256,1,2,,57260126,5746,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1035,624263,1,1,,57260126,5746,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1036,624263,1,1,,57260126,5746,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1037,624267,1,2,,57260126,5746,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1038,624267,1,2,,57260126,5746,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1039,624268,1,3,,57260126,5746,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1040,624288,1,1,,57260126,5746,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1041,624296,1,1,,57260126,5746,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1042,624297,1,1,,57260126,5746,Inconclusive,7705682.0,51053.0,10.3225,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1043,624304,1,2,,57260126,5746,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1044,624330,1,2,,57260126,5746,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1045,624349,1,2,,92308792,5746,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1046,624352,1,1,,57260126,5746,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1047,624354,1,1,,57260126,5746,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1048,624377,1,1,,57260126,5746,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1049,624414,1,1,,57260126,5746,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1050,624415,1,2,,57260126,5746,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1051,624416,1,1,,57260126,5746,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1052,624417,1,1,,57260126,5746,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1053,624418,1,1,,57260126,5746,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1054,624463,1,1,,57260126,5746,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1055,624464,1,1,,57260126,5746,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1056,624465,1,1,,57260126,5746,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1057,624466,1,3,,57260126,5746,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1058,624467,1,1,,57260126,5746,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1059,624483,1,1,,57260126,5746,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1060,625144,5,5,,103176321,5746,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1061,625145,4,7,,103176321,5746,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1062,625146,5,5,,103176321,5746,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1063,625147,4,7,,103176321,5746,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1064,625148,4,7,,103176321,5746,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1065,625149,4,7,,103176321,5746,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1066,625150,5,5,,103176321,5746,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1067,625151,4,7,,103176321,5746,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1068,625152,4,7,,103176321,5746,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1069,625153,4,7,,103176321,5746,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1070,625154,4,7,,103176321,5746,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1071,625155,4,7,,103176321,5746,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1072,625156,1,9,,103176321,5746,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1073,625157,6,2,,103176321,5746,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1074,625158,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1075,625159,5,5,,103176321,5746,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1076,625160,1,9,,103176321,5746,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1077,625161,4,7,,103176321,5746,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1078,625162,4,7,,103176321,5746,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1079,625163,4,7,,103176321,5746,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1080,625164,1,6,,103176321,5746,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1081,625165,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1082,625166,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1083,625167,5,5,,103176321,5746,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1084,625168,4,7,,103176321,5746,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1085,625169,1,6,,103176321,5746,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1086,625170,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1087,625171,4,7,,103176321,5746,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1088,625172,4,7,,103176321,5746,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1089,625173,5,5,,103176321,5746,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1090,625174,5,5,,103176321,5746,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1091,625175,5,5,,103176321,5746,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1092,625176,1,9,,103176321,5746,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1093,625177,5,5,,103176321,5746,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1094,625178,5,5,,103176321,5746,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1095,625179,1,9,,103176321,5746,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1096,625180,5,5,,103176321,5746,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1097,625181,5,5,,103176321,5746,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1098,625182,5,5,,103176321,5746,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1099,625183,5,5,,103176321,5746,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1100,625184,5,5,,103176321,5746,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1101,625185,5,5,,103176321,5746,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1102,625186,5,5,,103176321,5746,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1103,625187,5,5,,103176321,5746,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1104,625188,1,9,,103176321,5746,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1105,625189,1,7,,103176321,5746,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1106,625190,4,5,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1107,625191,4,7,,103176321,5746,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1108,625192,4,7,,103176321,5746,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1109,625193,5,5,,103176321,5746,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1110,625194,4,7,,103176321,5746,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1111,625195,4,7,,103176321,5746,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1112,625196,5,6,,103176321,5746,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1113,625197,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1114,625198,4,7,,103176321,5746,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1115,625199,4,7,,103176321,5746,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1116,625200,4,7,,103176321,5746,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1117,625201,4,7,,103176321,5746,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1118,625202,4,7,,103176321,5746,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1119,625203,4,7,,103176321,5746,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1120,625204,4,7,,103176321,5746,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1121,625205,4,7,,103176321,5746,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1122,625206,4,7,,103176321,5746,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1123,625207,4,7,,103176321,5746,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1124,625208,5,5,,103176321,5746,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1125,625209,4,7,,103176321,5746,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1126,625210,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1127,625211,1,6,,103176321,5746,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1128,625212,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1129,625213,4,7,,103176321,5746,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1130,625214,1,9,,103176321,5746,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1131,625215,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1132,625216,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1133,625217,4,7,,103176321,5746,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1134,625218,4,7,,103176321,5746,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1135,625219,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1136,625220,4,7,,103176321,5746,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1137,625221,4,7,,103176321,5746,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1138,625222,4,7,,103176321,5746,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1139,625223,4,7,,103176321,5746,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1140,625224,3,4,,103176321,5746,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1141,625225,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1142,625226,4,7,,103176321,5746,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1143,625227,4,7,,103176321,5746,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1144,625228,4,7,,103176321,5746,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1145,625229,5,5,,103176321,5746,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1146,625230,1,6,,103176321,5746,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1147,625231,4,7,,103176321,5746,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1148,625232,1,9,,103176321,5746,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1149,625233,4,7,,103176321,5746,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1150,625234,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1151,625235,4,7,,103176321,5746,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1152,625236,5,5,,103176321,5746,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1153,625237,4,7,,103176321,5746,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1154,625238,4,7,,103176321,5746,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1155,625239,4,7,,103176321,5746,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1156,625240,1,9,,103176321,5746,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1157,625241,4,7,,103176321,5746,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1158,625242,4,7,,103176321,5746,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1159,625243,5,5,,103176321,5746,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1160,625244,5,5,,103176321,5746,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1161,625245,5,5,,103176321,5746,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1162,625246,1,9,,103176321,5746,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1163,625247,5,5,,103176321,5746,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1164,625248,5,5,,103176321,5746,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1165,625249,5,5,,103176321,5746,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1166,625250,5,5,,103176321,5746,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1167,625251,5,5,,103176321,5746,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1168,625252,4,7,,103176321,5746,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1169,625253,4,7,,103176321,5746,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1170,625254,4,7,,103176321,5746,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1171,625255,4,7,,103176321,5746,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1172,625256,4,7,,103176321,5746,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1173,625257,4,7,,103176321,5746,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1174,625258,4,7,,103176321,5746,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1175,625259,4,7,,103176321,5746,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1176,625260,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1177,625261,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1178,625262,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1179,625263,4,7,,103176321,5746,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1180,625264,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1181,625265,1,6,,103176321,5746,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1182,625266,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1183,625267,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1184,625268,4,2,,103176321,5746,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1185,625268,4,2,,103176321,5746,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1186,625268,4,2,,103176321,5746,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1187,625268,4,2,,103176321,5746,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1188,625269,4,7,,103176321,5746,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1189,625270,4,7,,103176321,5746,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1190,625271,5,5,,103176321,5746,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1191,625272,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1192,625273,4,6,,103176321,5746,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1193,625274,1,6,,103176321,5746,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1194,625275,3,4,,103176321,5746,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1195,625278,1,3,,103176321,5746,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI,Other,21624500.0,
1196,625279,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1197,625280,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1198,625281,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1199,625282,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1200,625283,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1201,625284,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1202,625285,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1203,625286,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1204,625287,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1205,625288,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1206,625289,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1207,625290,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1208,625291,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1209,625292,1,3,,103176321,5746,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1210,633103,3,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human KB cells after 1 to 11 days by MTT assay,Other,22014827.0,
1211,633104,3,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay,Other,22014827.0,
1212,633105,3,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay,Other,22014827.0,
1213,633837,1,5,,103176321,5746,Unspecified,,,,,"Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal aberration at 3.5 mg/kg, ip after 24 hrs",Other,22142614.0,
1214,633838,1,5,,103176321,5746,Unspecified,,,,,"Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal aberration at 3.5 mg/kg, ip after 48 hrs",Other,22142614.0,
1215,633924,1,5,,103176321,5746,Unspecified,,,,,"Induction of mitosis in ICR mouse bone marrow cells assessed as mitotic index at 3.5 mg/kg, ip after 24 hrs",Other,22142614.0,
1216,633925,1,5,,103176321,5746,Unspecified,,,,,"Induction of mitosis in ICR mouse bone marrow cells assessed as mitotic index at 3.5 mg/kg, ip after 48 hrs",Other,22142614.0,
1217,633929,1,5,,103176321,5746,Unspecified,,,,,"Induction of clastogenic effect in ICR mouse bone marrow cells assessed as rearrangement in centromere to centromeric fusion at 3.5 mg/kg, ip after 24 hrs",Other,22142614.0,
1218,633930,1,5,,103176321,5746,Unspecified,,,,,"Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal breaks and fragmentation at 3.5 mg/kg, ip after 24 hrs",Other,22142614.0,
1219,635120,1,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 1 uM after 48 hrs by SRB assay,Other,22071256.0,
1220,635954,1,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human DU145 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
1221,635955,1,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human A549 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
1222,635956,1,5,,103176321,5746,Unspecified,,,,,Growth inhibition of human Hep2 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
1223,638412,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1224,638413,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1225,638414,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1226,638415,1,5,,103176321,5746,Unspecified,,,,,Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1227,638416,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1228,638417,1,4,,103176321,5746,Unspecified,,,,,Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
1229,644104,1,4,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 1 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
1230,644119,1,5,,103176321,5746,Unspecified,,,,,Growth inhibition of human Hep2 cells at 1 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
1231,651550,1,1,,57260126,5746,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1232,651560,1,1,,57260126,5746,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1233,651572,1,2,,57260126,5746,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1234,651582,1,1,,57260126,5746,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1235,651602,1,1,,57260126,5746,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1236,651602,1,1,,57260126,5746,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1237,651602,1,1,,57260126,5746,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1238,651610,2,1,,57260126,5746,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1239,651631,4,1,,144205046,5746,Active,269849759.0,7157.0,1.8834,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1240,651632,4,1,,144205046,5746,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1241,651633,4,1,,144205046,5746,Active,,,23.7101,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1242,651634,4,1,,144205046,5746,Inactive,,,0.3758,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1243,651635,1,3,,57260126,5746,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1244,651636,1,1,,57260126,5746,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1245,651640,1,1,,57260126,5746,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1246,651644,1,1,,57260126,5746,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1247,651647,1,1,,57260126,5746,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1248,651654,1,1,,57260126,5746,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1249,651658,1,1,,57260126,5746,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1250,651661,2,1,,57260126,5746,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1251,651687,1,1,,57260126,5746,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1252,651699,1,1,,57260126,5746,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1253,651699,1,1,,57260126,5746,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1254,651702,1,2,,57260126,5746,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1255,651704,2,1,,57260126,5746,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1256,651710,1,1,,57260126,5746,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1257,651711,2,1,,57260126,5746,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1258,651718,1,2,,57260126,5746,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1259,651723,1,1,,57260126,5746,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1260,651724,1,1,,57260126,5746,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1261,651725,1,1,,57260126,5746,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1262,651768,1,2,,57260126,5746,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1263,651800,1,1,,57260126,5746,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1264,651819,1,1,,57260126,5746,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1265,651820,1,1,,57260126,5746,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1266,651821,2,4,,57260126,5746,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1267,651828,1,2,,92308792,5746,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1268,651957,1,1,,57260126,5746,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1269,651958,1,1,,57260126,5746,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1270,651965,1,1,,57260126,5746,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1271,651999,1,1,,57260126,5746,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1272,652010,1,1,,57260126,5746,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1273,652017,1,1,,57260126,5746,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1274,652025,1,1,,57260126,5746,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1275,652039,1,1,,57260126,5746,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1276,652048,1,2,,57260126,5746,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1277,652048,1,2,,144205046,5746,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1278,652051,1,1,,57260126,5746,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1279,652051,1,1,,144205046,5746,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1280,652054,1,1,,57260126,5746,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1281,652067,1,4,,57260126,5746,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1282,652104,1,1,,57260126,5746,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1283,652105,1,1,,57260126,5746,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1284,652106,1,1,,57260126,5746,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1285,652115,1,1,,57260126,5746,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1286,652126,1,3,,57260126,5746,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1287,652154,1,1,,57260126,5746,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1288,652162,2,1,,57260126,5746,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1289,652163,1,1,,57260126,5746,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1290,652197,1,1,,57260126,5746,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1291,652257,1,1,,57260126,5746,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1292,659404,2,3,,103176321,5746,Active,,,0.46,IC50,Cytotoxicity against human GM00637 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay,Confirmatory,22522008.0,
1293,659405,2,2,,103176321,5746,Active,,,0.27,IC50,Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay,Confirmatory,22522008.0,
1294,659406,2,2,,103176321,5746,Active,,,0.17,IC50,Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay,Confirmatory,22522008.0,
1295,664044,1,4,,103176321,5746,Unspecified,,,,,"Antitumor activity against mouse EAC cells allografted in Swiss albino mouse assessed as decrease in tumor weight at 1 mg/kg, ip administered from day 1 to day 7 every 24 hrs",Other,22541394.0,
1296,664378,1,4,,103176321,5746,Unspecified,,,,,"Antitumor activity against mouse EAC cells allografted in Swiss albino mouse assessed as decrease in tumor cell at 1 mg/kg, ip administered from day 1 to day 7 every 24 hrs",Other,22541394.0,
1297,667183,3,1,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human HeLa cells after 6 days by MTT assay,Other,22672798.0,
1298,667184,3,1,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human Hep2 cells after 6 days by MTT assay,Other,22672798.0,
1299,667185,3,1,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human DaOY cells after 6 days by MTT assay,Other,22672798.0,
1300,667186,3,1,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 6 days by MTT assay,Other,22672798.0,
1301,668096,2,2,,103176321,5746,Active,,,0.1,IC50,Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay,Confirmatory,22537363.0,
1302,669354,2,2,,103176321,5746,Active,,,3.0,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22545792.0,
1303,674743,1,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 1 uM after 48 hrs by SRB assay,Other,22818042.0,
1304,676659,2,2,,103176321,5746,Active,,,1.8,IC50,Cytotoxicity against human HL60 cells after 48 hrs by SRB assay,Confirmatory,22642381.0,
1305,676660,2,3,,103176321,5746,Active,,,5.6,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay,Confirmatory,22642381.0,
1306,676661,2,2,,103176321,5746,Active,,,3.4,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,22642381.0,
1307,678712,1,8,,103176321,5746,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1308,678713,1,8,,103176321,5746,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1309,678714,1,8,,103176321,5746,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1310,678715,1,8,,103176321,5746,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1311,678716,1,8,,103176321,5746,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1312,678717,1,8,,103176321,5746,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1313,678718,1,5,,103176321,5746,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1314,678722,1,5,,103176321,5746,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1315,680289,1,8,,103176321,5746,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Mitomycin C: 20 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
1316,685156,1,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human MCF7 cells at 1 uM after 48 hrs by MTT assay,Other,22982123.0,
1317,685157,1,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human A549 cells at 1 uM after 48 hrs by MTT assay,Other,22982123.0,
1318,685158,1,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 1 uM after 48 hrs by MTT assay,Other,22982123.0,
1319,686940,1,1,,57260126,5746,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1320,686964,1,1,,57260126,5746,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1321,686970,1,2,,57260126,5746,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1322,686971,1,2,,57260126,5746,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1323,686978,1,1,,57260126,5746,Active,79154014.0,55775.0,0.7308,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1324,686978,1,1,,144205046,5746,Active,79154014.0,55775.0,0.0092,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1325,686979,1,1,,57260126,5746,Active,79154014.0,55775.0,0.5805,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1326,686979,1,1,,144205046,5746,Active,79154014.0,55775.0,0.0092,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1327,686992,2,1,,57260126,5746,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1328,686996,1,1,,57260126,5746,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1329,687014,1,1,,57260126,5746,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1330,687016,1,1,,57260126,5746,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1331,693017,1,2,,103176321,5746,Unspecified,,,,,Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 0.08 ug/mL incubated for 3 hrs measured post 21 hrs recovery in absence of rat liver S9 fraction (Rvb = 0.60%),Other,21353728.0,
1332,697852,1,7,,103176321,5746,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1333,697853,1,7,,103176321,5746,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1334,718246,1,2,,103176321,5746,Unspecified,,,,,Downregulation of uPA protein expression in human A549 cell extract at 0.40 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml),Other,23123017.0,
1335,718247,1,2,,103176321,5746,Unspecified,,,,,Downregulation of uPA protein expression in human A549 cell extract at 0.20 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml),Other,23123017.0,
1336,718248,1,2,,103176321,5746,Unspecified,,,,,Downregulation of uPA protein expression in human A549 cell extract at 0.10 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml),Other,23123017.0,
1337,718249,1,2,,103176321,5746,Unspecified,,,,,Downregulation of uPA protein expression in human A549 cell extract at 0.05 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml),Other,23123017.0,
1338,718400,2,2,,103176321,5746,Active,,,0.4,IC50,Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay,Confirmatory,23123017.0,
1339,720504,1,1,,57260126,5746,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1340,720508,1,1,,57260126,5746,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1341,720509,1,1,,57260126,5746,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1342,720511,1,1,,57260126,5746,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1343,720516,2,1,,144205046,5746,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1344,720532,1,1,,144205046,5746,Inconclusive,420597.0,,2.5119,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1345,720533,1,1,,144205046,5746,Inconclusive,,,2.2387,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1346,720542,1,2,,57260126,5746,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1347,720543,1,1,,57260126,5746,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1348,720551,1,2,,57260126,5746,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1349,720552,2,1,,144205046,5746,Active,269849759.0,7157.0,2.81796,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1350,720553,1,2,,57260126,5746,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1351,720579,2,1,,57260126,5746,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1352,720579,2,1,,144205046,5746,Inconclusive,222762.0,3707576.0,0.8913,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1353,720580,1,1,,57260126,5746,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1354,720580,1,1,,144205046,5746,Inconclusive,222762.0,3707576.0,6.3096,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1355,720582,1,1,,57260126,5746,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1356,720596,1,1,,57260126,5746,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1357,720634,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1358,720635,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1359,720637,2,1,,144205046,5746,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1360,720641,1,2,,92308792,5746,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1361,720647,1,2,,57260126,5746,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1362,720648,1,1,,57260126,5746,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1363,720674,2,2,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1364,720675,2,2,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1365,720678,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1366,720679,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1367,720680,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1368,720681,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1369,720682,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1370,720683,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1371,720684,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1372,720685,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1373,720686,2,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1374,720687,2,2,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1375,720691,4,1,,144205046,5746,Inactive,311348376.0,2908.0,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1376,720692,3,1,,144205046,5746,Active,311348376.0,2908.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1377,720693,3,1,,144205046,5746,Active,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1378,720700,1,4,,57260126,5746,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1379,720702,1,1,,57260126,5746,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1380,720704,1,4,,57260126,5746,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1381,720706,1,2,,57260126,5746,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1382,720707,1,2,,57260126,5746,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1383,720708,1,2,,57260126,5746,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1384,720709,1,2,,57260126,5746,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1385,720711,1,2,,57260126,5746,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1386,720717,1,3,,92308792,5746,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1387,720717,1,3,,92310160,5746,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1388,720719,2,1,,144205046,5746,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1389,720725,2,1,,144205046,5746,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1390,730258,1,3,,103176321,5746,Unspecified,,,,,Cytotoxicity against human PC3 cells at 1 uM after 48 hrs by sulforhodamine B assay,Other,23387901.0,
1391,733316,1,3,,103176321,5746,Unspecified,,,,,Growth inhibition of human PC3 cells at 10 uM after 48 hrs by MTT assay,Other,23419739.0,
1392,733835,1,2,,103176321,5746,Active,,,,,Induction of recA promoter in Bacillus subtilis YB3001 using 4-methylumbelliferyl beta D-galactopyranoside as substrate incubated for 3 hrs prior to substrate addition measured after 1 hr by beta galactosidase reporter gene assay relative to control,Other,23534483.0,
1393,734364,2,5,,103176321,5746,Active,123948.0,3620.0,25.0,Ki,Uncompetitive inhibition of hexahistidyl-tagged human IDO1,Confirmatory,23218716.0,
1394,735827,1,3,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay,Other,23451797.0,
1395,735828,1,2,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay,Other,23451797.0,
1396,735829,1,2,,103176321,5746,Unspecified,,,,,Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay,Other,23451797.0,
1397,741697,1,3,,103176321,5746,Active,,,1.42784,IC50,SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,Confirmatory,,
1398,741698,1,3,,103176321,5746,Active,,,1.46085,IC50,SANGER: Inhibition of human NCI-H1573 cell growth in a cell viability assay.,Confirmatory,,
1399,741699,1,3,,103176321,5746,Active,,,0.90674,IC50,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,Confirmatory,,
1400,741700,1,3,,103176321,5746,Active,,,0.11775999999999999,IC50,SANGER: Inhibition of human NCI-H1618 cell growth in a cell viability assay.,Confirmatory,,
1401,741701,1,3,,103176321,5746,Active,,,1.0142799999999998,IC50,SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.,Confirmatory,,
1402,741702,1,3,,103176321,5746,Active,,,0.5230100000000001,IC50,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,Confirmatory,,
1403,741703,1,3,,103176321,5746,Active,,,0.28257,IC50,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,Confirmatory,,
1404,741704,1,3,,103176321,5746,Active,,,0.00499,IC50,SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.,Confirmatory,,
1405,741706,1,3,,103176321,5746,Active,,,0.8996299999999999,IC50,SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.,Confirmatory,,
1406,741707,1,3,,103176321,5746,Active,,,0.41528000000000004,IC50,SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.,Confirmatory,,
1407,741708,1,3,,103176321,5746,Active,,,0.27688,IC50,SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,Confirmatory,,
1408,741709,1,3,,103176321,5746,Active,,,0.13685,IC50,SANGER: Inhibition of human NCI-H1734 cell growth in a cell viability assay.,Confirmatory,,
1409,741710,1,3,,103176321,5746,Active,,,5.43694,IC50,SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.,Confirmatory,,
1410,741711,1,3,,103176321,5746,Active,,,0.34265,IC50,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,Confirmatory,,
1411,741712,1,3,,103176321,5746,Active,,,0.69734,IC50,SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,Confirmatory,,
1412,741713,1,3,,103176321,5746,Active,,,1.81482,IC50,SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.,Confirmatory,,
1413,741714,1,3,,103176321,5746,Active,,,0.40419,IC50,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,Confirmatory,,
1414,741715,1,3,,103176321,5746,Active,,,0.70799,IC50,SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.,Confirmatory,,
1415,741716,1,3,,103176321,5746,Active,,,0.25709,IC50,SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.,Confirmatory,,
1416,741717,1,3,,103176321,5746,Active,,,0.9743700000000001,IC50,SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.,Confirmatory,,
1417,741719,1,3,,103176321,5746,Active,,,22.984,IC50,SANGER: Inhibition of human NCI-H1993 cell growth in a cell viability assay.,Confirmatory,,
1418,741720,1,3,,103176321,5746,Active,,,0.28857,IC50,SANGER: Inhibition of human NCI-H2009 cell growth in a cell viability assay.,Confirmatory,,
1419,741722,1,3,,103176321,5746,Active,,,0.21131999999999998,IC50,SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,Confirmatory,,
1420,741723,1,3,,103176321,5746,Active,,,1.98812,IC50,SANGER: Inhibition of human NCI-H2052 cell growth in a cell viability assay.,Confirmatory,,
1421,741724,1,3,,103176321,5746,Active,,,0.74057,IC50,SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.,Confirmatory,,
1422,741725,1,3,,103176321,5746,Active,,,0.08569,IC50,SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,Confirmatory,,
1423,741726,1,3,,103176321,5746,Active,,,0.00617,IC50,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,Confirmatory,,
1424,741728,1,3,,103176321,5746,Active,,,0.01396,IC50,SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,Confirmatory,,
1425,741729,1,3,,103176321,5746,Active,,,0.2602,IC50,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,Confirmatory,,
1426,741730,1,3,,103176321,5746,Active,,,0.8528100000000001,IC50,SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.,Confirmatory,,
1427,741731,1,3,,103176321,5746,Active,,,0.000151,IC50,SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,Confirmatory,,
1428,741732,1,3,,103176321,5746,Active,,,1.49785,IC50,SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.,Confirmatory,,
1429,741733,1,3,,103176321,5746,Active,,,0.8859999999999999,IC50,SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.,Confirmatory,,
1430,741734,1,3,,103176321,5746,Active,,,6.32364,IC50,SANGER: Inhibition of human NCI-H2227 cell growth in a cell viability assay.,Confirmatory,,
1431,741735,1,3,,103176321,5746,Active,,,0.000796,IC50,SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,Confirmatory,,
1432,741736,1,3,,103176321,5746,Active,,,0.7772100000000001,IC50,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,Confirmatory,,
1433,741738,1,3,,103176321,5746,Active,,,1.20661,IC50,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,Confirmatory,,
1434,741739,1,3,,103176321,5746,Active,,,0.06251,IC50,SANGER: Inhibition of human NCI-H2342 cell growth in a cell viability assay.,Confirmatory,,
1435,741740,1,3,,103176321,5746,Active,,,0.8499700000000001,IC50,SANGER: Inhibition of human NCI-H2347 cell growth in a cell viability assay.,Confirmatory,,
1436,741741,1,3,,103176321,5746,Active,,,0.29434,IC50,SANGER: Inhibition of human NCI-H2405 cell growth in a cell viability assay.,Confirmatory,,
1437,741742,1,3,,103176321,5746,Active,,,8.93628,IC50,SANGER: Inhibition of human NCI-H2452 cell growth in a cell viability assay.,Confirmatory,,
1438,741744,1,3,,103176321,5746,Active,,,2.4352400000000003,IC50,SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,Confirmatory,,
1439,741745,1,3,,103176321,5746,Active,,,0.88441,IC50,SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,Confirmatory,,
1440,741746,1,3,,103176321,5746,Active,,,1.80152,IC50,SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.,Confirmatory,,
1441,741747,1,3,,103176321,5746,Active,,,4.73193,IC50,SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.,Confirmatory,,
1442,741748,1,3,,103176321,5746,Active,,,0.27626,IC50,SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,Confirmatory,,
1443,741750,1,3,,103176321,5746,Active,,,0.0176,IC50,SANGER: Inhibition of human NCI-H441 cell growth in a cell viability assay.,Confirmatory,,
1444,741751,1,3,,103176321,5746,Active,,,12.4227,IC50,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,Confirmatory,,
1445,741752,1,3,,103176321,5746,Active,,,0.00645,IC50,SANGER: Inhibition of human NCI-H460 cell growth in a cell viability assay.,Confirmatory,,
1446,741753,1,3,,103176321,5746,Active,,,0.40281999999999996,IC50,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,Confirmatory,,
1447,741754,1,3,,103176321,5746,Active,,,0.16865,IC50,SANGER: Inhibition of human NCI-H520 cell growth in a cell viability assay.,Confirmatory,,
1448,741755,1,3,,103176321,5746,Active,,,0.16945,IC50,SANGER: Inhibition of human NCI-H522 cell growth in a cell viability assay.,Confirmatory,,
1449,741756,1,3,,103176321,5746,Active,,,2.7032,IC50,SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.,Confirmatory,,
1450,741757,1,3,,103176321,5746,Active,,,0.06737,IC50,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,Confirmatory,,
1451,741758,1,3,,103176321,5746,Active,,,1.5377,IC50,SANGER: Inhibition of human NCI-H596 cell growth in a cell viability assay.,Confirmatory,,
1452,741760,1,3,,103176321,5746,Active,,,1.53444,IC50,SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.,Confirmatory,,
1453,741761,1,3,,103176321,5746,Active,,,0.34407,IC50,SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,Confirmatory,,
1454,741762,1,3,,103176321,5746,Active,,,0.5415800000000001,IC50,SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,Confirmatory,,
1455,741763,1,3,,103176321,5746,Active,,,1.67882,IC50,SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,Confirmatory,,
1456,741764,1,3,,103176321,5746,Active,,,2.82042,IC50,SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.,Confirmatory,,
1457,741765,1,3,,103176321,5746,Active,,,0.03512,IC50,SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.,Confirmatory,,
1458,741766,1,3,,103176321,5746,Active,,,1.54425,IC50,SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.,Confirmatory,,
1459,741767,1,3,,103176321,5746,Active,,,0.2118,IC50,SANGER: Inhibition of human NCI-H727 cell growth in a cell viability assay.,Confirmatory,,
1460,741768,1,3,,103176321,5746,Active,,,0.41158999999999996,IC50,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,Confirmatory,,
1461,741769,1,3,,103176321,5746,Active,,,0.059539999999999996,IC50,SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.,Confirmatory,,
1462,741770,1,3,,103176321,5746,Active,,,0.25161,IC50,SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,Confirmatory,,
1463,741771,1,3,,103176321,5746,Active,,,2.80193,IC50,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,Confirmatory,,
1464,741772,1,3,,103176321,5746,Active,,,1.23291,IC50,SANGER: Inhibition of human NCI-H838 cell growth in a cell viability assay.,Confirmatory,,
1465,741773,1,3,,103176321,5746,Active,,,2.48342,IC50,SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.,Confirmatory,,
1466,741774,1,3,,103176321,5746,Active,,,0.43812,IC50,SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,Confirmatory,,
1467,741775,1,3,,103176321,5746,Active,,,0.15624000000000002,IC50,SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.,Confirmatory,,
1468,741776,1,3,,103176321,5746,Active,,,6.74309,IC50,SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.,Confirmatory,,
1469,741777,1,3,,103176321,5746,Active,,,0.14121,IC50,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,Confirmatory,,
1470,741778,1,3,,103176321,5746,Active,,,0.18677,IC50,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,Confirmatory,,
1471,741779,1,3,,103176321,5746,Active,,,0.13913,IC50,SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.,Confirmatory,,
1472,741780,1,3,,103176321,5746,Active,,,0.00783,IC50,SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.,Confirmatory,,
1473,741781,1,3,,103176321,5746,Active,,,0.21675,IC50,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,Confirmatory,,
1474,741782,1,3,,103176321,5746,Active,,,0.15141,IC50,SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.,Confirmatory,,
1475,741783,1,3,,103176321,5746,Active,,,1.50227,IC50,SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.,Confirmatory,,
1476,741784,1,4,,103176321,5746,Active,,,2.2100000000000002e-05,IC50,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,Confirmatory,,
1477,741785,1,3,,103176321,5746,Active,,,0.01695,IC50,SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,Confirmatory,,
1478,741786,1,3,,103176321,5746,Active,,,0.6573899999999999,IC50,SANGER: Inhibition of human NY cell growth in a cell viability assay.,Confirmatory,,
1479,741787,1,3,,103176321,5746,Active,,,0.44065,IC50,SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,Confirmatory,,
1480,741788,1,3,,103176321,5746,Active,,,0.08942,IC50,SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,Confirmatory,,
1481,741790,1,3,,103176321,5746,Active,,,0.0018899999999999998,IC50,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,Confirmatory,,
1482,741791,1,3,,103176321,5746,Active,,,0.10298,IC50,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,Confirmatory,,
1483,741792,1,3,,103176321,5746,Active,,,0.36496,IC50,SANGER: Inhibition of human OE19 cell growth in a cell viability assay.,Confirmatory,,
1484,741793,1,3,,103176321,5746,Active,,,0.3378,IC50,SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,Confirmatory,,
1485,741794,1,3,,103176321,5746,Active,,,0.38955,IC50,SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.,Confirmatory,,
1486,741795,1,3,,103176321,5746,Active,,,0.32955999999999996,IC50,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,Confirmatory,,
1487,741796,1,3,,103176321,5746,Active,,,6.34857,IC50,SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.,Confirmatory,,
1488,741797,1,3,,103176321,5746,Active,,,0.2637,IC50,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,Confirmatory,,
1489,741798,1,3,,103176321,5746,Active,,,1.1278700000000002,IC50,SANGER: Inhibition of human OVCAR-3 cell growth in a cell viability assay.,Confirmatory,,
1490,741799,1,3,,103176321,5746,Active,,,0.69691,IC50,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,Confirmatory,,
1491,741800,1,3,,103176321,5746,Active,,,0.48711000000000004,IC50,SANGER: Inhibition of human OVCAR-5 cell growth in a cell viability assay.,Confirmatory,,
1492,741801,1,3,,103176321,5746,Active,,,0.17554,IC50,SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,Confirmatory,,
1493,741802,1,3,,103176321,5746,Active,,,0.00479,IC50,SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,Confirmatory,,
1494,741803,1,3,,103176321,5746,Active,,,0.00484,IC50,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,Confirmatory,,
1495,741804,1,3,,103176321,5746,Active,,,3.45775,IC50,SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.,Confirmatory,,
1496,741805,1,3,,103176321,5746,Active,,,0.02351,IC50,SANGER: Inhibition of human PA-1 cell growth in a cell viability assay.,Confirmatory,,
1497,741806,1,3,,103176321,5746,Active,,,0.16716,IC50,SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,Confirmatory,,
1498,741807,1,3,,103176321,5746,Active,,,2.39777,IC50,SANGER: Inhibition of human PANC-08-13 cell growth in a cell viability assay.,Confirmatory,,
1499,741808,1,3,,103176321,5746,Active,,,0.07375,IC50,SANGER: Inhibition of human PANC-10-05 cell growth in a cell viability assay.,Confirmatory,,
1500,741809,1,3,,103176321,5746,Active,,,0.49127,IC50,SANGER: Inhibition of human PC-14 cell growth in a cell viability assay.,Confirmatory,,
1501,741810,1,3,,103176321,5746,Active,,,4.0715900000000005,IC50,SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,Confirmatory,,
1502,741811,1,3,,103176321,5746,Active,,,0.25063,IC50,SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,Confirmatory,,
1503,741812,1,3,,103176321,5746,Active,,,5.88351,IC50,SANGER: Inhibition of human PFSK-1 cell growth in a cell viability assay.,Confirmatory,,
1504,741813,1,3,,103176321,5746,Active,,,4.194459999999999,IC50,SANGER: Inhibition of human PLC-PRF-5 cell growth in a cell viability assay.,Confirmatory,,
1505,741814,1,3,,103176321,5746,Active,,,0.00255,IC50,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,Confirmatory,,
1506,741815,1,3,,103176321,5746,Active,,,0.11957999999999999,IC50,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,Confirmatory,,
1507,741816,1,3,,103176321,5746,Active,,,1.3493600000000001,IC50,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,Confirmatory,,
1508,741817,1,3,,103176321,5746,Active,,,0.8472799999999999,IC50,SANGER: Inhibition of human RCM-1 cell growth in a cell viability assay.,Confirmatory,,
1509,741818,1,3,,103176321,5746,Active,,,1.8984599999999998,IC50,SANGER: Inhibition of human RD cell growth in a cell viability assay.,Confirmatory,,
1510,741819,1,3,,103176321,5746,Active,,,0.00255,IC50,SANGER: Inhibition of human REH cell growth in a cell viability assay.,Confirmatory,,
1511,741820,1,3,,103176321,5746,Active,,,1.03157,IC50,SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,Confirmatory,,
1512,741821,1,3,,103176321,5746,Active,,,0.049569999999999996,IC50,SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.,Confirmatory,,
1513,741823,1,3,,103176321,5746,Active,,,0.12529,IC50,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,Confirmatory,,
1514,741824,1,3,,103176321,5746,Active,,,5.43657,IC50,SANGER: Inhibition of human RL cell growth in a cell viability assay.,Confirmatory,,
1515,741826,1,3,,103176321,5746,Active,,,3.46127,IC50,SANGER: Inhibition of human RMG-I cell growth in a cell viability assay.,Confirmatory,,
1516,741827,1,3,,103176321,5746,Active,,,13.3274,IC50,SANGER: Inhibition of human RO82-W-1 cell growth in a cell viability assay.,Confirmatory,,
1517,741828,1,3,,103176321,5746,Active,,,0.19575,IC50,SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,Confirmatory,,
1518,741829,1,3,,103176321,5746,Active,,,0.21961,IC50,SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,Confirmatory,,
1519,741830,1,3,,103176321,5746,Active,,,0.16755,IC50,SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,Confirmatory,,
1520,741831,1,3,,103176321,5746,Active,,,1.2384700000000002,IC50,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,Confirmatory,,
1521,741832,1,3,,103176321,5746,Active,,,0.017130000000000003,IC50,SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,Confirmatory,,
1522,741833,1,3,,103176321,5746,Active,,,1.31777,IC50,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,Confirmatory,,
1523,741834,1,3,,103176321,5746,Active,,,0.03486,IC50,SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.,Confirmatory,,
1524,741835,1,3,,103176321,5746,Active,,,0.17798,IC50,SANGER: Inhibition of human RT-112 cell growth in a cell viability assay.,Confirmatory,,
1525,741836,1,3,,103176321,5746,Active,,,1.69923,IC50,SANGER: Inhibition of human RT4 cell growth in a cell viability assay.,Confirmatory,,
1526,741837,1,3,,103176321,5746,Active,,,0.62917,IC50,SANGER: Inhibition of human RVH-421 cell growth in a cell viability assay.,Confirmatory,,
1527,741838,1,3,,103176321,5746,Active,,,4.38975,IC50,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,Confirmatory,,
1528,741839,1,3,,103176321,5746,Active,,,1.22094,IC50,SANGER: Inhibition of human Raji cell growth in a cell viability assay.,Confirmatory,,
1529,741840,1,3,,103176321,5746,Active,,,2.54572,IC50,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,Confirmatory,,
1530,741841,1,3,,103176321,5746,Active,,,0.59244,IC50,SANGER: Inhibition of human S-117 cell growth in a cell viability assay.,Confirmatory,,
1531,741842,1,3,,103176321,5746,Active,,,0.61465,IC50,SANGER: Inhibition of human SAS cell growth in a cell viability assay.,Confirmatory,,
1532,741843,1,3,,103176321,5746,Active,,,0.4477,IC50,SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.,Confirmatory,,
1533,741844,1,3,,103176321,5746,Active,,,0.00259,IC50,SANGER: Inhibition of human SBC-5 cell growth in a cell viability assay.,Confirmatory,,
1534,741845,1,3,,103176321,5746,Active,,,0.8638600000000001,IC50,SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.,Confirmatory,,
1535,741846,1,3,,103176321,5746,Active,,,0.87036,IC50,SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,Confirmatory,,
1536,741847,1,3,,103176321,5746,Active,,,0.00852,IC50,SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,Confirmatory,,
1537,741848,1,3,,103176321,5746,Active,,,0.3877,IC50,SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,Confirmatory,,
1538,741849,1,3,,103176321,5746,Active,,,3.7875300000000003,IC50,SANGER: Inhibition of human SCC-9 cell growth in a cell viability assay.,Confirmatory,,
1539,741850,1,3,,103176321,5746,Unspecified,,,1063.77,IC50,SANGER: Inhibition of human SCH cell growth in a cell viability assay.,Confirmatory,,
1540,741851,1,3,,103176321,5746,Active,,,0.9630299999999999,IC50,SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.,Confirmatory,,
1541,741852,1,3,,103176321,5746,Active,,,1.40565,IC50,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,Confirmatory,,
1542,741853,1,3,,103176321,5746,Active,,,0.17085999999999998,IC50,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,Confirmatory,,
1543,741854,1,3,,103176321,5746,Active,,,0.011479999999999999,IC50,SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,Confirmatory,,
1544,741855,1,3,,103176321,5746,Active,,,0.12702,IC50,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,Confirmatory,,
1545,741856,1,3,,103176321,5746,Active,,,0.38726,IC50,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,Confirmatory,,
1546,741857,1,3,,103176321,5746,Active,,,1.3783,IC50,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,Confirmatory,,
1547,741858,1,3,,103176321,5746,Active,,,0.00352,IC50,SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,Confirmatory,,
1548,741859,1,3,,103176321,5746,Active,,,0.24141999999999997,IC50,SANGER: Inhibition of human SIMA cell growth in a cell viability assay.,Confirmatory,,
1549,741860,1,3,,103176321,5746,Active,,,1.6742,IC50,SANGER: Inhibition of human SJRH30 cell growth in a cell viability assay.,Confirmatory,,
1550,741861,1,3,,103176321,5746,Active,,,0.13155999999999998,IC50,SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.,Confirmatory,,
1551,741862,1,3,,103176321,5746,Active,,,0.20181,IC50,SANGER: Inhibition of human SK-CO-1 cell growth in a cell viability assay.,Confirmatory,,
1552,741863,1,3,,103176321,5746,Active,,,0.64566,IC50,SANGER: Inhibition of human SK-HEP-1 cell growth in a cell viability assay.,Confirmatory,,
1553,741864,1,3,,103176321,5746,Active,,,0.43928999999999996,IC50,SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.,Confirmatory,,
1554,741865,1,3,,103176321,5746,Active,,,0.0022199999999999998,IC50,SANGER: Inhibition of human SK-LU-1 cell growth in a cell viability assay.,Confirmatory,,
1555,741866,1,3,,103176321,5746,Active,,,1.88815,IC50,SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.,Confirmatory,,
1556,741867,1,3,,103176321,5746,Active,,,3.97464,IC50,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,Confirmatory,,
1557,741868,1,3,,103176321,5746,Active,,,1.3742299999999998,IC50,SANGER: Inhibition of human SK-MEL-24 cell growth in a cell viability assay.,Confirmatory,,
1558,741869,1,3,,103176321,5746,Active,,,18.9731,IC50,SANGER: Inhibition of human SK-MEL-28 cell growth in a cell viability assay.,Confirmatory,,
1559,741870,1,3,,103176321,5746,Active,,,0.71112,IC50,SANGER: Inhibition of human SK-MEL-3 cell growth in a cell viability assay.,Confirmatory,,
1560,741871,1,3,,103176321,5746,Active,,,0.47431,IC50,SANGER: Inhibition of human SK-MEL-30 cell growth in a cell viability assay.,Confirmatory,,
1561,741873,1,3,,103176321,5746,Active,,,0.05112,IC50,SANGER: Inhibition of human SK-MES-1 cell growth in a cell viability assay.,Confirmatory,,
1562,741875,1,3,,103176321,5746,Active,,,2.71695,IC50,SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.,Confirmatory,,
1563,741876,1,3,,103176321,5746,Active,,,1.79073,IC50,SANGER: Inhibition of human SK-N-AS cell growth in a cell viability assay.,Confirmatory,,
1564,741877,1,3,,103176321,5746,Active,,,2.38958,IC50,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,Confirmatory,,
1565,741878,1,3,,103176321,5746,Active,,,39.7075,IC50,SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.,Confirmatory,,
1566,741879,1,3,,103176321,5746,Active,,,0.16652999999999998,IC50,SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.,Confirmatory,,
1567,741880,1,3,,103176321,5746,Active,,,0.14264000000000002,IC50,SANGER: Inhibition of human SK-OV-3 cell growth in a cell viability assay.,Confirmatory,,
1568,741881,1,3,,103176321,5746,Active,,,0.06376,IC50,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,Confirmatory,,
1569,741882,1,3,,103176321,5746,Active,,,0.0828,IC50,SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.,Confirmatory,,
1570,741883,1,3,,103176321,5746,Active,,,0.37738,IC50,SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,Confirmatory,,
1571,741885,1,3,,103176321,5746,Active,,,3.4617699999999996,IC50,SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,Confirmatory,,
1572,741886,1,3,,103176321,5746,Active,,,0.30346,IC50,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,Confirmatory,,
1573,741887,1,3,,103176321,5746,Active,,,0.13417,IC50,SANGER: Inhibition of human SNG-M cell growth in a cell viability assay.,Confirmatory,,
1574,741888,1,3,,103176321,5746,Active,,,2.93467,IC50,SANGER: Inhibition of human SNU-387 cell growth in a cell viability assay.,Confirmatory,,
1575,741889,1,3,,103176321,5746,Active,,,1.52181,IC50,SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,Confirmatory,,
1576,741890,1,3,,103176321,5746,Active,,,3.3620900000000002,IC50,SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,Confirmatory,,
1577,741891,1,3,,103176321,5746,Active,,,0.81314,IC50,SANGER: Inhibition of human SNU-475 cell growth in a cell viability assay.,Confirmatory,,
1578,741892,1,3,,103176321,5746,Active,,,1.9140000000000001,IC50,SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.,Confirmatory,,
1579,741893,1,3,,103176321,5746,Active,,,0.29505,IC50,SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,Confirmatory,,
1580,741894,1,3,,103176321,5746,Active,,,0.01346,IC50,SANGER: Inhibition of human SR cell growth in a cell viability assay.,Confirmatory,,
1581,741895,1,3,,103176321,5746,Active,,,0.49436,IC50,SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,Confirmatory,,
1582,741896,1,3,,103176321,5746,Active,,,0.00861,IC50,SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.,Confirmatory,,
1583,741897,1,3,,103176321,5746,Active,,,0.1104,IC50,SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.,Confirmatory,,
1584,741898,1,3,,103176321,5746,Active,,,4.66827,IC50,SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,Confirmatory,,
1585,741900,1,3,,103176321,5746,Active,,,0.64249,IC50,SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,Confirmatory,,
1586,741901,1,3,,103176321,5746,Active,,,1.00545,IC50,SANGER: Inhibition of human SW1417 cell growth in a cell viability assay.,Confirmatory,,
1587,741902,1,3,,103176321,5746,Active,,,2.08169,IC50,SANGER: Inhibition of human SW1463 cell growth in a cell viability assay.,Confirmatory,,
1588,741903,1,3,,103176321,5746,Active,,,0.14468,IC50,SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,Confirmatory,,
1589,741904,1,3,,103176321,5746,Active,,,0.07257999999999999,IC50,SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,Confirmatory,,
1590,741905,1,3,,103176321,5746,Active,,,0.03858,IC50,SANGER: Inhibition of human SW1783 cell growth in a cell viability assay.,Confirmatory,,
1591,741906,1,3,,103176321,5746,Active,,,0.63705,IC50,SANGER: Inhibition of human SW1990 cell growth in a cell viability assay.,Confirmatory,,
1592,741907,1,3,,103176321,5746,Active,,,0.19336,IC50,SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,Confirmatory,,
1593,741908,1,3,,103176321,5746,Active,,,0.03979,IC50,SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,Confirmatory,,
1594,741909,1,3,,103176321,5746,Active,,,0.28622,IC50,SANGER: Inhibition of human SW626 cell growth in a cell viability assay.,Confirmatory,,
1595,741910,1,3,,103176321,5746,Unspecified,,,112.568,IC50,SANGER: Inhibition of human SW684 cell growth in a cell viability assay.,Confirmatory,,
1596,741911,1,3,,103176321,5746,Active,,,0.59691,IC50,SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,Confirmatory,,
1597,741912,1,3,,103176321,5746,Unspecified,,,438.75800000000004,IC50,SANGER: Inhibition of human SW780 cell growth in a cell viability assay.,Confirmatory,,
1598,741913,1,3,,103176321,5746,Active,,,0.27613000000000004,IC50,SANGER: Inhibition of human SW837 cell growth in a cell viability assay.,Confirmatory,,
1599,741914,1,3,,103176321,5746,Active,,,0.000676,IC50,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,Confirmatory,,
1600,741916,1,3,,103176321,5746,Active,,,3.7528099999999998,IC50,SANGER: Inhibition of human SW948 cell growth in a cell viability assay.,Confirmatory,,
1601,741917,1,3,,103176321,5746,Active,,,0.044910000000000005,IC50,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,Confirmatory,,
1602,741918,1,3,,103176321,5746,Active,,,0.15755,IC50,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,Confirmatory,,
1603,741919,1,3,,103176321,5746,Active,,,0.10472999999999999,IC50,SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,Confirmatory,,
1604,741920,1,3,,103176321,5746,Active,,,1.40649,IC50,SANGER: Inhibition of human Saos-2 cell growth in a cell viability assay.,Confirmatory,,
1605,741921,1,3,,103176321,5746,Active,,,1.8934,IC50,SANGER: Inhibition of human SiHa cell growth in a cell viability assay.,Confirmatory,,
1606,741922,1,3,,103176321,5746,Active,,,0.24577,IC50,SANGER: Inhibition of human T-24 cell growth in a cell viability assay.,Confirmatory,,
1607,741923,1,3,,103176321,5746,Active,,,6.37191,IC50,SANGER: Inhibition of human T47D cell growth in a cell viability assay.,Confirmatory,,
1608,741924,1,3,,103176321,5746,Active,,,0.17334000000000002,IC50,SANGER: Inhibition of human T84 cell growth in a cell viability assay.,Confirmatory,,
1609,741925,1,3,,103176321,5746,Active,,,0.52375,IC50,SANGER: Inhibition of human T98G cell growth in a cell viability assay.,Confirmatory,,
1610,741926,1,3,,103176321,5746,Active,,,2.3955,IC50,SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.,Confirmatory,,
1611,741928,1,3,,103176321,5746,Active,,,0.4817,IC50,SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,Confirmatory,,
1612,741929,1,3,,103176321,5746,Active,,,0.16538,IC50,SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.,Confirmatory,,
1613,741930,1,3,,103176321,5746,Active,,,0.14407,IC50,SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,Confirmatory,,
1614,741931,1,3,,103176321,5746,Active,,,0.03053,IC50,SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,Confirmatory,,
1615,741932,1,3,,103176321,5746,Active,,,0.03193,IC50,SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,Confirmatory,,
1616,741933,1,3,,103176321,5746,Active,,,0.00176,IC50,SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,Confirmatory,,
1617,741934,1,3,,103176321,5746,Active,,,0.08739,IC50,SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,Confirmatory,,
1618,741935,1,3,,103176321,5746,Active,,,0.000128,IC50,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,Confirmatory,,
1619,741936,1,3,,103176321,5746,Active,,,0.007109999999999999,IC50,SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,Confirmatory,,
1620,741937,1,3,,103176321,5746,Active,,,0.01401,IC50,SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,Confirmatory,,
1621,741938,1,3,,103176321,5746,Active,,,0.10400000000000001,IC50,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,Confirmatory,,
1622,741939,1,3,,103176321,5746,Active,,,0.15575,IC50,SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,Confirmatory,,
1623,741940,1,3,,103176321,5746,Active,,,0.42983000000000005,IC50,SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,Confirmatory,,
1624,741941,1,3,,103176321,5746,Active,,,0.25745,IC50,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,Confirmatory,,
1625,741942,1,3,,103176321,5746,Active,,,0.53752,IC50,SANGER: Inhibition of human A172 cell growth in a cell viability assay.,Confirmatory,,
1626,741943,1,3,,103176321,5746,Active,,,0.08419,IC50,SANGER: Inhibition of human A204 cell growth in a cell viability assay.,Confirmatory,,
1627,741944,1,3,,103176321,5746,Active,,,0.1151,IC50,SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,Confirmatory,,
1628,741945,1,3,,103176321,5746,Active,,,0.34564,IC50,SANGER: Inhibition of human A253 cell growth in a cell viability assay.,Confirmatory,,
1629,741946,1,3,,103176321,5746,Active,,,0.10662999999999999,IC50,SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,Confirmatory,,
1630,741947,1,3,,103176321,5746,Active,,,0.034960000000000005,IC50,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,Confirmatory,,
1631,741948,1,3,,103176321,5746,Active,,,0.13942000000000002,IC50,SANGER: Inhibition of human A375 cell growth in a cell viability assay.,Confirmatory,,
1632,741949,1,3,,103176321,5746,Active,,,0.20722,IC50,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,Confirmatory,,
1633,741950,1,3,,103176321,5746,Active,,,0.22543000000000002,IC50,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,Confirmatory,,
1634,741951,1,3,,103176321,5746,Active,,,0.30133000000000004,IC50,SANGER: Inhibition of human A427 cell growth in a cell viability assay.,Confirmatory,,
1635,741952,1,3,,103176321,5746,Active,,,0.043769999999999996,IC50,SANGER: Inhibition of human A431 cell growth in a cell viability assay.,Confirmatory,,
1636,741953,1,3,,103176321,5746,Unspecified,,,376.968,IC50,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,Confirmatory,,
1637,741955,1,3,,103176321,5746,Active,,,0.7896,IC50,SANGER: Inhibition of human A673 cell growth in a cell viability assay.,Confirmatory,,
1638,741956,1,3,,103176321,5746,Active,,,2.38311,IC50,SANGER: Inhibition of human A704 cell growth in a cell viability assay.,Confirmatory,,
1639,741957,1,3,,103176321,5746,Active,,,0.0612,IC50,SANGER: Inhibition of human ABC-1 cell growth in a cell viability assay.,Confirmatory,,
1640,741958,1,3,,103176321,5746,Active,,,0.07207999999999999,IC50,SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,Confirmatory,,
1641,741959,1,3,,103176321,5746,Active,,,0.12791,IC50,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,Confirmatory,,
1642,741960,1,3,,103176321,5746,Active,,,0.1058,IC50,SANGER: Inhibition of human AGS cell growth in a cell viability assay.,Confirmatory,,
1643,741961,1,3,,103176321,5746,Active,,,0.03098,IC50,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,Confirmatory,,
1644,741962,1,3,,103176321,5746,Active,,,0.22116,IC50,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,Confirmatory,,
1645,741963,1,3,,103176321,5746,Active,,,0.52328,IC50,SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,Confirmatory,,
1646,741964,1,3,,103176321,5746,Active,,,0.24331,IC50,SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,Confirmatory,,
1647,741965,1,3,,103176321,5746,Active,,,0.01739,IC50,SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.,Confirmatory,,
1648,741966,1,3,,103176321,5746,Active,,,0.5009600000000001,IC50,SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,Confirmatory,,
1649,741967,1,3,,103176321,5746,Active,,,2.89855,IC50,SANGER: Inhibition of human AsPC-1 cell growth in a cell viability assay.,Confirmatory,,
1650,741969,1,3,,103176321,5746,Active,,,0.030610000000000002,IC50,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,Confirmatory,,
1651,741970,1,3,,103176321,5746,Active,,,0.35252,IC50,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,Confirmatory,,
1652,741971,1,3,,103176321,5746,Active,,,0.14470999999999998,IC50,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,Confirmatory,,
1653,741972,1,3,,103176321,5746,Active,,,0.08881,IC50,SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.,Confirmatory,,
1654,741973,1,3,,103176321,5746,Active,,,0.21208000000000002,IC50,SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.,Confirmatory,,
1655,741974,1,3,,103176321,5746,Active,,,0.2396,IC50,SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,Confirmatory,,
1656,741975,1,3,,103176321,5746,Active,,,0.000167,IC50,SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.,Confirmatory,,
1657,741976,1,3,,103176321,5746,Active,,,0.93516,IC50,SANGER: Inhibition of human BEN cell growth in a cell viability assay.,Confirmatory,,
1658,741977,1,3,,103176321,5746,Active,,,0.09269,IC50,SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,Confirmatory,,
1659,741978,1,3,,103176321,5746,Active,,,0.08527,IC50,SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,Confirmatory,,
1660,741979,1,3,,103176321,5746,Active,,,1.7402900000000001,IC50,SANGER: Inhibition of human BHT-101 cell growth in a cell viability assay.,Confirmatory,,
1661,741980,1,3,,103176321,5746,Active,,,0.07528,IC50,SANGER: Inhibition of human BHY cell growth in a cell viability assay.,Confirmatory,,
1662,741981,1,3,,103176321,5746,Active,,,0.2949,IC50,SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,Confirmatory,,
1663,741982,1,3,,103176321,5746,Active,,,1.27667,IC50,SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,Confirmatory,,
1664,741983,1,3,,103176321,5746,Active,,,0.10378,IC50,SANGER: Inhibition of human BOKU cell growth in a cell viability assay.,Confirmatory,,
1665,741984,1,3,,103176321,5746,Active,,,0.0299,IC50,SANGER: Inhibition of human BPH-1 cell growth in a cell viability assay.,Confirmatory,,
1666,741985,1,3,,103176321,5746,Active,,,0.31196999999999997,IC50,SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,Confirmatory,,
1667,741986,1,3,,103176321,5746,Active,,,2.6232599999999997,IC50,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,Confirmatory,,
1668,741988,1,3,,103176321,5746,Active,,,0.00607,IC50,SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.,Confirmatory,,
1669,741989,1,3,,103176321,5746,Active,,,0.8623200000000001,IC50,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,Confirmatory,,
1670,741990,1,3,,103176321,5746,Active,,,0.77478,IC50,SANGER: Inhibition of human BxPC-3 cell growth in a cell viability assay.,Confirmatory,,
1671,741991,1,3,,103176321,5746,Active,,,0.48686999999999997,IC50,SANGER: Inhibition of human C-33-A cell growth in a cell viability assay.,Confirmatory,,
1672,741992,1,3,,103176321,5746,Active,,,0.10350999999999999,IC50,SANGER: Inhibition of human C-4-II cell growth in a cell viability assay.,Confirmatory,,
1673,741993,1,3,,103176321,5746,Active,,,9.283999999999999,IC50,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,Confirmatory,,
1674,741994,1,3,,103176321,5746,Active,,,1.52834,IC50,SANGER: Inhibition of human C32 cell growth in a cell viability assay.,Confirmatory,,
1675,741995,1,3,,103176321,5746,Active,,,0.19430999999999998,IC50,SANGER: Inhibition of human C3A cell growth in a cell viability assay.,Confirmatory,,
1676,741996,1,3,,103176321,5746,Active,,,0.93232,IC50,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,Confirmatory,,
1677,741997,1,3,,103176321,5746,Active,,,1.0198,IC50,SANGER: Inhibition of human CA46 cell growth in a cell viability assay.,Confirmatory,,
1678,741998,1,3,,103176321,5746,Active,,,0.02332,IC50,SANGER: Inhibition of human CAKI-1 cell growth in a cell viability assay.,Confirmatory,,
1679,741999,1,3,,103176321,5746,Active,,,5.963509999999999,IC50,SANGER: Inhibition of human CAL-120 cell growth in a cell viability assay.,Confirmatory,,
1680,742000,1,3,,103176321,5746,Active,,,0.49125,IC50,SANGER: Inhibition of human CAL-12T cell growth in a cell viability assay.,Confirmatory,,
1681,742001,1,3,,103176321,5746,Active,,,0.017830000000000002,IC50,SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.,Confirmatory,,
1682,742002,1,3,,103176321,5746,Active,,,0.04118,IC50,SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,Confirmatory,,
1683,742003,1,3,,103176321,5746,Active,,,0.5365300000000001,IC50,SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,Confirmatory,,
1684,742004,1,3,,103176321,5746,Active,,,0.04649,IC50,SANGER: Inhibition of human CAL-39 cell growth in a cell viability assay.,Confirmatory,,
1685,742005,1,3,,103176321,5746,Active,,,0.030860000000000002,IC50,SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,Confirmatory,,
1686,742006,1,3,,103176321,5746,Active,,,1.84148,IC50,SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,Confirmatory,,
1687,742007,1,3,,103176321,5746,Active,,,0.24185,IC50,SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,Confirmatory,,
1688,742008,1,3,,103176321,5746,Active,,,46.7339,IC50,SANGER: Inhibition of human CAL-72 cell growth in a cell viability assay.,Confirmatory,,
1689,742009,1,3,,103176321,5746,Active,,,0.06588,IC50,SANGER: Inhibition of human CAL-85-1 cell growth in a cell viability assay.,Confirmatory,,
1690,742010,1,3,,103176321,5746,Active,,,0.0726,IC50,SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.,Confirmatory,,
1691,742011,1,3,,103176321,5746,Active,,,0.09177,IC50,SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.,Confirmatory,,
1692,742012,1,3,,103176321,5746,Active,,,0.18983,IC50,SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.,Confirmatory,,
1693,742013,1,3,,103176321,5746,Active,,,0.0737,IC50,SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.,Confirmatory,,
1694,742014,1,3,,103176321,5746,Active,,,1.60276,IC50,SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.,Confirmatory,,
1695,742015,1,3,,103176321,5746,Active,,,0.13224,IC50,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,Confirmatory,,
1696,742016,1,3,,103176321,5746,Active,,,0.8936700000000001,IC50,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,Confirmatory,,
1697,742017,1,3,,103176321,5746,Active,,,0.03586,IC50,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,Confirmatory,,
1698,742018,1,3,,103176321,5746,Active,,,0.50049,IC50,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,Confirmatory,,
1699,742020,1,3,,103176321,5746,Active,,,1.21141,IC50,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,Confirmatory,,
1700,742021,1,3,,103176321,5746,Active,,,0.71,IC50,SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,Confirmatory,,
1701,742022,1,3,,103176321,5746,Active,,,2.7580299999999998,IC50,SANGER: Inhibition of human TGW cell growth in a cell viability assay.,Confirmatory,,
1702,742023,1,3,,103176321,5746,Active,,,0.5955,IC50,SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.,Confirmatory,,
1703,742025,1,3,,103176321,5746,Active,,,0.52832,IC50,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,Confirmatory,,
1704,742026,1,3,,103176321,5746,Active,,,3.67775,IC50,SANGER: Inhibition of human TT cell growth in a cell viability assay.,Confirmatory,,
1705,742027,1,3,,103176321,5746,Active,,,0.18967,IC50,SANGER: Inhibition of human TUR cell growth in a cell viability assay.,Confirmatory,,
1706,742028,1,3,,103176321,5746,Active,,,0.05873,IC50,SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,Confirmatory,,
1707,742029,1,3,,103176321,5746,Active,,,3.14284,IC50,SANGER: Inhibition of human U-118-MG cell growth in a cell viability assay.,Confirmatory,,
1708,742030,1,3,,103176321,5746,Active,,,23.6987,IC50,SANGER: Inhibition of human U-2-OS cell growth in a cell viability assay.,Confirmatory,,
1709,742031,1,3,,103176321,5746,Active,,,0.86618,IC50,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,Confirmatory,,
1710,742032,1,3,,103176321,5746,Active,,,1.60291,IC50,SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.,Confirmatory,,
1711,742033,1,3,,103176321,5746,Active,,,1.27372,IC50,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,Confirmatory,,
1712,742034,1,4,,103176321,5746,Active,,,0.3658,IC50,SANGER: Inhibition of human U031 cell growth in a cell viability assay.,Confirmatory,,
1713,742035,1,3,,103176321,5746,Active,,,0.12872999999999998,IC50,SANGER: Inhibition of human U251 cell growth in a cell viability assay.,Confirmatory,,
1714,742036,1,3,,103176321,5746,Active,,,1.56566,IC50,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,Confirmatory,,
1715,742037,1,3,,103176321,5746,Active,,,2.1553299999999997,IC50,SANGER: Inhibition of human UACC-62 cell growth in a cell viability assay.,Confirmatory,,
1716,742038,1,3,,103176321,5746,Active,,,16.8306,IC50,SANGER: Inhibition of human UACC-812 cell growth in a cell viability assay.,Confirmatory,,
1717,742039,1,3,,103176321,5746,Active,,,0.41801000000000005,IC50,SANGER: Inhibition of human UACC-893 cell growth in a cell viability assay.,Confirmatory,,
1718,742040,1,3,,103176321,5746,Active,,,0.10182999999999999,IC50,SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,Confirmatory,,
1719,742041,1,3,,103176321,5746,Active,,,0.56701,IC50,SANGER: Inhibition of human UMC-11 cell growth in a cell viability assay.,Confirmatory,,
1720,742042,1,3,,103176321,5746,Active,,,0.052160000000000005,IC50,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,Confirmatory,,
1721,742043,1,3,,103176321,5746,Active,,,0.26082,IC50,SANGER: Inhibition of human VM-CUB-1 cell growth in a cell viability assay.,Confirmatory,,
1722,742044,1,3,,103176321,5746,Active,,,0.19877,IC50,SANGER: Inhibition of human VMRC-RCZ cell growth in a cell viability assay.,Confirmatory,,
1723,742045,1,3,,103176321,5746,Unspecified,,,84.2377,IC50,SANGER: Inhibition of human WM-115 cell growth in a cell viability assay.,Confirmatory,,
1724,742046,1,3,,103176321,5746,Active,,,0.19204000000000002,IC50,SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.,Confirmatory,,
1725,742047,1,3,,103176321,5746,Active,,,4.36751,IC50,SANGER: Inhibition of human YAPC cell growth in a cell viability assay.,Confirmatory,,
1726,742049,1,3,,103176321,5746,Active,,,0.545,IC50,SANGER: Inhibition of human YKG-1 cell growth in a cell viability assay.,Confirmatory,,
1727,742050,1,3,,103176321,5746,Active,,,0.46333,IC50,SANGER: Inhibition of human YT cell growth in a cell viability assay.,Confirmatory,,
1728,742052,1,3,,103176321,5746,Active,,,0.2996,IC50,SANGER: Inhibition of human no-10 cell growth in a cell viability assay.,Confirmatory,,
1729,742053,1,3,,103176321,5746,Active,,,7.74202,IC50,SANGER: Inhibition of human no-11 cell growth in a cell viability assay.,Confirmatory,,
1730,742054,1,3,,103176321,5746,Active,,,0.54059,IC50,SANGER: Inhibition of human CAMA-1 cell growth in a cell viability assay.,Confirmatory,,
1731,742055,1,3,,103176321,5746,Active,,,0.1164,IC50,SANGER: Inhibition of human CAPAN-1 cell growth in a cell viability assay.,Confirmatory,,
1732,742056,1,3,,103176321,5746,Active,,,3.38185,IC50,SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.,Confirmatory,,
1733,742057,1,3,,103176321,5746,Active,,,0.21559,IC50,SANGER: Inhibition of human CCF-STTG1 cell growth in a cell viability assay.,Confirmatory,,
1734,742058,1,3,,103176321,5746,Active,,,0.06168,IC50,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,Confirmatory,,
1735,742059,1,3,,103176321,5746,Active,,,0.2254,IC50,SANGER: Inhibition of human CESS cell growth in a cell viability assay.,Confirmatory,,
1736,742061,1,3,,103176321,5746,Active,,,0.03874,IC50,SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.,Confirmatory,,
1737,742062,1,3,,103176321,5746,Active,,,0.22516,IC50,SANGER: Inhibition of human CHL-1 cell growth in a cell viability assay.,Confirmatory,,
1738,742063,1,3,,103176321,5746,Active,,,0.07244,IC50,SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.,Confirmatory,,
1739,742065,1,3,,103176321,5746,Active,,,0.004370000000000001,IC50,SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,Confirmatory,,
1740,742066,1,3,,103176321,5746,Active,,,0.00583,IC50,SANGER: Inhibition of human CMK cell growth in a cell viability assay.,Confirmatory,,
1741,742067,1,3,,103176321,5746,Active,,,0.01433,IC50,SANGER: Inhibition of human COLO-205 cell growth in a cell viability assay.,Confirmatory,,
1742,742068,1,3,,103176321,5746,Active,,,1.0792,IC50,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,Confirmatory,,
1743,742069,1,3,,103176321,5746,Active,,,0.00755,IC50,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,Confirmatory,,
1744,742070,1,3,,103176321,5746,Active,,,2.88691,IC50,SANGER: Inhibition of human COLO-678 cell growth in a cell viability assay.,Confirmatory,,
1745,742071,1,3,,103176321,5746,Active,,,0.09025,IC50,SANGER: Inhibition of human COLO-679 cell growth in a cell viability assay.,Confirmatory,,
1746,742072,1,3,,103176321,5746,Active,,,0.2441,IC50,SANGER: Inhibition of human COLO-680N cell growth in a cell viability assay.,Confirmatory,,
1747,742073,1,3,,103176321,5746,Active,,,0.7993,IC50,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,Confirmatory,,
1748,742074,1,3,,103176321,5746,Active,,,2.19928,IC50,SANGER: Inhibition of human COLO-741 cell growth in a cell viability assay.,Confirmatory,,
1749,742075,1,3,,103176321,5746,Active,,,1.50264,IC50,SANGER: Inhibition of human COLO-792 cell growth in a cell viability assay.,Confirmatory,,
1750,742076,1,3,,103176321,5746,Active,,,0.07866000000000001,IC50,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,Confirmatory,,
1751,742077,1,3,,103176321,5746,Active,,,1.44461,IC50,SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.,Confirmatory,,
1752,742078,1,3,,103176321,5746,Active,,,2.08684,IC50,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,Confirmatory,,
1753,742079,1,3,,103176321,5746,Active,,,1.61317,IC50,SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,Confirmatory,,
1754,742080,1,3,,103176321,5746,Active,,,0.24094000000000002,IC50,SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,Confirmatory,,
1755,742081,1,3,,103176321,5746,Active,,,0.00554,IC50,SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,Confirmatory,,
1756,742082,1,3,,103176321,5746,Active,,,0.31914000000000003,IC50,SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.,Confirmatory,,
1757,742083,1,3,,103176321,5746,Active,,,0.78003,IC50,SANGER: Inhibition of human CP50-MEL-B cell growth in a cell viability assay.,Confirmatory,,
1758,742084,1,3,,103176321,5746,Active,,,0.64495,IC50,SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,Confirmatory,,
1759,742086,1,3,,103176321,5746,Active,,,0.38066,IC50,SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.,Confirmatory,,
1760,742088,1,3,,103176321,5746,Active,,,0.30637,IC50,SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.,Confirmatory,,
1761,742089,1,3,,103176321,5746,Active,,,0.01867,IC50,SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.,Confirmatory,,
1762,742090,1,3,,103176321,5746,Active,,,7.727580000000001,IC50,SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.,Confirmatory,,
1763,742091,1,3,,103176321,5746,Active,,,0.05375,IC50,SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,Confirmatory,,
1764,742092,1,3,,103176321,5746,Active,,,0.15557,IC50,SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,Confirmatory,,
1765,742093,1,3,,103176321,5746,Active,,,0.46878000000000003,IC50,SANGER: Inhibition of human CaR-1 cell growth in a cell viability assay.,Confirmatory,,
1766,742094,1,3,,103176321,5746,Active,,,4.8072,IC50,SANGER: Inhibition of human Calu-1 cell growth in a cell viability assay.,Confirmatory,,
1767,742095,1,3,,103176321,5746,Active,,,0.32095,IC50,SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,Confirmatory,,
1768,742096,1,3,,103176321,5746,Active,,,0.31971,IC50,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,Confirmatory,,
1769,742097,1,3,,103176321,5746,Active,,,0.16172,IC50,SANGER: Inhibition of human Caov-3 cell growth in a cell viability assay.,Confirmatory,,
1770,742099,1,3,,103176321,5746,Active,,,2.7852799999999998,IC50,SANGER: Inhibition of human Capan-2 cell growth in a cell viability assay.,Confirmatory,,
1771,742100,1,3,,103176321,5746,Active,,,1.9103299999999999,IC50,SANGER: Inhibition of human ChaGo-K-1 cell growth in a cell viability assay.,Confirmatory,,
1772,742102,1,3,,103176321,5746,Active,,,0.54004,IC50,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,Confirmatory,,
1773,742103,1,4,,103176321,5746,Active,,,0.22069,IC50,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,Confirmatory,,
1774,742105,1,3,,103176321,5746,Active,,,6.68451,IC50,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,Confirmatory,,
1775,742107,1,3,,103176321,5746,Unspecified,,,84.7243,IC50,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,Confirmatory,,
1776,742108,1,3,,103176321,5746,Active,,,0.60165,IC50,SANGER: Inhibition of human D-542MG cell growth in a cell viability assay.,Confirmatory,,
1777,742110,1,3,,103176321,5746,Active,,,0.42995,IC50,SANGER: Inhibition of human DB cell growth in a cell viability assay.,Confirmatory,,
1778,742111,1,3,,103176321,5746,Active,,,0.57026,IC50,SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,Confirmatory,,
1779,742112,1,3,,103176321,5746,Active,,,0.048389999999999996,IC50,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,Confirmatory,,
1780,742113,1,3,,103176321,5746,Active,,,6.2494,IC50,SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.,Confirmatory,,
1781,742114,1,3,,103176321,5746,Active,,,1.03304,IC50,SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.,Confirmatory,,
1782,742115,1,3,,103176321,5746,Active,,,21.666999999999998,IC50,SANGER: Inhibition of human DK-MG cell growth in a cell viability assay.,Confirmatory,,
1783,742116,1,3,,103176321,5746,Active,,,2.08692,IC50,SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.,Confirmatory,,
1784,742117,1,3,,103176321,5746,Active,,,0.42526,IC50,SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.,Confirmatory,,
1785,742118,1,3,,103176321,5746,Active,,,0.16083,IC50,SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,Confirmatory,,
1786,742119,1,3,,103176321,5746,Active,,,0.8085600000000001,IC50,SANGER: Inhibition of human DMS-53 cell growth in a cell viability assay.,Confirmatory,,
1787,742120,1,3,,103176321,5746,Active,,,2.4716299999999998,IC50,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,Confirmatory,,
1788,742121,1,3,,103176321,5746,Active,,,0.09383,IC50,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,Confirmatory,,
1789,742122,1,3,,103176321,5746,Active,,,5.1551,IC50,SANGER: Inhibition of human DOK cell growth in a cell viability assay.,Confirmatory,,
1790,742123,1,3,,103176321,5746,Active,,,0.09652999999999999,IC50,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,Confirmatory,,
1791,742124,1,3,,103176321,5746,Active,,,0.006520000000000001,IC50,SANGER: Inhibition of human DU-145 cell growth in a cell viability assay.,Confirmatory,,
1792,742125,1,3,,103176321,5746,Active,,,0.04747,IC50,SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,Confirmatory,,
1793,742126,1,3,,103176321,5746,Active,,,2.92143,IC50,SANGER: Inhibition of human DV-90 cell growth in a cell viability assay.,Confirmatory,,
1794,742127,1,3,,103176321,5746,Active,,,0.08801,IC50,SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,Confirmatory,,
1795,742128,1,3,,103176321,5746,Active,,,0.39242,IC50,SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,Confirmatory,,
1796,742129,1,3,,103176321,5746,Active,,,0.17026,IC50,SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,Confirmatory,,
1797,742130,1,3,,103176321,5746,Active,,,0.18037,IC50,SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,Confirmatory,,
1798,742131,1,3,,103176321,5746,Active,,,3.19768,IC50,SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.,Confirmatory,,
1799,742132,1,3,,103176321,5746,Active,,,0.06536,IC50,SANGER: Inhibition of human EB2 cell growth in a cell viability assay.,Confirmatory,,
1800,742133,1,3,,103176321,5746,Active,,,14.9132,IC50,SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.,Confirmatory,,
1801,742136,1,3,,103176321,5746,Active,,,5.07036,IC50,SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.,Confirmatory,,
1802,742137,1,3,,103176321,5746,Active,,,1.38125,IC50,SANGER: Inhibition of human EFE-184 cell growth in a cell viability assay.,Confirmatory,,
1803,742138,1,3,,103176321,5746,Active,,,2.0889599999999997,IC50,SANGER: Inhibition of human EFM-19 cell growth in a cell viability assay.,Confirmatory,,
1804,742139,1,3,,103176321,5746,Active,,,0.59114,IC50,SANGER: Inhibition of human EFO-21 cell growth in a cell viability assay.,Confirmatory,,
1805,742140,1,3,,103176321,5746,Active,,,1.1312200000000001,IC50,SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,Confirmatory,,
1806,742141,1,3,,103176321,5746,Active,,,2.39059,IC50,SANGER: Inhibition of human EGI-1 cell growth in a cell viability assay.,Confirmatory,,
1807,742142,1,3,,103176321,5746,Active,,,0.67213,IC50,SANGER: Inhibition of human EHEB cell growth in a cell viability assay.,Confirmatory,,
1808,742143,1,3,,103176321,5746,Active,,,0.893,IC50,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,Confirmatory,,
1809,742144,1,3,,103176321,5746,Active,,,1.0337399999999999,IC50,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,Confirmatory,,
1810,742146,1,3,,103176321,5746,Active,,,0.0072900000000000005,IC50,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,Confirmatory,,
1811,742147,1,3,,103176321,5746,Active,,,0.00788,IC50,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,Confirmatory,,
1812,742148,1,3,,103176321,5746,Active,,,0.00156,IC50,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,Confirmatory,,
1813,742149,1,3,,103176321,5746,Active,,,0.10242000000000001,IC50,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,Confirmatory,,
1814,742150,1,3,,103176321,5746,Active,,,0.74562,IC50,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,Confirmatory,,
1815,742151,1,3,,103176321,5746,Active,,,0.00365,IC50,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,Confirmatory,,
1816,742152,1,3,,103176321,5746,Active,,,0.0017100000000000001,IC50,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,Confirmatory,,
1817,742153,1,3,,103176321,5746,Active,,,0.013919999999999998,IC50,SANGER: Inhibition of human ESS-1 cell growth in a cell viability assay.,Confirmatory,,
1818,742154,1,3,,103176321,5746,Active,,,0.10824,IC50,SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.,Confirmatory,,
1819,742155,1,3,,103176321,5746,Active,,,1.57368,IC50,SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.,Confirmatory,,
1820,742156,1,3,,103176321,5746,Active,,,0.08807000000000001,IC50,SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.,Confirmatory,,
1821,742157,1,3,,103176321,5746,Active,,,0.51336,IC50,SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.,Confirmatory,,
1822,742159,1,3,,103176321,5746,Active,,,0.05251,IC50,SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.,Confirmatory,,
1823,742160,1,3,,103176321,5746,Active,,,0.00031,IC50,SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.,Confirmatory,,
1824,742161,1,3,,103176321,5746,Active,,,3.9388,IC50,SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.,Confirmatory,,
1825,742163,1,3,,103176321,5746,Active,,,0.7829699999999999,IC50,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,Confirmatory,,
1826,742164,1,3,,103176321,5746,Active,,,0.06195,IC50,SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,Confirmatory,,
1827,742165,1,3,,103176321,5746,Active,,,0.01214,IC50,SANGER: Inhibition of human EW-7 cell growth in a cell viability assay.,Confirmatory,,
1828,742166,1,3,,103176321,5746,Active,,,0.16239,IC50,SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.,Confirmatory,,
1829,742167,1,3,,103176321,5746,Active,,,0.12829000000000002,IC50,SANGER: Inhibition of human FADU cell growth in a cell viability assay.,Confirmatory,,
1830,742168,1,3,,103176321,5746,Active,,,0.51722,IC50,SANGER: Inhibition of human FTC-133 cell growth in a cell viability assay.,Confirmatory,,
1831,742169,1,3,,103176321,5746,Active,,,0.12393,IC50,SANGER: Inhibition of human G-361 cell growth in a cell viability assay.,Confirmatory,,
1832,742170,1,3,,103176321,5746,Active,,,0.63447,IC50,SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,Confirmatory,,
1833,742171,1,3,,103176321,5746,Active,,,0.08592000000000001,IC50,SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,Confirmatory,,
1834,742172,1,3,,103176321,5746,Active,,,0.59624,IC50,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,Confirmatory,,
1835,742173,1,3,,103176321,5746,Active,,,0.42821000000000004,IC50,SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,Confirmatory,,
1836,742174,1,3,,103176321,5746,Active,,,0.45218,IC50,SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.,Confirmatory,,
1837,742175,1,3,,103176321,5746,Active,,,0.41098999999999997,IC50,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,Confirmatory,,
1838,742176,1,3,,103176321,5746,Active,,,4.6047,IC50,SANGER: Inhibition of human GCT cell growth in a cell viability assay.,Confirmatory,,
1839,742177,1,3,,103176321,5746,Active,,,0.37746,IC50,SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.,Confirmatory,,
1840,742178,1,3,,103176321,5746,Active,,,0.035160000000000004,IC50,SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.,Confirmatory,,
1841,742179,1,3,,103176321,5746,Active,,,1.39089,IC50,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,Confirmatory,,
1842,742180,1,3,,103176321,5746,Active,,,3.8380699999999996,IC50,SANGER: Inhibition of human GMS-10 cell growth in a cell viability assay.,Confirmatory,,
1843,742181,1,3,,103176321,5746,Active,,,0.55371,IC50,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,Confirmatory,,
1844,742182,1,3,,103176321,5746,Active,,,0.084,IC50,SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,Confirmatory,,
1845,742183,1,3,,103176321,5746,Active,,,0.12134,IC50,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,Confirmatory,,
1846,742184,1,3,,103176321,5746,Active,,,0.31823,IC50,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,Confirmatory,,
1847,742186,1,3,,103176321,5746,Active,,,0.012440000000000001,IC50,SANGER: Inhibition of human H4 cell growth in a cell viability assay.,Confirmatory,,
1848,742188,1,3,,103176321,5746,Active,,,0.01573,IC50,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,Confirmatory,,
1849,742189,1,3,,103176321,5746,Active,,,0.15650999999999998,IC50,SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.,Confirmatory,,
1850,742190,1,3,,103176321,5746,Active,,,1.0664,IC50,SANGER: Inhibition of human HCC1143 cell growth in a cell viability assay.,Confirmatory,,
1851,742191,1,3,,103176321,5746,Active,,,8.9213,IC50,SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.,Confirmatory,,
1852,742192,1,3,,103176321,5746,Active,,,1.05754,IC50,SANGER: Inhibition of human HCC1395 cell growth in a cell viability assay.,Confirmatory,,
1853,742193,1,3,,103176321,5746,Active,,,3.4840199999999997,IC50,SANGER: Inhibition of human HCC1419 cell growth in a cell viability assay.,Confirmatory,,
1854,742194,1,3,,103176321,5746,Active,,,0.64461,IC50,SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,Confirmatory,,
1855,742195,1,3,,103176321,5746,Active,,,0.12017,IC50,SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.,Confirmatory,,
1856,742196,1,3,,103176321,5746,Active,,,0.13454000000000002,IC50,SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,Confirmatory,,
1857,742197,1,3,,103176321,5746,Active,,,0.59382,IC50,SANGER: Inhibition of human HCC1937 cell growth in a cell viability assay.,Confirmatory,,
1858,742198,1,3,,103176321,5746,Active,,,2.28119,IC50,SANGER: Inhibition of human HCC1954 cell growth in a cell viability assay.,Confirmatory,,
1859,742199,1,3,,103176321,5746,Active,,,0.72685,IC50,SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.,Confirmatory,,
1860,742200,1,3,,103176321,5746,Active,,,0.58882,IC50,SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,Confirmatory,,
1861,742201,1,3,,103176321,5746,Active,,,0.16013,IC50,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,Confirmatory,,
1862,742202,1,3,,103176321,5746,Active,,,0.60411,IC50,SANGER: Inhibition of human HCC38 cell growth in a cell viability assay.,Confirmatory,,
1863,742203,1,3,,103176321,5746,Active,,,0.69433,IC50,SANGER: Inhibition of human HCC70 cell growth in a cell viability assay.,Confirmatory,,
1864,742204,1,3,,103176321,5746,Active,,,0.05794,IC50,SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,Confirmatory,,
1865,742205,1,3,,103176321,5746,Active,,,0.37153,IC50,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,Confirmatory,,
1866,742206,1,3,,103176321,5746,Active,,,1.01502,IC50,SANGER: Inhibition of human HCT-116 cell growth in a cell viability assay.,Confirmatory,,
1867,742207,1,3,,103176321,5746,Active,,,0.46462,IC50,SANGER: Inhibition of human HCT-15 cell growth in a cell viability assay.,Confirmatory,,
1868,742208,1,3,,103176321,5746,Active,,,0.64025,IC50,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,Confirmatory,,
1869,742209,1,3,,103176321,5746,Active,,,1.4601,IC50,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,Confirmatory,,
1870,742210,1,3,,103176321,5746,Active,,,0.69824,IC50,SANGER: Inhibition of human HEC-1 cell growth in a cell viability assay.,Confirmatory,,
1871,742211,1,3,,103176321,5746,Active,,,0.0358,IC50,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,Confirmatory,,
1872,742212,1,3,,103176321,5746,Active,,,0.04929,IC50,SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,Confirmatory,,
1873,742213,1,3,,103176321,5746,Active,,,1.0738,IC50,SANGER: Inhibition of human HH cell growth in a cell viability assay.,Confirmatory,,
1874,742214,1,3,,103176321,5746,Active,,,0.10605999999999999,IC50,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,Confirmatory,,
1875,742215,1,3,,103176321,5746,Active,,,0.49832,IC50,SANGER: Inhibition of human HLE cell growth in a cell viability assay.,Confirmatory,,
1876,742216,1,3,,103176321,5746,Active,,,0.16605999999999999,IC50,SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,Confirmatory,,
1877,742217,1,3,,103176321,5746,Active,,,0.78254,IC50,SANGER: Inhibition of human HN cell growth in a cell viability assay.,Confirmatory,,
1878,742218,1,3,,103176321,5746,Active,,,0.44064,IC50,SANGER: Inhibition of human HO-1-N-1 cell growth in a cell viability assay.,Confirmatory,,
1879,742219,1,3,,103176321,5746,Active,,,0.0202,IC50,SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,Confirmatory,,
1880,742220,1,3,,103176321,5746,Active,,,1.93658,IC50,SANGER: Inhibition of human HOP-92 cell growth in a cell viability assay.,Confirmatory,,
1881,742221,1,3,,103176321,5746,Active,,,0.1067,IC50,SANGER: Inhibition of human HOS cell growth in a cell viability assay.,Confirmatory,,
1882,742222,1,3,,103176321,5746,Active,,,1.09715,IC50,SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,Confirmatory,,
1883,742223,1,3,,103176321,5746,Active,,,0.08342000000000001,IC50,SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,Confirmatory,,
1884,742224,1,3,,103176321,5746,Active,,,0.07554,IC50,SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,Confirmatory,,
1885,742225,1,3,,103176321,5746,Active,,,0.43445,IC50,SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,Confirmatory,,
1886,742226,1,3,,103176321,5746,Active,,,1.53659,IC50,SANGER: Inhibition of human HT cell growth in a cell viability assay.,Confirmatory,,
1887,742227,1,3,,103176321,5746,Active,,,0.35370999999999997,IC50,SANGER: Inhibition of human HT-1080 cell growth in a cell viability assay.,Confirmatory,,
1888,742228,1,3,,103176321,5746,Active,,,2.0217400000000003,IC50,SANGER: Inhibition of human HT-1197 cell growth in a cell viability assay.,Confirmatory,,
1889,742229,1,3,,103176321,5746,Active,,,0.96711,IC50,SANGER: Inhibition of human HT-1376 cell growth in a cell viability assay.,Confirmatory,,
1890,742230,1,3,,103176321,5746,Active,,,0.02375,IC50,SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.,Confirmatory,,
1891,742231,1,3,,103176321,5746,Active,,,0.036019999999999996,IC50,SANGER: Inhibition of human HT-29 cell growth in a cell viability assay.,Confirmatory,,
1892,742232,1,3,,103176321,5746,Active,,,0.00293,IC50,SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,Confirmatory,,
1893,742233,1,3,,103176321,5746,Active,,,1.9545700000000001,IC50,SANGER: Inhibition of human HT55 cell growth in a cell viability assay.,Confirmatory,,
1894,742234,1,3,,103176321,5746,Active,,,5.78944,IC50,SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,Confirmatory,,
1895,742235,1,3,,103176321,5746,Active,,,0.00483,IC50,SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,Confirmatory,,
1896,742236,1,3,,103176321,5746,Active,,,6.2030199999999995,IC50,SANGER: Inhibition of human Hs-578-T cell growth in a cell viability assay.,Confirmatory,,
1897,742237,1,3,,103176321,5746,Active,,,0.90351,IC50,SANGER: Inhibition of human HuCCT1 cell growth in a cell viability assay.,Confirmatory,,
1898,742238,1,3,,103176321,5746,Active,,,3.22286,IC50,SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,Confirmatory,,
1899,742239,1,3,,103176321,5746,Active,,,6.45452,IC50,SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,Confirmatory,,
1900,742241,1,3,,103176321,5746,Active,,,0.71055,IC50,SANGER: Inhibition of human HuP-T3 cell growth in a cell viability assay.,Confirmatory,,
1901,742242,1,3,,103176321,5746,Active,,,0.1081,IC50,SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,Confirmatory,,
1902,742243,1,3,,103176321,5746,Active,,,0.10862999999999999,IC50,SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,Confirmatory,,
1903,742244,1,3,,103176321,5746,Active,,,0.3216,IC50,SANGER: Inhibition of human IGR-1 cell growth in a cell viability assay.,Confirmatory,,
1904,742245,1,3,,103176321,5746,Active,,,0.10597000000000001,IC50,SANGER: Inhibition of human IGROV-1 cell growth in a cell viability assay.,Confirmatory,,
1905,742246,1,3,,103176321,5746,Active,,,0.056220000000000006,IC50,SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.,Confirmatory,,
1906,742247,1,3,,103176321,5746,Active,,,0.000308,IC50,SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.,Confirmatory,,
1907,742248,1,3,,103176321,5746,Active,,,1.22841,IC50,SANGER: Inhibition of human IPC-298 cell growth in a cell viability assay.,Confirmatory,,
1908,742249,1,3,,103176321,5746,Active,,,0.00168,IC50,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,Confirmatory,,
1909,742250,1,3,,103176321,5746,Active,,,4.14621,IC50,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,Confirmatory,,
1910,742251,1,3,,103176321,5746,Active,,,1.4462,IC50,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,Confirmatory,,
1911,742252,1,3,,103176321,5746,Active,,,0.38761999999999996,IC50,SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,Confirmatory,,
1912,742253,1,3,,103176321,5746,Active,,,0.1858,IC50,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,Confirmatory,,
1913,742254,1,3,,103176321,5746,Active,,,0.00011899999999999999,IC50,SANGER: Inhibition of human J82 cell growth in a cell viability assay.,Confirmatory,,
1914,742255,1,3,,103176321,5746,Active,,,4.56384,IC50,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,Confirmatory,,
1915,742256,1,3,,103176321,5746,Active,,,2.23191,IC50,SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,Confirmatory,,
1916,742257,1,3,,103176321,5746,Active,,,0.39734,IC50,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,Confirmatory,,
1917,742258,1,3,,103176321,5746,Active,,,2.64752,IC50,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,Confirmatory,,
1918,742259,1,4,,103176321,5746,Active,,,0.62954,IC50,SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.,Confirmatory,,
1919,742260,1,3,,103176321,5746,Active,,,1.97869,IC50,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,Confirmatory,,
1920,742261,1,3,,103176321,5746,Active,,,0.14934,IC50,SANGER: Inhibition of human K052 cell growth in a cell viability assay.,Confirmatory,,
1921,742262,1,3,,103176321,5746,Active,,,1.78398,IC50,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,Confirmatory,,
1922,742263,1,3,,103176321,5746,Active,,,0.12914,IC50,SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.,Confirmatory,,
1923,742264,1,3,,103176321,5746,Active,,,1.41651,IC50,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,Confirmatory,,
1924,742265,1,3,,103176321,5746,Active,,,0.9073899999999999,IC50,SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,Confirmatory,,
1925,742266,1,3,,103176321,5746,Active,,,2.27184,IC50,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,Confirmatory,,
1926,742268,1,3,,103176321,5746,Active,,,0.00164,IC50,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,Confirmatory,,
1927,742269,1,3,,103176321,5746,Active,,,0.59714,IC50,SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.,Confirmatory,,
1928,742270,1,3,,103176321,5746,Active,,,0.20713,IC50,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,Confirmatory,,
1929,742271,1,3,,103176321,5746,Active,,,8.61164,IC50,SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.,Confirmatory,,
1930,742272,1,3,,103176321,5746,Active,,,2.98224,IC50,SANGER: Inhibition of human KLE cell growth in a cell viability assay.,Confirmatory,,
1931,742273,1,3,,103176321,5746,Active,,,0.13045,IC50,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,Confirmatory,,
1932,742274,1,3,,103176321,5746,Active,,,1.08364,IC50,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,Confirmatory,,
1933,742275,1,3,,103176321,5746,Active,,,1.6241299999999999,IC50,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,Confirmatory,,
1934,742276,1,3,,103176321,5746,Active,,,3.8278800000000004,IC50,SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.,Confirmatory,,
1935,742277,1,3,,103176321,5746,Active,,,1.09239,IC50,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,Confirmatory,,
1936,742279,1,3,,103176321,5746,Active,,,1.59446,IC50,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,Confirmatory,,
1937,742280,1,3,,103176321,5746,Active,,,1.53103,IC50,SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,Confirmatory,,
1938,742281,1,3,,103176321,5746,Active,,,0.09315,IC50,SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,Confirmatory,,
1939,742283,1,3,,103176321,5746,Active,,,3.41535,IC50,SANGER: Inhibition of human KP-N-YN cell growth in a cell viability assay.,Confirmatory,,
1940,742284,1,3,,103176321,5746,Active,,,0.64012,IC50,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,Confirmatory,,
1941,742285,1,3,,103176321,5746,Active,,,0.36415,IC50,SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.,Confirmatory,,
1942,742286,1,3,,103176321,5746,Active,,,3.35835,IC50,SANGER: Inhibition of human KU-19-19 cell growth in a cell viability assay.,Confirmatory,,
1943,742287,1,3,,103176321,5746,Active,,,0.14995999999999998,IC50,SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,Confirmatory,,
1944,742288,1,3,,103176321,5746,Active,,,0.52344,IC50,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,Confirmatory,,
1945,742289,1,3,,103176321,5746,Active,,,1.65078,IC50,SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,Confirmatory,,
1946,742290,1,3,,103176321,5746,Active,,,0.38134,IC50,SANGER: Inhibition of human KYSE-140 cell growth in a cell viability assay.,Confirmatory,,
1947,742291,1,3,,103176321,5746,Active,,,0.034089999999999995,IC50,SANGER: Inhibition of human KYSE-150 cell growth in a cell viability assay.,Confirmatory,,
1948,742292,1,3,,103176321,5746,Active,,,0.20219,IC50,SANGER: Inhibition of human KYSE-180 cell growth in a cell viability assay.,Confirmatory,,
1949,742293,1,3,,103176321,5746,Active,,,0.10284000000000001,IC50,SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,Confirmatory,,
1950,742294,1,3,,103176321,5746,Active,,,0.5835899999999999,IC50,SANGER: Inhibition of human KYSE-410 cell growth in a cell viability assay.,Confirmatory,,
1951,742295,1,3,,103176321,5746,Active,,,0.56311,IC50,SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,Confirmatory,,
1952,742296,1,3,,103176321,5746,Active,,,0.000149,IC50,SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,Confirmatory,,
1953,742297,1,3,,103176321,5746,Active,,,0.77218,IC50,SANGER: Inhibition of human KYSE-520 cell growth in a cell viability assay.,Confirmatory,,
1954,742298,1,3,,103176321,5746,Active,,,0.22430999999999998,IC50,SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,Confirmatory,,
1955,742299,1,3,,103176321,5746,Active,,,0.43417,IC50,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,Confirmatory,,
1956,742300,1,3,,103176321,5746,Active,,,1.15778,IC50,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,Confirmatory,,
1957,742301,1,3,,103176321,5746,Active,,,0.09514,IC50,SANGER: Inhibition of human L-540 cell growth in a cell viability assay.,Confirmatory,,
1958,742302,1,3,,103176321,5746,Active,,,0.64166,IC50,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,Confirmatory,,
1959,742303,1,3,,103176321,5746,Active,,,0.32779,IC50,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,Confirmatory,,
1960,742304,1,3,,103176321,5746,Active,,,0.0136,IC50,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,Confirmatory,,
1961,742305,1,3,,103176321,5746,Active,,,0.01319,IC50,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,Confirmatory,,
1962,742306,1,3,,103176321,5746,Active,,,0.53456,IC50,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,Confirmatory,,
1963,742307,1,3,,103176321,5746,Active,,,0.42962,IC50,SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,Confirmatory,,
1964,742308,1,3,,103176321,5746,Active,,,0.33608000000000005,IC50,SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.,Confirmatory,,
1965,742309,1,3,,103176321,5746,Active,,,0.77974,IC50,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,Confirmatory,,
1966,742310,1,3,,103176321,5746,Active,,,0.81608,IC50,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,Confirmatory,,
1967,742311,1,3,,103176321,5746,Active,,,0.01768,IC50,SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,Confirmatory,,
1968,742312,1,3,,103176321,5746,Active,,,0.8623299999999999,IC50,SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.,Confirmatory,,
1969,742313,1,3,,103176321,5746,Active,,,0.00024900000000000004,IC50,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,Confirmatory,,
1970,742314,1,3,,103176321,5746,Active,,,1.23959,IC50,SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.,Confirmatory,,
1971,742315,1,3,,103176321,5746,Active,,,0.46087,IC50,SANGER: Inhibition of human LCLC-103H cell growth in a cell viability assay.,Confirmatory,,
1972,742316,1,3,,103176321,5746,Active,,,0.13872,IC50,SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,Confirmatory,,
1973,742317,1,3,,103176321,5746,Active,,,0.35814,IC50,SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,Confirmatory,,
1974,742318,1,3,,103176321,5746,Active,,,2.15428,IC50,SANGER: Inhibition of human LN-405 cell growth in a cell viability assay.,Confirmatory,,
1975,742319,1,3,,103176321,5746,Active,,,0.45008000000000004,IC50,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,Confirmatory,,
1976,742320,1,3,,103176321,5746,Active,,,0.026189999999999998,IC50,SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.,Confirmatory,,
1977,742321,1,3,,103176321,5746,Active,,,0.3525,IC50,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,Confirmatory,,
1978,742322,1,3,,103176321,5746,Active,,,4.55967,IC50,SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.,Confirmatory,,
1979,742323,1,3,,103176321,5746,Active,,,0.030160000000000003,IC50,SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.,Confirmatory,,
1980,742324,1,3,,103176321,5746,Active,,,1.7200099999999998,IC50,SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.,Confirmatory,,
1981,742325,1,3,,103176321,5746,Active,,,0.32176,IC50,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,Confirmatory,,
1982,742326,1,3,,103176321,5746,Active,,,1.17808,IC50,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,Confirmatory,,
1983,742327,1,3,,103176321,5746,Active,,,0.04672,IC50,SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.,Confirmatory,,
1984,742329,1,3,,103176321,5746,Active,,,1.21841,IC50,SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.,Confirmatory,,
1985,742330,1,3,,103176321,5746,Active,,,0.5131100000000001,IC50,SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.,Confirmatory,,
1986,742331,1,4,,103176321,5746,Active,,,1.01247,IC50,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,Confirmatory,,
1987,742332,1,3,,103176321,5746,Active,,,0.22424000000000002,IC50,SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,Confirmatory,,
1988,742333,1,3,,103176321,5746,Active,,,0.05537,IC50,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,Confirmatory,,
1989,742334,1,3,,103176321,5746,Active,,,0.43068,IC50,SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,Confirmatory,,
1990,742335,1,3,,103176321,5746,Active,,,0.1006,IC50,SANGER: Inhibition of human M059J cell growth in a cell viability assay.,Confirmatory,,
1991,742336,1,3,,103176321,5746,Active,,,1.3376,IC50,SANGER: Inhibition of human M14 cell growth in a cell viability assay.,Confirmatory,,
1992,742337,1,3,,103176321,5746,Active,,,0.16091,IC50,SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.,Confirmatory,,
1993,742338,1,3,,103176321,5746,Active,,,0.000638,IC50,SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,Confirmatory,,
1994,742339,1,3,,103176321,5746,Active,,,1.41664,IC50,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,Confirmatory,,
1995,742340,1,3,,103176321,5746,Active,,,0.0139,IC50,SANGER: Inhibition of human MCF7 cell growth in a cell viability assay.,Confirmatory,,
1996,742341,1,3,,103176321,5746,Active,,,2.1586,IC50,SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.,Confirmatory,,
1997,742342,1,3,,103176321,5746,Active,,,2.19254,IC50,SANGER: Inhibition of human MDA-MB-157 cell growth in a cell viability assay.,Confirmatory,,
1998,742343,1,3,,103176321,5746,Active,,,3.1581900000000003,IC50,SANGER: Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay.,Confirmatory,,
1999,742344,1,3,,103176321,5746,Active,,,3.23964,IC50,SANGER: Inhibition of human MDA-MB-231 cell growth in a cell viability assay.,Confirmatory,,
2000,742345,1,3,,103176321,5746,Active,,,0.80898,IC50,SANGER: Inhibition of human MDA-MB-361 cell growth in a cell viability assay.,Confirmatory,,
2001,742346,1,3,,103176321,5746,Active,,,0.72395,IC50,SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,Confirmatory,,
2002,742347,1,3,,103176321,5746,Active,,,1.07917,IC50,SANGER: Inhibition of human MDA-MB-453 cell growth in a cell viability assay.,Confirmatory,,
2003,742348,1,3,,103176321,5746,Active,,,0.34531,IC50,SANGER: Inhibition of human MDA-MB-468 cell growth in a cell viability assay.,Confirmatory,,
2004,742349,1,3,,103176321,5746,Active,,,0.04011,IC50,SANGER: Inhibition of human ME-180 cell growth in a cell viability assay.,Confirmatory,,
2005,742350,1,3,,103176321,5746,Active,,,0.6833600000000001,IC50,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,Confirmatory,,
2006,742351,1,3,,103176321,5746,Active,,,0.0394,IC50,SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,Confirmatory,,
2007,742352,1,3,,103176321,5746,Active,,,0.05125,IC50,SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,Confirmatory,,
2008,742353,1,3,,103176321,5746,Active,,,0.14494,IC50,SANGER: Inhibition of human MES-SA cell growth in a cell viability assay.,Confirmatory,,
2009,742354,1,3,,103176321,5746,Active,,,8.34873,IC50,SANGER: Inhibition of human MFE-280 cell growth in a cell viability assay.,Confirmatory,,
2010,742355,1,3,,103176321,5746,Active,,,0.28623000000000004,IC50,SANGER: Inhibition of human MFE-296 cell growth in a cell viability assay.,Confirmatory,,
2011,742356,1,3,,103176321,5746,Active,,,0.07061,IC50,SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,Confirmatory,,
2012,742357,1,3,,103176321,5746,Active,,,10.3807,IC50,SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.,Confirmatory,,
2013,742358,1,3,,103176321,5746,Active,,,0.22618000000000002,IC50,SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,Confirmatory,,
2014,742359,1,3,,103176321,5746,Active,,,0.00606,IC50,SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.,Confirmatory,,
2015,742360,1,3,,103176321,5746,Active,,,0.01626,IC50,SANGER: Inhibition of human MHH-ES-1 cell growth in a cell viability assay.,Confirmatory,,
2016,742361,1,3,,103176321,5746,Active,,,0.19255,IC50,SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.,Confirmatory,,
2017,742362,1,3,,103176321,5746,Active,,,3.14735,IC50,SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.,Confirmatory,,
2018,742363,1,3,,103176321,5746,Active,,,0.27545,IC50,SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,Confirmatory,,
2019,742364,1,3,,103176321,5746,Active,,,0.54081,IC50,SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,Confirmatory,,
2020,742365,1,3,,103176321,5746,Active,,,0.23009000000000002,IC50,SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,Confirmatory,,
2021,742366,1,3,,103176321,5746,Active,,,0.16504000000000002,IC50,SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,Confirmatory,,
2022,742367,1,3,,103176321,5746,Active,,,27.8562,IC50,SANGER: Inhibition of human MKN7 cell growth in a cell viability assay.,Confirmatory,,
2023,742368,1,3,,103176321,5746,Active,,,0.00878,IC50,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,Confirmatory,,
2024,742369,1,3,,103176321,5746,Active,,,1.30978,IC50,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,Confirmatory,,
2025,742370,1,3,,103176321,5746,Active,,,1.01163,IC50,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,Confirmatory,,
2026,742371,1,3,,103176321,5746,Active,,,1.26332,IC50,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,Confirmatory,,
2027,742373,1,3,,103176321,5746,Active,,,0.58519,IC50,SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.,Confirmatory,,
2028,742374,1,3,,103176321,5746,Active,,,3.2500000000000004e-05,IC50,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,Confirmatory,,
2029,742375,1,4,,103176321,5746,Active,,,0.07235,IC50,SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,Confirmatory,,
2030,742376,1,3,,103176321,5746,Active,,,0.9912200000000001,IC50,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,Confirmatory,,
2031,742377,1,3,,103176321,5746,Active,,,0.11025,IC50,SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.,Confirmatory,,
2032,742378,1,3,,103176321,5746,Active,,,0.34402,IC50,SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.,Confirmatory,,
2033,742379,1,3,,103176321,5746,Active,,,2.82369,IC50,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,Confirmatory,,
2034,742380,1,3,,103176321,5746,Active,,,0.00173,IC50,SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.,Confirmatory,,
2035,742381,1,3,,103176321,5746,Active,,,0.45011,IC50,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,Confirmatory,,
2036,742382,1,3,,103176321,5746,Active,,,0.43246999999999997,IC50,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,Confirmatory,,
2037,742383,1,3,,103176321,5746,Active,,,0.33255999999999997,IC50,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,Confirmatory,,
2038,742384,1,3,,103176321,5746,Active,,,9.55233,IC50,SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,Confirmatory,,
2039,742385,1,4,,103176321,5746,Active,,,8.91163,IC50,SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.,Confirmatory,,
2040,742386,1,3,,103176321,5746,Active,,,0.00107,IC50,SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,Confirmatory,,
2041,742387,1,3,,103176321,5746,Active,,,0.18661,IC50,SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,Confirmatory,,
2042,742388,1,3,,103176321,5746,Active,,,0.08165,IC50,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,Confirmatory,,
2043,742389,1,3,,103176321,5746,Active,,,1.20371,IC50,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,Confirmatory,,
2044,742390,1,3,,103176321,5746,Active,,,0.64603,IC50,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,Confirmatory,,
2045,742393,1,3,,103176321,5746,Active,,,0.3579,IC50,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,Confirmatory,,
2046,742394,1,3,,103176321,5746,Active,,,2.23352,IC50,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,Confirmatory,,
2047,742395,1,3,,103176321,5746,Active,,,0.17506,IC50,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,Confirmatory,,
2048,742398,1,3,,103176321,5746,Active,,,1.01024,IC50,SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,Confirmatory,,
2049,742400,1,3,,103176321,5746,Active,,,3.2799,IC50,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,Confirmatory,,
2050,742401,1,3,,103176321,5746,Active,,,0.87336,IC50,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,Confirmatory,,
2051,742403,1,3,,103176321,5746,Active,,,0.21841,IC50,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,Confirmatory,,
2052,742404,1,3,,103176321,5746,Active,,,0.37523,IC50,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,Confirmatory,,
2053,742405,1,3,,103176321,5746,Active,,,0.1168,IC50,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,Confirmatory,,
2054,742406,1,3,,103176321,5746,Active,,,2.23483,IC50,SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.,Confirmatory,,
2055,742407,1,3,,103176321,5746,Active,,,0.2369,IC50,SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.,Confirmatory,,
2056,742408,1,3,,103176321,5746,Active,,,1.9274200000000001,IC50,SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.,Confirmatory,,
2057,742409,1,3,,103176321,5746,Active,,,0.12625999999999998,IC50,SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,Confirmatory,,
2058,742410,1,3,,103176321,5746,Active,,,3.23546,IC50,SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.,Confirmatory,,
2059,743012,3,1,,144205046,5746,Active,,,0.0084,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2060,743014,3,1,,144205046,5746,Inconclusive,,,0.003,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2061,743015,3,1,,144205046,5746,Active,,,0.0422,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2062,743033,3,1,,144205046,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2063,743035,2,1,,144205046,5746,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2064,743036,2,1,,144205046,5746,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2065,743040,3,1,,144205046,5746,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2066,743041,3,1,,144205046,5746,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2067,743042,3,1,,144205046,5746,Active,124375976.0,367.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2068,743053,2,1,,144205046,5746,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2069,743054,2,1,,144205046,5746,Active,124375976.0,367.0,16.1535,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2070,743063,2,1,,144205046,5746,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2071,743064,3,1,,144205046,5746,Active,,,2.371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2072,743065,3,1,,144205046,5746,Active,399498506.0,24831.0,1.3333,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2073,743066,3,1,,144205046,5746,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2074,743067,2,1,,144205046,5746,Inconclusive,399498506.0,24831.0,1.28312,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2075,743069,2,1,,144205046,5746,Active,348019627.0,2099.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2076,743074,2,1,,144205046,5746,Inconclusive,,,2.6832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2077,743075,2,1,,144205046,5746,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2078,743077,2,1,,144205046,5746,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2079,743078,2,1,,144205046,5746,Active,348019627.0,2099.0,15.6793,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2080,743079,3,1,,144205046,5746,Inconclusive,348019627.0,2099.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2081,743080,3,1,,144205046,5746,Active,348019627.0,2099.0,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2082,743081,3,1,,144205046,5746,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2083,743083,3,1,,144205046,5746,Active,119597822.0,1588.0,29.8493,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2084,743084,3,1,,144205046,5746,Inconclusive,,,16.7855,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2085,743085,3,1,,144205046,5746,Inconclusive,51095037.0,196.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2086,743086,3,1,,144205046,5746,Active,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2087,743091,2,1,,144205046,5746,Active,348019627.0,2099.0,8.095939999999999,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2088,743094,3,1,,144205046,5746,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2089,743122,2,1,,144205046,5746,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2090,743126,1,1,,57260126,5746,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2091,743139,2,1,,144205046,5746,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2092,743140,2,1,,144205046,5746,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2093,743191,3,1,,170464814,5746,Inconclusive,216409692.0,5468.0,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2094,743194,3,1,,170464814,5746,Inconclusive,,,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2095,743199,2,1,,170464814,5746,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2096,743202,4,1,,170464814,5746,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2097,743203,3,1,,170464814,5746,Active,,,16.7842,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2098,743209,3,1,,170464814,5746,Inconclusive,,,21.13,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2099,743210,4,1,,170464814,5746,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2100,743211,3,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2101,743212,3,1,,170464814,5746,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2102,743213,3,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2103,743215,3,1,,170464814,5746,Inconclusive,216409690.0,5467.0,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2104,743217,3,1,,170464814,5746,Inconclusive,325495553.0,9971.0,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2105,743218,3,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2106,743219,3,1,,170464814,5746,Inconclusive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2107,743220,3,1,,170464814,5746,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2108,743221,3,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2109,743222,3,1,,170464814,5746,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2110,743223,3,1,,170464814,5746,Inconclusive,216409708.0,7421.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2111,743224,3,1,,170464814,5746,Inconclusive,,,16.7842,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2112,743225,3,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2113,743226,2,1,,170464814,5746,Active,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2114,743227,2,1,,170464814,5746,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2115,743228,3,1,,170464814,5746,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2116,743238,1,1,,57260126,5746,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2117,743239,2,1,,170464814,5746,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2118,743240,2,1,,170464814,5746,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2119,743241,2,1,,170464814,5746,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2120,743242,2,1,,170464814,5746,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2121,743244,1,1,,144205046,5746,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2122,743255,1,1,,57260126,5746,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2123,743266,1,2,,57260126,5746,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2124,743269,1,1,,57260126,5746,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2125,743269,1,1,,57260126,5746,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2126,743279,1,2,,57260126,5746,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2127,743287,1,1,,57260126,5746,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2128,743344,1,1,,174007310,5746,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2129,743345,1,1,,174007310,5746,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2130,743346,1,1,,174007310,5746,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2131,743347,1,1,,174007310,5746,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2132,743397,1,1,,57260126,5746,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2133,743398,1,1,,57260126,5746,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2134,744296,1,2,,103176321,5746,Active,,,0.5,IC50,Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
2135,747039,1,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human HCT15 cells at 1 uM after 48 hrs by SRB assay,Other,23584541.0,
2136,747042,1,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human Hep2 cells at 1 uM after 48 hrs by SRB assay,Other,23584541.0,
2137,763929,1,1,,103176321,5746,Unspecified,,,,,Growth inhibition of human MCF7 cells assessed as dead cells at 1 uM after 48 hrs by sulforhodamine-B assay relative to control,Other,23811086.0,
2138,763931,1,1,,103176321,5746,Unspecified,,,,,Growth inhibition of human A549 cells assessed as dead cells at 1 uM after 48 hrs by sulforhodamine-B assay relative to control,Other,23811086.0,
2139,764651,1,2,,103176321,5746,Unspecified,,,,,Genotoxicity in human lymphocytes assessed as chromosome aberration at 0.300 u/mL relative to control,Other,23867164.0,
2140,773057,1,1,,103176321,5746,Active,,,2.05,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,23999045.0,
2141,773058,1,2,,103176321,5746,Active,,,1.68,IC50,Cytotoxicity against human SPCA1 cells after 48 hrs by MTT assay,Confirmatory,23999045.0,
2142,774654,1,1,,103176321,5746,Active,,,1.0,IC50,Trypanocidal activity against Trypanosoma brucei brucei by Alamar Blue assay,Confirmatory,23927763.0,
2143,775721,1,1,,103176321,5746,Active,,,2.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,24056146.0,
2144,775723,1,1,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,24056146.0,
2145,929119,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020108,Other,,
2146,929120,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020108,Other,,
2147,929121,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020108,Other,,
2148,929122,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020108,Other,,
2149,929123,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020108,Other,,
2150,929124,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020108,Other,,
2151,929125,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020108,Other,,
2152,929126,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020108,Other,,
2153,929127,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020108,Other,,
2154,931361,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020108,Other,,
2155,931362,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020108,Other,,
2156,931363,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020108,Other,,
2157,931364,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020108,Other,,
2158,931365,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020108,Other,,
2159,931366,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020108,Other,,
2160,931367,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020108,Other,,
2161,931368,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020108,Other,,
2162,931369,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020108",Other,,
2163,931370,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020108,Other,,
2164,931371,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020108,Other,,
2165,931372,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020108,Other,,
2166,931373,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020108,Other,,
2167,931374,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020108,Other,,
2168,931375,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020108,Other,,
2169,931376,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020108,Other,,
2170,931377,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020108,Other,,
2171,931378,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020108,Other,,
2172,931379,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020108,Other,,
2173,931770,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020108,Other,,
2174,931771,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020108,Other,,
2175,931772,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020108",Other,,
2176,931773,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020108,Other,,
2177,931774,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020108,Other,,
2178,931775,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020108,Other,,
2179,931776,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020108,Other,,
2180,931777,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020108,Other,,
2181,931778,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020108,Other,,
2182,931779,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020108,Other,,
2183,937212,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020108,Other,,
2184,937213,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020108,Other,,
2185,937214,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020108,Other,,
2186,937215,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020108,Other,,
2187,937216,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020108,Other,,
2188,937217,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020108,Other,,
2189,945229,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020108,Other,,
2190,945230,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020108,Other,,
2191,945231,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020108,Other,,
2192,945232,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020108,Other,,
2193,945233,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020108,Other,,
2194,945234,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020108",Other,,
2195,945235,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020108,Other,,
2196,945236,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020108,Other,,
2197,945237,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020108,Other,,
2198,945238,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020108,Other,,
2199,945239,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020108,Other,,
2200,945240,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020108,Other,,
2201,945241,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020108,Other,,
2202,945242,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020108,Other,,
2203,945243,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020108,Other,,
2204,945244,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020108,Other,,
2205,945245,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020108,Other,,
2206,945246,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020108,Other,,
2207,945247,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020108,Other,,
2208,945248,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020108,Other,,
2209,945249,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020108,Other,,
2210,945250,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020108,Other,,
2211,945251,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020108,Other,,
2212,945252,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020108,Other,,
2213,945253,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020108,Other,,
2214,945254,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020108,Other,,
2215,945255,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020108,Other,,
2216,945256,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020108,Other,,
2217,945257,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020108,Other,,
2218,945258,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020108,Other,,
2219,945259,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020108",Other,,
2220,945260,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020108,Other,,
2221,949457,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020108,Other,,
2222,949458,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020108,Other,,
2223,949459,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020108,Other,,
2224,949460,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020108,Other,,
2225,949461,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020108,Other,,
2226,949462,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020108,Other,,
2227,949463,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020108,Other,,
2228,949464,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020108,Other,,
2229,949465,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020108,Other,,
2230,949466,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020108,Other,,
2231,949467,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020108,Other,,
2232,949468,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020108,Other,,
2233,949469,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020108,Other,,
2234,949470,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020108,Other,,
2235,949471,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020108,Other,,
2236,949472,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020108,Other,,
2237,949473,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020108,Other,,
2238,949474,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020108,Other,,
2239,949475,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020108,Other,,
2240,949476,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020108,Other,,
2241,949477,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020108,Other,,
2242,949478,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020108,Other,,
2243,949479,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020108,Other,,
2244,949480,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020108,Other,,
2245,949481,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020108,Other,,
2246,950114,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020108,Other,,
2247,950115,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020108,Other,,
2248,950116,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020108,Other,,
2249,950117,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020108,Other,,
2250,950118,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020108,Other,,
2251,950119,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020108,Other,,
2252,950120,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020108,Other,,
2253,950121,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020108,Other,,
2254,957849,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020108,Other,,
2255,957850,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020108,Other,,
2256,957851,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020108,Other,,
2257,957852,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020108,Other,,
2258,957853,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020108,Other,,
2259,963671,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020108,Other,,
2260,963672,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020108,Other,,
2261,963673,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020108,Other,,
2262,963674,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020108,Other,,
2263,963675,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020108,Other,,
2264,965471,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020108,Other,,
2265,965472,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020108,Other,,
2266,965473,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020108,Other,,
2267,965474,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020108,Other,,
2268,965475,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020108,Other,,
2269,965476,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020108,Other,,
2270,965477,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020108,Other,,
2271,965478,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020108,Other,,
2272,965479,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020108,Other,,
2273,965480,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020108,Other,,
2274,965481,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020108,Other,,
2275,965482,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020108,Other,,
2276,965483,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020108,Other,,
2277,965484,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020108,Other,,
2278,970402,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020108,Other,,
2279,970403,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020108,Other,,
2280,970404,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020108,Other,,
2281,970405,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020108,Other,,
2282,970406,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020108,Other,,
2283,970407,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020108,Other,,
2284,970408,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020108,Other,,
2285,970409,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020108,Other,,
2286,970410,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020108,Other,,
2287,970411,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020108,Other,,
2288,970412,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020108,Other,,
2289,970413,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020108,Other,,
2290,970414,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020108,Other,,
2291,970415,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020108,Other,,
2292,971045,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020108,Other,,
2293,971046,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020108,Other,,
2294,973069,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020108,Other,,
2295,973070,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020108,Other,,
2296,973071,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020108,Other,,
2297,1007601,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2298,1007602,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2299,1007603,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020108",Other,,
2300,1007604,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020108",Other,,
2301,1008839,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020108,Other,,
2302,1008840,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020108",Other,,
2303,1008841,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2304,1008842,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2305,1008843,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020108",Other,,
2306,1008844,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020108",Other,,
2307,1008845,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020108",Other,,
2308,1008846,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020108",Other,,
2309,1008847,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020108",Other,,
2310,1008848,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020108,Other,,
2311,1008849,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020108",Other,,
2312,1008850,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2313,1008851,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2314,1008852,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2315,1008853,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020108",Other,,
2316,1008854,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020108",Other,,
2317,1008855,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020108,Other,,
2318,1008856,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2319,1008857,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020108",Other,,
2320,1008858,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020108",Other,,
2321,1008859,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020108",Other,,
2322,1008860,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020108",Other,,
2323,1008861,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2324,1008862,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020108",Other,,
2325,1008863,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020108",Other,,
2326,1008864,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020108",Other,,
2327,1008865,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020108",Other,,
2328,1008866,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020108",Other,,
2329,1008867,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020108",Other,,
2330,1008868,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020108",Other,,
2331,1008869,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020108",Other,,
2332,1008870,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020108,Other,,
2333,1008871,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2334,1008872,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020108",Other,,
2335,1008873,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020108",Other,,
2336,1008874,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020108",Other,,
2337,1008875,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020108,Other,,
2338,1008876,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2339,1008877,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020108",Other,,
2340,1009457,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2341,1010076,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2342,1010077,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020108",Other,,
2343,1010078,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020108",Other,,
2344,1010079,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2345,1010080,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2346,1010081,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020108",Other,,
2347,1010082,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020108",Other,,
2348,1010083,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2349,1010084,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2350,1010085,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2351,1010086,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2352,1010087,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2353,1010088,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2354,1010089,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020108",Other,,
2355,1010090,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2356,1010091,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2357,1011933,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020108,Other,,
2358,1011934,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2359,1011962,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020108",Other,,
2360,1011963,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2361,1011964,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020108,Other,,
2362,1011965,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020108,Other,,
2363,1011966,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020108",Other,,
2364,1011967,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2365,1011968,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020108",Other,,
2366,1011969,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020108,Other,,
2367,1011970,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2368,1011971,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2369,1011972,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2370,1011973,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020108",Other,,
2371,1011974,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020108",Other,,
2372,1011975,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020108,Other,,
2373,1011976,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2374,1011977,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020108",Other,,
2375,1011978,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020108",Other,,
2376,1011979,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2377,1011980,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2378,1012564,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020108",Other,,
2379,1012565,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020108",Other,,
2380,1012566,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020108",Other,,
2381,1012567,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2382,1012568,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020108,Other,,
2383,1012569,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2384,1012570,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020108",Other,,
2385,1012571,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020108,Other,,
2386,1012572,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2387,1012573,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020108",Other,,
2388,1012574,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2389,1012575,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2390,1012576,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2391,1012577,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020108",Other,,
2392,1013801,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020108",Other,,
2393,1013802,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020108",Other,,
2394,1013803,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020108",Other,,
2395,1013804,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2396,1014387,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2397,1014388,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2398,1014389,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020108",Other,,
2399,1014390,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020108",Other,,
2400,1014391,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020108",Other,,
2401,1014392,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020108",Other,,
2402,1014393,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020108,Other,,
2403,1014394,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020108",Other,,
2404,1014395,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020108,Other,,
2405,1014396,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020108",Other,,
2406,1014397,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2407,1014398,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020108",Other,,
2408,1014399,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020108",Other,,
2409,1014400,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2410,1014401,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020108",Other,,
2411,1014402,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2412,1014403,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020108",Other,,
2413,1014404,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020108",Other,,
2414,1014405,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020108",Other,,
2415,1014406,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020108,Other,,
2416,1014407,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S020108,Other,,
2417,1014408,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020108",Other,,
2418,1014409,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2419,1014410,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020108",Other,,
2420,1014411,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2421,1014412,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2422,1014413,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2423,1014414,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020108",Other,,
2424,1014415,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020108",Other,,
2425,1014416,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020108",Other,,
2426,1014417,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020108",Other,,
2427,1014418,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020108",Other,,
2428,1014419,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020108",Other,,
2429,1014420,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020108",Other,,
2430,1014421,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S020108,Other,,
2431,1014422,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020108,Other,,
2432,1017486,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2433,1017487,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020108",Other,,
2434,1017488,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020108",Other,,
2435,1017489,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020108",Other,,
2436,1017490,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020108",Other,,
2437,1017491,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020108",Other,,
2438,1017492,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020108,Other,,
2439,1017493,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020108",Other,,
2440,1017494,1,3,,103176321,5746,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020108,Other,,
2441,1017495,1,3,,103176321,5746,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020108",Other,,
2442,1053197,1,1,,57260126,5746,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2443,1061799,1,2,,103176321,5746,Inconclusive,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
2444,1061801,1,2,,103176321,5746,Inconclusive,,,,,Cytotoxicity against human HeLa cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
2445,1061804,1,2,,103176321,5746,Inconclusive,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
2446,1061805,1,1,,103176321,5746,Inconclusive,,,,,Cytotoxicity against human IMR32 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
2447,1061807,1,1,,103176321,5746,Unspecified,,,,,Cytotoxicity against human prostate cancer cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
2448,1062115,1,2,,103176321,5746,Active,,,1.25,EC50,Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days,Confirmatory,24436995.0,
2449,1062116,1,2,,103176321,5746,Active,,,0.10300000000000001,EC50,Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days,Confirmatory,24436995.0,
2450,1065290,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
2451,1065294,1,1,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human MG63 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
2452,1065297,1,1,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
2453,1065300,1,2,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
2454,1065303,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
2455,1079931,1,1,,103176321,5746,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2456,1079932,1,1,,103176321,5746,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2457,1079933,1,1,,103176321,5746,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2458,1079934,1,1,,103176321,5746,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2459,1079935,1,1,,103176321,5746,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2460,1079936,1,1,,103176321,5746,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2461,1079937,1,1,,103176321,5746,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2462,1079938,1,1,,103176321,5746,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2463,1079939,1,1,,103176321,5746,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2464,1079940,1,1,,103176321,5746,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2465,1079941,1,1,,103176321,5746,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2466,1079942,1,1,,103176321,5746,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2467,1079943,1,1,,103176321,5746,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2468,1079944,1,1,,103176321,5746,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2469,1079945,1,1,,103176321,5746,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2470,1079946,1,1,,103176321,5746,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2471,1079947,1,1,,103176321,5746,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2472,1079948,1,1,,103176321,5746,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2473,1079949,1,1,,103176321,5746,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2474,1083982,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay,Confirmatory,,
2475,1083983,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay,Confirmatory,,
2476,1083984,1,2,,103176321,5746,Active,,,1.8,IC50,Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay,Confirmatory,,
2477,1083985,1,2,,103176321,5746,Active,,,1.4,IC50,Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay,Confirmatory,,
2478,1083986,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay,Confirmatory,,
2479,1083987,1,2,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay,Confirmatory,,
2480,1086707,1,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as growth inhibition at 1 x 10'-5 mole after 48 hr by SRB assay,Other,,
2481,1086721,1,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PC3 cells assessed as growth inhibition at 1 x 10'-5 mole after 48 hr by SRB assay,Other,,
2482,1095936,1,2,,103176321,5746,Unspecified,,,,,Growth inhibition of Homo sapiens (human) SF295 cells at 10'-5 M after 48 hr by SRB assay,Other,,
2483,1095937,1,2,,103176321,5746,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PC3 cells at 10'-5 M after 48 hr by SRB assay,Other,,
2484,1095940,1,2,,103176321,5746,Unspecified,,,,,Growth inhibition of Homo sapiens (human) IGROV1 cells at 10'-5 M after 48 hr by SRB assay,Other,,
2485,1105882,1,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) OVCAR5 cells assessed as growth inhibition at 1 uM after 48 hr by SRB assay,Other,,
2486,1105891,1,2,,103176321,5746,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition at 1 uM after 48 hr by SRB assay,Other,,
2487,1106543,1,2,,103176321,5746,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PC3 cells at 10 uM after 48 hr by SRB assay,Other,,
2488,1114756,1,2,,103176321,5746,Inconclusive,,,,,Growth inhibition of Homo sapiens (human) COLO205 cells at 10 uM by SRB assay,Other,,
2489,1114759,1,2,,103176321,5746,Unspecified,,,,,Growth inhibition of Homo sapiens (human) THP1 cells at 10 uM by SRB assay,Other,,
2490,1114760,1,2,,103176321,5746,Inconclusive,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10 uM by SRB assay,Other,,
2491,1116068,1,2,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay,Confirmatory,,
2492,1116069,1,2,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay,Confirmatory,,
2493,1116070,1,2,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay,Confirmatory,,
2494,1116071,1,2,,103176321,5746,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) Caco2 cells after 48 hr by SRB assay,Confirmatory,,
2495,1117298,1,2,,170464814,5746,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2496,1117301,1,2,,170464814,5746,Inactive,,,0.2818,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2497,1117302,1,2,,170464814,5746,Inactive,,,0.3162,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2498,1117303,1,2,,170464814,5746,Inactive,,,7.95,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2499,1117304,1,2,,170464814,5746,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2500,1117305,1,2,,170464814,5746,Inactive,,,44.6684,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2501,1117310,1,1,,170464814,5746,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2502,1117311,1,1,,170464814,5746,Inactive,,,0.28183800000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2503,1117312,1,1,,170464814,5746,Inactive,,,44.6684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2504,1117314,1,1,,170464814,5746,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2505,1117315,1,1,,170464814,5746,Inactive,,,0.316228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2506,1117318,1,1,,170464814,5746,Inactive,,,7.943280000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2507,1117322,1,1,,170464814,5746,Active,,,0.9953,IC50,RKO viability from Cell TiterGlo-IC50,Confirmatory,,
2508,1117323,1,1,,170464814,5746,Inactive,,,8.1272,IC50,SNU-C1 viability from Cell TiterGlo-IC50,Confirmatory,,
2509,1117324,1,1,,170464814,5746,Inactive,,,5.96125,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
2510,1117326,1,1,,170464814,5746,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2511,1117329,1,1,,170464814,5746,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2512,1117330,1,1,,170464814,5746,Active,,,2.5705,IC50,HT-29 viability from Cell TiterGlo-IC50,Confirmatory,,
2513,1117332,1,1,,170464814,5746,Inactive,,,13.6261,IC50,HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
2514,1117334,1,1,,170464814,5746,Inactive,,,12.5546,IC50,Colo320 viability from Cell TiterGlo-IC50,Confirmatory,,
2515,1117336,1,1,,170464814,5746,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2516,1117337,1,1,,170464814,5746,Active,,,0.1019,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
2517,1117338,1,1,,170464814,5746,Inactive,,,12.0548,IC50,SW480 viability from Cell TiterGlo-IC50,Confirmatory,,
2518,1117339,1,1,,170464814,5746,Inactive,,,20.0,IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
2519,1117340,1,1,,170464814,5746,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2520,1117341,1,1,,170464814,5746,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2521,1117342,1,1,,170464814,5746,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2522,1117343,1,1,,170464814,5746,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2523,1117346,1,1,,170464814,5746,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2524,1117347,1,1,,170464814,5746,Active,,,0.07733,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
2525,1117348,1,1,,170464814,5746,Active,,,0.14282999999999998,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
2526,1117349,1,1,,170464814,5746,Active,,,0.0133,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
2527,1117350,1,1,,170464814,5746,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
2528,1117351,1,1,,170464814,5746,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
2529,1117352,1,1,,170464814,5746,Inactive,,,5.6318,IC50,DLD-1 viability from Cell TiterGlo-IC50,Confirmatory,,
2530,1121630,1,1,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay,Confirmatory,,
2531,1121631,1,2,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human THP1 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay,Confirmatory,,
2532,1121632,1,1,,103176321,5746,Active,,,0.4,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay,Confirmatory,,
2533,1130144,1,1,,103176321,5746,Unspecified,,,,,Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to increase 40% life span administered as continuous injection,Other,458799.0,
2534,1130145,1,1,,103176321,5746,Unspecified,,,,,Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to give maximum increase in life span administered as continuous injection,Other,458799.0,
2535,1130146,1,1,,103176321,5746,Unspecified,,,,,"Chemotherapeutic index, ratio of antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to give maximum increase in life span administered as continuous injection to antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to increase 40% life span administered as continuous injection",Other,458799.0,
2536,1134751,1,1,,103176321,5746,Inconclusive,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 12.5 ug/ml,Other,96254.0,
2537,1134752,1,1,,103176321,5746,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 50 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2538,1134753,1,1,,103176321,5746,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 16.6 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2539,1134754,1,1,,103176321,5746,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 12.5 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2540,1134755,1,1,,103176321,5746,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 5.5 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2541,1134756,1,1,,103176321,5746,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 3.1 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2542,1134757,1,1,,103176321,5746,Unspecified,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 0.8 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2543,1134758,1,1,,103176321,5746,Unspecified,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 0.2 ug/ml in 100 mm disk at pH 8.0 by single-disk method,Other,96254.0,
2544,1134759,1,1,,103176321,5746,Inconclusive,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 3.1 ug/ml,Other,96254.0,
2545,1134760,1,1,,103176321,5746,Inconclusive,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.8 ug/ml,Other,96254.0,
2546,1134761,1,1,,103176321,5746,Inconclusive,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.2 ug/ml,Other,96254.0,
2547,1134762,1,1,,103176321,5746,Unspecified,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.5 ug/ml,Other,96254.0,
2548,1134763,1,1,,103176321,5746,Unspecified,,,,,Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.0125 ug/ml,Other,96254.0,
2549,1134766,1,1,,103176321,5746,Unspecified,,,,,Toxicity in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) at 0.5 ug/ml,Other,96254.0,
2550,1134767,1,1,,103176321,5746,Unspecified,,,,,In vivo antitumor activity against mouse P388 cells at 6.4 mg/kg relative to control,Other,96254.0,
2551,1149649,1,1,,103176321,5746,Unspecified,,,,,Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.05 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins,Other,874953.0,
2552,1149650,1,1,,103176321,5746,Unspecified,,,,,Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.0125 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins,Other,874953.0,
2553,1149651,1,1,,103176321,5746,Unspecified,,,,,Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.003 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins,Other,874953.0,
2554,1149654,1,1,,103176321,5746,Unspecified,,,,,Toxicity in Escherichia coli W1709(lambda) at 0.2 ug/ml,Other,874953.0,
2555,1149655,1,1,,103176321,5746,Unspecified,,,,,Toxicity in Escherichia coli W1709(lambda) at 0.05 ug/ml,Other,874953.0,
2556,1149657,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 3.2 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2557,1149658,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 1.6 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2558,1149659,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.8 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2559,1149660,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.4 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2560,1149661,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.2 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2561,1149662,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.1 mg/kg/day administered qd on day 1 and 5 relative to control,Other,874953.0,
2562,1149664,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 3.2 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2563,1149665,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 1.6 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2564,1149666,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.8 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2565,1149667,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.4 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2566,1149668,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.2 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2567,1149669,1,1,,103176321,5746,Unspecified,,,,,Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.1 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g),Other,874953.0,
2568,1149671,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 3.2 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2569,1149672,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 1.6 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2570,1149673,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.8 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2571,1149674,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.4 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2572,1149675,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.2 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2573,1149676,1,1,,103176321,5746,Active,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.1 mg/kg/day administered qd on day 1 and 5 measured on day 5,Other,874953.0,
2574,1149679,1,1,,103176321,5746,Inactive,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 1.6 mg/kg/day administered qd on day 1 and 5 measured on day 30,Other,874953.0,
2575,1149681,1,1,,103176321,5746,Inactive,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.4 mg/kg/day administered qd on day 1 and 5 measured on day 30,Other,874953.0,
2576,1149682,1,1,,103176321,5746,Inactive,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.2 mg/kg/day administered qd on day 1 and 5 measured on day 30,Other,874953.0,
2577,1149683,1,1,,103176321,5746,Inactive,,,,,Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.1 mg/kg/day administered qd on day 1 and 5 measured on day 30,Other,874953.0,
2578,1155390,1,1,,103176321,5746,Active,,,0.5,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
2579,1158651,1,1,,103176321,5746,Active,,,3.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB method,Confirmatory,24913558.0,
2580,1158657,1,1,,103176321,5746,Active,,,3.0,IC50,Cytotoxicity against human HL60 cells after 48 hrs by SRB method,Confirmatory,24913558.0,
2581,1158658,1,1,,103176321,5746,Active,,,3.0,IC50,Cytotoxicity against human SMMC-7221 cells after 48 hrs by SRB method,Confirmatory,24913558.0,
2582,1159509,1,1,,170464814,5746,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2583,1159515,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2584,1159516,1,1,,170464814,5746,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2585,1159517,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2586,1159518,1,1,,170464814,5746,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2587,1159519,1,1,,170464814,5746,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2588,1159520,1,1,,170464814,5746,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2589,1159521,1,1,,170464814,5746,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2590,1159523,1,1,,170464814,5746,Inconclusive,15928672.0,19885.0,13.3332,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2591,1159524,1,1,,57260126,5746,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2592,1159524,1,1,,144205046,5746,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2593,1159525,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2594,1159526,1,1,,170464814,5746,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2595,1159527,1,1,,170464814,5746,Inconclusive,325495497.0,6256.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2596,1159528,1,1,,170464814,5746,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2597,1159529,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2598,1159531,1,1,,170464814,5746,Inconclusive,325495497.0,6256.0,25.8222,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2599,1159550,3,1,,252401901,5746,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2600,1159551,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2601,1159552,1,1,,170464814,5746,Active,325495463.0,5914.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2602,1159553,2,1,,170464814,5746,Inconclusive,325495463.0,5914.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2603,1159555,1,1,,170464814,5746,Active,325495463.0,5914.0,15.5454,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2604,1159606,1,1,,57260126,5746,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2605,1159614,1,2,,170464814,5746,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2606,1159620,1,1,,103176321,5746,Active,,,,,Summary of drug indications.,Other,,
2607,1162264,1,1,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
2608,1162265,1,1,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
2609,1162266,1,1,,103176321,5746,Active,,,1.5,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
2610,1162267,1,1,,103176321,5746,Active,,,2.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
2611,1162268,1,1,,103176321,5746,Inconclusive,,,,IC50,Cytotoxicity against human Hep cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
2612,1166321,1,2,,103176321,5746,Active,,,0.1,IC50,Cytotoxicity against human THP1 cells after 48 hrs by SRB assay,Confirmatory,25259515.0,
2613,1166322,1,1,,103176321,5746,Active,,,0.04,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Confirmatory,25259515.0,
2614,1166324,1,1,,103176321,5746,Active,,,0.2,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,25259515.0,
2615,1172675,1,1,,103176321,5746,Active,,,0.45,IC50,Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay,Confirmatory,25442306.0,
2616,1224824,1,1,,174007310,5746,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2617,1224825,1,1,,174007310,5746,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2618,1224834,3,1,,170464814,5746,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2619,1224835,1,1,,170464814,5746,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2620,1224836,1,1,,170464814,5746,Active,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2621,1224837,1,1,,170464814,5746,Active,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2622,1224838,1,1,,170464814,5746,Active,66775687.0,9970.0,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2623,1224839,1,1,,170464814,5746,Inactive,66775687.0,9970.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2624,1224840,3,1,,170464814,5746,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2625,1224841,3,1,,170464814,5746,Active,325495545.0,2101.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2626,1224842,3,1,,170464814,5746,Inactive,325495545.0,2101.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2627,1224843,1,1,,170464814,5746,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2628,1224844,1,1,,170464814,5746,Active,,,9.5205,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2629,1224845,1,1,,170464814,5746,Inconclusive,344243002.0,100757539.0,21.9741,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2630,1224846,1,1,,170464814,5746,Inconclusive,11995455.0,3091.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2631,1224847,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2632,1224848,3,1,,170464814,5746,Active,325495545.0,2101.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2633,1224849,3,1,,170464814,5746,Inactive,325495545.0,2101.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2634,1224857,2,1,,170464814,5746,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2635,1224857,2,1,,174007310,5746,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2636,1224859,2,1,,170464814,5746,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2637,1224859,2,1,,174007310,5746,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2638,1224863,1,1,,176484191,5746,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2639,1224865,1,2,,57260126,5746,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2640,1224867,1,1,,170464814,5746,Active,,,6.007000000000001,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2641,1224868,1,1,,170464814,5746,Active,,,0.8485,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2642,1224869,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2643,1224870,1,1,,170464814,5746,Active,,,5.3538,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2644,1224871,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2645,1224872,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2646,1224873,1,1,,170464814,5746,Active,,,1.3448,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2647,1224874,1,1,,170464814,5746,Active,,,0.674,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2648,1224875,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2649,1224876,1,1,,170464814,5746,Inconclusive,,,9.5205,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2650,1224877,1,1,,170464814,5746,Active,,,5.3538,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2651,1224878,1,1,,170464814,5746,Active,,,8.4852,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2652,1224879,1,1,,170464814,5746,Active,,,6.74,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2653,1224880,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2654,1224881,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2655,1224882,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2656,1224883,1,1,,170464814,5746,Active,,,8.4852,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2657,1224884,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2658,1224885,1,1,,170464814,5746,Active,,,3.378,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2659,1224886,1,1,,170464814,5746,Inconclusive,,,1.3448,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2660,1224887,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2661,1224888,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2662,1224889,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2663,1224890,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2664,1224892,1,1,,170464814,5746,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2665,1224893,1,1,,170464814,5746,Active,66775687.0,9970.0,0.643084,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2666,1224894,1,1,,170464814,5746,Inconclusive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2667,1224895,1,1,,170464814,5746,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2668,1224896,1,1,,170464814,5746,Active,344243002.0,100757539.0,16.7975,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2669,1224905,2,1,,92308792,5746,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2670,1224905,2,1,,92308792,5746,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2671,1232056,1,1,,103176321,5746,Unspecified,,,,,Antitumor activity against against mouse B16 cells implanted in mouse assessed as mouse survival at 1 mg/kg/day (Rvb = 16 days),Other,25089179.0,
2672,1243436,1,1,,103176321,5746,Unspecified,,,,,Toxicity in 2-Gy gamma irradiated human PBL assessed as cytokinesis-block proliferation index at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs (Rvb = 1.6 +/- 0.1 No_unit),Other,26290401.0,
2673,1243449,1,1,,103176321,5746,Unspecified,,,,,Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as binucleated cells with micronuclei at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 15.5 +/- 0.6%),Other,26290401.0,
2674,1243462,1,1,,103176321,5746,Unspecified,,,,,Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in 1000 binucleated cells at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 183 +/- 9.6 No_unit),Other,26290401.0,
2675,1243477,1,1,,103176321,5746,Unspecified,,,,,Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in binucleated cells at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 1.2 +/- 0.03 No_unit),Other,26290401.0,
2676,1243489,1,1,,103176321,5746,Unspecified,,,,,Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as frequency of micronuclei at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay relative to control,Other,26290401.0,
2677,1243801,1,1,,103176321,5746,Unspecified,,,,,Mutagenicity in Salmonella typhimurium TA102 assessed as mutagenicity index at 0.5 ug/plate incubated for 90 mins at 37 degC in absence of liver S9 fractions by Ames test relative to untreated control,Other,26112378.0,
2678,1243849,1,1,,103176321,5746,Unspecified,,,,,Mutagenicity in Salmonella typhimurium TA102 assessed as mutagenicity index at 0.5 ug/plate incubated for 90 mins at 37 degC in absence of liver S9 fractions by Ames test relative to control,Other,26112378.0,
2679,1254406,1,1,,103176321,5746,Active,,,1.87,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2680,1254407,1,1,,103176321,5746,Active,,,2.937,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2681,1254408,1,1,,103176321,5746,Active,,,16.97,IC50,Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2682,1254409,1,1,,103176321,5746,Active,,,0.41,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2683,1254410,1,1,,103176321,5746,Active,,,0.066,IC50,Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2684,1254411,1,1,,103176321,5746,Active,,,0.578,IC50,Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2685,1254412,1,1,,103176321,5746,Active,,,0.303,IC50,Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay,Confirmatory,26541587.0,
2686,1254423,1,1,,103176321,5746,Unspecified,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as tail extent moments at 10 uM under aerobic condition by alkaline comet assay in presence of 100 uM H2O2,Other,26541587.0,
2687,1254424,1,1,,103176321,5746,Unspecified,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as tail extent moments at 10 uM under hypoxic condition by alkaline comet assay in presence of 100 uM H2O2,Other,26541587.0,
2688,1254425,1,1,,103176321,5746,Active,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as increase in amount of crosslink DNA at 10 uM for 1 hr under aerobic condition by Hoechst-33342 staining based fluorescence assay,Other,26541587.0,
2689,1254426,1,1,,103176321,5746,Active,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as increase in amount of crosslink DNA at 10 uM for 1 hr under hypoxic condition by Hoechst-33342 staining based fluorescence assay,Other,26541587.0,
2690,1254427,1,1,,103176321,5746,Unspecified,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as increase in DNA-protein crosslink at 100 uM under aerobic condition by K-SDS assay (Rvb = 4.5. +/- 1.5%),Other,26541587.0,
2691,1254429,1,1,,103176321,5746,Inactive,,,,,Induction of DNA modifying activity in human Jurkat cells assessed as DNA-protein crosslink at 100 uM under hypoxic condition by K-SDS assay,Other,26541587.0,
2692,1254818,1,1,,103176321,5746,Active,,,0.54,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTS assay,Confirmatory,26335269.0,
2693,1254819,1,1,,103176321,5746,Active,,,0.58,IC50,Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay,Confirmatory,26335269.0,
2694,1254820,1,1,,103176321,5746,Active,,,0.038,IC50,Cytotoxicity against human SF539 cells after 72 hrs by MTS assay,Confirmatory,26335269.0,
2695,1254821,1,1,,103176321,5746,Active,,,0.47,IC50,Cytotoxicity against human M14 cells after 72 hrs by MTS assay,Confirmatory,26335269.0,
2696,1254822,1,1,,103176321,5746,Active,,,0.5,IC50,Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay,Confirmatory,26335269.0,
2697,1256921,1,1,,103176321,5746,Active,,,5.2,EC50,Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay,Confirmatory,26508550.0,
2698,1259241,1,1,,170464814,5746,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2699,1259242,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2700,1259243,1,1,,170464814,5746,Active,124375976.0,367.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2701,1259244,1,1,,170464814,5746,Active,348019627.0,2099.0,3.7578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2702,1259247,1,1,,170464814,5746,Active,124375976.0,367.0,11.8832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2703,1259248,1,1,,170464814,5746,Active,348019627.0,2099.0,3.6163199999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2704,1259252,1,1,,174007310,5746,Active,169655958.0,,0.0332,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
2705,1259253,1,1,,174007310,5746,Active,169655958.0,,0.0418,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
2706,1259255,1,1,,174007310,5746,Active,169655958.0,,0.0662,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
2707,1259256,1,1,,174007310,5746,Active,169655958.0,,0.0037,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
2708,1259313,1,1,,57260126,5746,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
2709,1259318,1,1,,57260126,5746,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
2710,1259344,1,1,,144205046,5746,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2711,1259355,1,1,,144205046,5746,Active,,,17.7828,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
2712,1259356,1,1,,144205046,5746,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
2713,1259364,1,1,,170464814,5746,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2714,1259365,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2715,1259366,1,1,,170464814,5746,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2716,1259367,1,1,,170464814,5746,Inconclusive,,,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2717,1259368,1,1,,170464814,5746,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2718,1259369,1,1,,170464814,5746,Active,109731339.0,2737.0,0.2985,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2719,1259377,1,1,,170464814,5746,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2720,1259378,1,1,,170464814,5746,Active,54288833.0,2100.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2721,1259379,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2722,1259380,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2723,1259381,1,1,,170464814,5746,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2724,1259382,1,1,,170464814,5746,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2725,1259383,1,1,,170464814,5746,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2726,1259384,1,1,,170464814,5746,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2727,1259385,1,1,,170464814,5746,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2728,1259386,1,1,,170464814,5746,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2729,1259387,1,1,,170464814,5746,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2730,1259388,1,1,,170464814,5746,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2731,1259389,1,1,,175608004,5746,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
2732,1259390,1,1,,170464814,5746,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2733,1259391,1,1,,170464814,5746,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2734,1259392,1,1,,170464814,5746,Active,109731339.0,2737.0,0.87418,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2735,1259393,1,1,,170464814,5746,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2736,1259394,1,1,,170464814,5746,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2737,1259395,1,1,,170464814,5746,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2738,1259396,1,1,,170464814,5746,Active,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2739,1259400,1,1,,170464814,5746,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
2740,1259401,1,1,,170464814,5746,Inconclusive,325495545.0,2101.0,19.5704,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2741,1259402,1,1,,170464814,5746,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2742,1259403,1,1,,170464814,5746,Inconclusive,325495545.0,2101.0,10.1922,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2743,1259404,1,1,,170464814,5746,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2744,1259407,1,1,,363898364,5746,Active,,,,,CCRIS mutagenicity studies,Other,,
2745,1259408,1,1,,363894750,5746,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
2746,1259409,1,1,,363898364,5746,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
2747,1259411,1,1,,363898364,5746,Active,,,,,CCRIS carcinogenicity studies,Other,,
2748,1259415,1,1,,57260126,5746,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
2749,1259416,1,2,,375178317,5746,Inconclusive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2750,1259421,1,1,,375178317,5746,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
